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The ubiquitous second messenger molecule, cyclic adenosine monophosphate (cAMP), 
regulates a multitude of cellular functions, with Protein Kinase (PK)A being the major effector 
of its actions.  There is increasing evidence to suggest that phosphodiesterases (PDEs), a class 
of enzymes that selectively hydrolyses cyclic nucleotides, play a key role in determining cAMP 
signalling specificity to a number of PKA substrates in the heart.  Phospholemman (PLM) is a 
phosphoprotein that is physically and functionally coupled to the cardiac Na/K-ATPase (NKA).  
The latter provides the primary route of Na extrusion from mammalian cardiac myocytes, 
thereby contributing to the maintenance of transmembrane ion gradients and the indirect control 
of myocardial contractility.   
The work described in this thesis investigated whether individual cardiac PDE subtype(s) are 
responsible for modulating cAMP signalling to PLM and the NKA in adult rat ventricular 
myocytes (ARVMs).  The use of selective inhibitors for PDE subtypes 2-4 in biochemical 
assays identified PDE4 as the predominant PDE involved in modulating PLM phosphorylation 
at   Ser68,   the   consensus   PKA   site,   in   the   presence   of   the   β-AR agonist isoprenaline 
hydrochloride (ISO).  The augmentation of PLM-Ser68 phosphorylation was accompanied by a 
corresponding increase in intracellular cAMP accumulation, indicating that PDE4 selectively 
modulates downstream PKA activity via cAMP hydrolysis.  In contrast, ISO-mediated PDE2 
inhibition was found to induce the greatest increase in NKA activity, suggesting that upon 
neurohormonal stimulation, PDE2 may modulate NKA function via a mechanism independent 
of PKA phosphorylation of PLM. 
As PDE2 activity comprises a relatively low proportion of total cardiac PDE activity in the rat 
heart, our findings suggest that the actions of PDE2 may be compartmentalised.  A recombinant 
adenovirus encoding a novel fluorescence resonance energy transfer (FRET)-based cAMP 
sensor, PLM-Epac1-camps, was generated to enable direct monitoring of cAMP levels in the 
vicinity of PLM/NKA in ARVMs.  Using fluorescence confocal microscopy, PLM-Epac1-
camps was observed to be predominantly targeted to the perinuclear regions of the myocytes.  
However, preliminary ratiometric FRET measurements using a dual-photometer setup 
demonstrated a robust response to intracellular cAMP elevation with forskolin.  Collectively, 
our findings suggest that further characterisation of this methodology could provide insights 
into whether PDE2 activity locally regulates cAMP signalling to the NKA in a 
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PKAI   protein kinase A holoenzyme type I 
PKAII   protein kinase A holoenzyme type II 
PKC   protein kinase C 
PLB   phospholamban 
xix 
 
PLM   phospholemman 
PLM-Epac1-camps Epac1-based cAMP sensor with PLM sequence attached 
PLM-KO  phospholemman knock-out 
PLM-KI  phospholemman knock-in  
PLMS   phospholemman-like protein from shark 
PLM-WT  phospholemman wildtype 
PMA   phorbol-12-myristate-13-acetate 
PVDF   polyvinylidene difluoride 
Racc   access resistance 
RIA   radioimmunoassay  
RNA   ribonucleic acid 
Rol rolipram 
Rpip open pipette resistance 
rpm   revolutions per minute 
Rs   seal resistance 
Rtip   electrode tip and cell membrane resistance 
RyR   ryanodine receptor 
s   second 
SDS   sodium dodecyl sulphate 
SDS-PAGE  sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SEM   standard error of the mean 
Ser   serine residue 
SERCA sarco/endoplasmic reticulum calcium ATPase 
siRNA small interfering RNA 





Thr threonine residue 
T-tubule transverse tubule 
Tris tris(hydroxymethyl)aminomethane 
U amount of enzyme that catalyses the transformation of 1 
micromole of substrate per minute under standard conditions 
UCR upstream conserved region 
μg microgram 
μl   microlitre 
μmol/L micromolar 
UV ultraviolet 
[x] concentration of x 
[x]i intracellular concentration of x 
V Volt 
Vmax  maximal enzyme reaction rate  
VPC   voltage-patch-clamping  
v/v volume per 100 ml 
w/v weight per 100 ml 
YFP yellow fluorescent protein 
WB Western blotting 
WT wildtype  
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1 GENERAL INTRODUCTION 
1.1 β-adrenergic receptor stimulation and the cardiac cAMP 
signalling pathway 
The 3’-5’-cyclic adenosine monophosphate (cAMP) signalling pathway is involved in 
the regulation of a multitude of cellular functions in virtually all mammalian tissues, and 
is  widely   regarded   as   the   ‘classical’  messenger   pathway.  In the heart, this signalling 
cascade is responsible for regulating cardiac contractility, relaxation, automaticity, 
metabolism and gene expression; as such, it is potentially the most important 
sympathetic modulator of heart function.1  Specifically,  the  activation  of  cardiac  β1- and 
β2-adrenergic receptors (-ARs) by noradrenaline (NA), a catecholamine released from 
intracardiac nerve terminals, triggers Gs protein-coupled activation of adenylyl cyclases 
(ACs), a family of largely plasma membrane-bound enzymes that catalyse the 
conversion  of  5’-adenosine triphosphate (ATP) to cAMP [Figure 1.1].2  This results in 
an increased intracellular concentration of this ubiquitous second messenger. 
cAMP exerts its functions through the activation of three effectors; the primary and 
most-studied one is protein kinase A (PKA), the others being exchange protein directly 
activated by cAMP (Epac) and hyperpolarisation-activated cyclic nucleotide-gated 
(CNG) channels.  PKA is a broad spectrum Ser/Thr kinase that can phosphorylate a 
multiplicity of cytoplasmic and nuclear targets, thus mediating a wide variety of 
functional effects.  Specifically with regards to the catecholaminergic control of 
contractile function, PKA phosphorylates a number of key proteins involved in the 
excitation-contraction coupling (ECC) system upon sympathetic stimulation [Figure 
1.1].  These include L-type calcium (Ca) channels (LTCCs), ryanodine receptors 
(RyRs), cardiac troponin I (cTnI), cardiac myosin binding protein C (cMyBP-C), 
phospholamban (PLB) and of particular relevance to this thesis, phospholemman 
(PLM).  Phosphorylation of these PKA targets exerts an intricately coordinated 
combination of positively inotropic, lusitropic and chronotropic effects on the intact 
heart that contribute  to  the  characteristic  ‘fight-or-flight’ response, namely an increased 
force and frequency of cardiac contractions.3,4  Functionally, the activation of the 
cAMP-PKA   signalling   cascade   upon   β-AR stimulation could be regarded as a major 
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compensatory mechanism that serves to maintain or augment cardiac performance 
during physiologically stressful conditions, enabling the necessary adjustments to 
confront imminent danger or to prevent precipitous drops in blood pressure.  At the 
same time, inappropriate or excessive activation of the adrenergic signalling pathway 
can potentially contribute to a number of disease states including heart failure (HF).5 
1.1.1 cAMP – one messenger for multiple messages  
The molecular basis for the cAMP-PKA signalling pathway was the subject of much 
speculation during the late 1970s and early 1980s.  This was borne out of the numerous 
examples of cAMP-dependent signalling that could not be satisfactorily explained by 
the notion of random diffusion of cascade components and contemporary models of 
‘collision  coupling’  between  receptors  and  effectors.    Additionally,  it gradually became 
apparent that  the  interior  of  most  cells  is  not  an  aqueous  ‘sac’  of  protein  and  solutes,  but  
constructed of highly ordered lattices of various cytoskeletal networks continuous with 
intracellular organelles and the plasma membrane.  In particular, a series of studies in 
isolated rat hearts provided the first conclusive evidence that distinct responses result 
from different external stimuli converging on the cAMP-PKA signalling cascade.  
Specifically, both the non-selective β-AR agonist isoprenaline hydrochloride (ISO) and 
prostaglandin E1 (PGE1) were shown to trigger cAMP synthesis and PKA activation, yet 
different functional responses were elicited by the two agonists; β-AR stimulation was 
found to augment contractility and promote glycogen metabolism, while PGE-1 
stimulation produced neither of these effects.6  This observation raised the question of 
how the cell is able to distinguish between different stimuli acting via the same second 
messenger. 
A first clue to this paradoxical observation was the identification of two isoforms of the 
PKA holoenzyme (PKAI and PKAII) in the myocardium, differing by the nature of their 
regulatory subunits (RI and RII) and by their distribution.  Whereas PKAI is mostly 
soluble, PKAII is associated with the particulate fraction.7,8  In rabbit heart 
homogenates, it has been shown that up to 50% of the PKA could be localised to the 
sarcolemma.7  Interestingly, ISO was found to activate both the soluble and particulate 
fractions of PKA and increase the activity of phosphorylase kinase6, glycogen 
phosphorylase,6 and cTnI,9 whereas PGE1 activated only the soluble fraction of PKA 
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without affecting the phosphorylation states of these substrates.6,9  This suggested that 
β-AR effects specifically correlate with the action of particulate but not cytosolic PKA, 
in contrast to PGE1 stimulation.  On the basis of these findings, Hayes and Brunton 
postulated in 1982 that the cAMP-PKA signalling cascade is confined into distinct 
intracellular compartments, which allows signalling specificity to be conferred upon 
activation of individual Gs protein-coupled membrane receptors (GsPCR).10   
Importantly, this functional dichotomy of ISO and PGE1 in isolated hearts was 
reproduced in isolated myocytes, indicating that the differences observed had a 
subcellular basis and were not due to the different cell types present in the whole 
heart.11  This distinction in cAMP/PKA-dependent functional responses has 
subsequently been extended to several other GsPCRs present in the heart, including 
glucagon receptors12,13 and glucagon-like peptide-1 receptors.14  While activation of 
these receptors results in intracellular cAMP elevation, the resulting functional 
responses are markedly different from those induced by β-AR stimulation.12-14  
Interestingly, the level of specificity is sophisticated; even β1- and β2-ARs have 
subsequently been observed to elicit qualitatively different responses in isolated 
myocytes, with activation of β2-ARs appearing more restricted and unable to 
phosphorylate the entire spectrum of PKA substrates observed for β1-AR stimulation.15-
17  On the whole, these data support the notion that in addition to β1- and   β2-ARs, 
cardiac myocytes express a multitude of GsPCRs that share the cAMP-PKA signalling 




Figure 1.1 β-Adrenergic receptor activation, the cAMP signalling pathway and PKA 
phosphorylation targets relevant to excitation contraction coupling.  
AC,   adenylyl   cyclase;;   ACh,   acetycholine;;   AKAP,   A   kinase   anchoring   protein;;   β-AR,   β-
adrenergic receptor; M2-Rec, M2-muscarinic receptor; PLB, phospholamban; Reg, PKA 
regulatory subunit; SR, sarcoplasmic reticulum [taken from 3]. 
1.1.2 Intracellular compartmentalisation of cAMP signals 
The finding that the functional outcome is dependent upon the activation of the 
particulate or the cytosolic fraction of PKA indicated that selective localisation of PKA 
activity may be an important mechanism for achieving a specificity of response.  This 
notion was highly consistent with the functional promiscuity of PKA.  Further studies 
and the development of biochemical techniques for investigating protein-protein 
interactions19 led to the discovery of A-kinase anchoring proteins (AKAPs) in the early 
1990s.20-24  AKAPs are a large (≥50 members) and diverse family of scaffolding 
proteins that sequester PKA to distinct intracellular domains in proximity of its 
substrates, thereby allowing for their preferential phosphorylation and ensuring that the 
specificity of parallel signalling pathways is maintained [Figure 1.2].24-26  The 
identification of AKAPs has further substantiated the concept that PKA is physically 




Figure 1.2 Schematic representation of the AKAPs involved in the control of Ca  
handling in cardiac myocytes.   
The relative localisation of the different AKAP complexes is shown.  AKAP18a is found 
in association with the L-type Ca channel, mAKAP forms a complex with the ryanodine 
receptor (RyR) at the SR, whereas the AKAP18  complex consists of phospholamban 
(PLB) and SERCA2. Finally the b-adrenergic receptors (β-ARs) have been shown to 
interact with both AKAP79 and AKPA250 [taken from 27].   
Considering the diversity of the components constituting the pathway, the tight 
functional coupling of PKA and cAMP, in addition to the complex interconnectivity of 
the cAMP pathway with other signalling pathways,1 it became clear that in order for 
stimuli-specific responses to be generated, spatial control not only involves PKA, but 
also cAMP itself.28,29  cAMP is a small, hydrophilic molecule that is highly diffusible;30 
on the basis of its molecular weight and cell viscosity, the second messenger has been 
estimated to have a diffusion constant of up to 700 μm2/s30,31 and a diffusion distance of 
~220 µm.32  If unchecked, it is envisaged that cAMP generated by ACs at the plasma 
membrane would uniformly saturate the entire cell within a fraction of a second, leading 
to non-selective phosphorylation of all PKA substrates irrespective of what they are 
coupled to.   
There is substantial evidence of cAMP compartmentalisation in cardiac myocytes.18  
Studies comparing the effects of ISO and forskolin (FRSK; a direct, non-selective AC 
activator) found that achieving equal post-PKA responses generally requires a smaller 
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elevation of cAMP with ISO than that with FRSK.33  Conversely, if cellular or tissue 
cAMP were elevated to similar levels by these two agonists, the downstream effects are 
more pronounced with ISO.33  Indeed, it has been demonstrated that ISO results in a 
proportionally greater accumulation of cAMP in the particulate fraction than with FRSK 
in isolated canine ventricular myocytes, with this increase in particulate cAMP 
corresponding to an increase in Ca transient amplitude and decay kinetics.29  In contrast, 
FRSK was found to mainly increase cAMP in a compartment not accessible to PKA and 
not coupled to the measured responses in the isolated perfused rat heart.33   
Extending from these findings, subsequent studies in live myocytes provided further 
evidence for a spatial restriction of cAMP signals upon β-AR stimulation.  In 1996, a 
study using a double microperfusion system enabled ICa,L to be simultaneously 
measured on two physically isolated portions of frog ventricular myocytes using whole-
cell patch-clamping.34  The authors found that application of ISO induced a local 
activation of the current while FRSK resulted in a more uniform activation, suggesting 
the existence of a local pool of cAMP in the vicinity of the LTCC that is activated upon 
β-AR stimulation.34  In line with this idea, measurement of whole cell CNG current 
(ICNG) as an index of subsarcolemmal [cAMP]i in ARVMs over-expressing a 
recombinant rat olfactory CNG channel demonstrated that only a limited number of 
CNG channels are activated near-maximally upon β-AR stimulation.35  An important 
advancement in the field was the development of real-time imaging techniques that 
enabled the quantitative monitoring of changes in cAMP concentration within distinct 
intracellular compartments in single living cardiac myocytes [Figure 1.3],36,37 in 
particular those based on fluorescence resonance energy transfer (FRET).38  The 
approach used in one such study made use of a ratiometric FRET-based biosensor39 to 
demonstrate for the first time the generation of multiple, localised microdomains with 






Figure 1.3 Principles of 
cAMP sensors constructed 
using PKA, CNGCs and 
Epac.   
A: in absence of cAMP, PKA 
sensor is a complex of two 
regulatory (R) and two 
catalytic (C) subunits tagged 
with rhodamine (Rh)/CFP and 
fluorescein (Fl)/YFP, 
respectively, and high FRET 
is observed.  After cAMP 
binding to the two sites in 
each regulatory subunit, 
catalytic subunits are 
released from the complex 
that results in the loss of 
FRET. B: olfactory CNGCs 
are gated by subsarcolemmal 
pools of cAMP. Increases in 
cAMP result in a current, 
which can be measured 
electrophysiologically for 
monovalent cations and 
calcium. Calcium influx can 
also be visualized in cells by 
imaging of a calcium-sensitive 
dye, e.g., Fura. C: Epac-
based cAMP sensors (camps) 
are comprised of a single 
cyclic nucleotide binding 
domains (CNBD) fused 
between CFP and YFP.  
cAMP induces a 
conformational change 
leading to an increase in 
distance between the 
fluorophores, which is 
measured as a decrease in 
FRET [taken from 41]. 
Recent work using real-time detection of cAMP signals in intact cells showed that the 
β-AR and the PGE1 receptor generate spatially distinct pools of cAMP which in turn 
preferentially activate different subsets of AKAP-anchored PKA enzymes, leading to 
the phosphorylation of distinct downstream targets.42  The finding that catecholamines, 
but not PGE1, raise the phosphorylation level of key components of the ECC machinery 
and increase myocyte contractility via generation of a spatially confined pool of cAMP, 
is entirely consistent with their distinct effects on cardiac inotropism, as 
aforementioned.6,9  Similarly, in accordance with the functional effects associated with 
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the two β-AR subtypes,15 live imaging using a cAMP-FRET sensor in adult rat cardiac 
myocytes (ARVMs) has revealed that β1-ARs induce far-reaching cAMP signals, 
whereas β2-AR-induced cAMP remains locally confined.43  Again, such differences 
have been shown to translate to distinct PKA activities.44  These findings underline the 
spatial confinement of the multiple elements of the cAMP-PKA signalling pathway, 
with cAMP compartmentalisation playing a central role in this scheme.   
 
Figure 1.4 Microdomains of cAMP 
monitored in live cardiac 
myocytes using a cAMP sensor 
based on FRET and PKA. 
(a) A cardiac myocyte transfected 
with C–YFP (C, the catalytic subunit 
of PKA) and R–CFP (R, the 
regulatory subunit of PKA) shows a 
localisation of the probe in thin 
parallel striations in correspondence 
of the sarcomeric Z line.  (b) The 
effect of the β-adrenergic agonist 
norepinephrine (Ne, white bar) and 
of the broad range PDE inhibitor 
IBMX (black bar) on the 
concentration of cAMP is monitored 
by measuring FRET changes.  The 
cell is excited at 440 nm (the CFP 
excitation wavelength).  
Fluorescence emission of both CFP 
(at 480 nm) and YFP (at 545 nm) is 
collected and the 480 nm : 545 nm 
fluorescence ratio value is plotted 
against time. The values shown in 
(b) are the mean ratio values 
calculated over the entire area of the 
cell.  (c) & (d) The detail delimited 
by the box in Panel (a) is shown in 
pseudocolour. Different colours correspond to different fluorescence ratio values, 
according to the colour bar indicated in Panel (b). (c) The cell was imaged at the peak of 
the response to norepinephrine (time = 60 s) and red, corresponding to the sarcomeric Z 
lines, indicates localised regions of high cAMP levels. Addition of IBMX abolishes this 
subcellular heterogeneity, and the level of cAMP rises uniformly in the cytosol, as 
indicated in (d), which illustrates the same cell imaged at the plateau of its response to 
IBMX (time = 200 s) [taken from 45]. 
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1.2 Phosphodiesterases  
The tight local regulation of cAMP hydrolysis helps explain the observation that 
stimulation of β-ARs leads to highly restricted elevations of the second messenger, 
despite its effects on global myocardial contractile function.  In the identification of the 
mechanisms responsible for restricting cAMP diffusion, it was initially thought that 
physical barriers created by specialised membrane structures exist within the cytosol, 
with such a scenario proposed to explain the limited diffusion of cAMP from the plasma 
membrane to the deep cytosol in HEK293 cells upon PGE1-R stimulation.46  However, 
although cardiac myocytes are rich in physical submembrane microdomains, an 
experimental proof for this hypothesis remains lacking.  In contrast, there is an 
increasing  body  of  evidence  suggesting   that   the  degradation  of  cAMP  by  3’,  5’-cyclic 
nucleotide phosphodiesterases (PDEs) is critical for the formation of dynamic cAMP 
microdomains.  PDEs consist of a superfamily of evolutionarily conserved 
phosphohydrolases that are the only enzymes currently known to degrade cAMP and 
other cyclic nucleotides [Figure 1.5: Panel (a)].47-52 cAMP is converted into the inactive 
metabolite   5’-adenosine   monophosphate   (5’-AMP) when the hydrolysis of its 
phosphodiester bond is catalysed by PDE activity.  As such, the amplitude and duration 
of the cAMP signal is dependent on the activity of the cAMP-degrading PDEs.     
1.2.1 General characteristics  
Mammalian PDEs are encoded by 21 different genes and are subdivided into 11 
families (PDE1-11) based on primary amino acid sequence homology, enzymatic 
properties and sensitivity to inhibitors.51,52  Cardiac myocytes express several PDE 
families: PDEs 1, 2, 3, 4, 5, 8 and 9, with PDEs 1 – 4 thought to be primarily 
responsible for cAMP degradation in the heart.51  While PDE4 is selective for cAMP 
(Km = 2 – 4 μmol/L) , PDEs 1-3 can hydrolyse both cAMP and cGMP, albeit with 
different affinities and catalytic rates.  In particular, PDE2 and PDE3 induce a crosstalk 
between these two cyclic nucleotide pathways, providing a means by which cGMP 
signals can modulate cAMP signals (see Section 1.2.4).   
Each PDE family encompasses 1 to 4 distinct genes; specifically, PDE2 consists of 1 
gene (PDE2A), PDE3 has 2 genes (PDE3A & B), while 4 genes are present in the PDE4 
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family (PDE4A – D).  It is currently thought that cardiac myocytes express 2 forms of 
PDE2A,53 3 forms of PDE3A54 (and possibly PDE3B) and more than 5 forms of PDE4 
encoded by PDE4A, B and D.55-57  Specifically, a number of studies have provided 
direct or indirect evidence for the presence of these PDE gene products in rat cardiac 
tissues.56,58-61  
Importantly, the individual genes encode for multiple isoforms within each PDE family, 
either as products of alternative splicing or transcription from distinct promoters.51  The 
individual isoforms, of which ≥80 have been identified to date, are thought to generally 
exist as dimers and exert specific, non-redundant functional roles as a consequence of a 
unique combination of intracellular localisation, tissue-expression patterns, substrate 
specificity, regulatory mechanisms and enzyme kinetics.51,52  Despite this, the 
monomeric structure of these PDE isoforms has common features with three distinct 
domains.  The N-terminal regulatory domain characterises each family and their 
variants.  The catalytic domain is relatively conserved, sharing 25% to 52% homology 
with other mammalian PDE catalytic domains, and contains a zinc ion binding site.  The 
C-terminal domain can be prenylated62 or phosphorylated by mitogen-activated protein 
kinase.63  A number of these PDE isoforms will be described in more detail in Sections 










Figure 1.5 Schematic representation of the main PDE families expressed 
in the cardiovascular system.   
The N-terminal targeting domain characterises each family and its isoforms, 
while the C-terminal domain is relatively conserved.  The activity of PDEs can 
be regulated by a number of mechanisms; for example, binding of cGMP to 
the GAF-B domain of PDE2 results in the  latter’s stimulation, while cGMP is a 
competitive inhibitor of PDE3 activity.  Additionally, PKA phosphorylation has 
been shown to increase the activity of both PDE3 and PDE4 isoforms, the 
latter via binding to the UCR1 domain present on long isoforms of the 
enzyme.   
 
UCR: upstream conserved region; GAF: cGMP-binding PDEs; Ca/CaM: Ca 
calmodulin binding domains; Pi: inorganic phosphate (taken from 50).   
1.2.2 Contribution to intracellular cAMP compartmentalisation  
Investigation of the functional roles of PDEs has been made possible by the 
development of pharmacological agents that selectively inhibit their activities; indeed, 
the effects of PDE inhibition have been studied extensively in cardiac myocytes.  
Among the earliest indications of a potential contribution of PDEs to modulation of 
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cAMP signalling stemmed from a comparison of the effects of ISO, the broad-spectrum 
PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX) and the PDE3 inhibitor milrinone 
in guinea pig perfused hearts.  Although each of these pharmacological agents increased 
intracellular cAMP and produced positive inotropic and lusitropic effects, they were 
found to induce different patterns of PLB, cTnI and cMyBP-C phosphorylation.64  
Moreover, it was demonstrated that approximately 45% of the total cAMP in canine 
ventricular myocytes is found in the particulate fraction in response to ISO, with this 
fraction declining to <20% on the addition of the non-selective PDE inhibitor IBMX in 
combination with ISO, although total cAMP still increased 3-4 fold.29  Similarly, while 
local application of ISO to half of a cell was found to increase ICa,L half maximally, 
corresponding to activation of the channels located in the same part of the cell as the β-
AR agonist, addition of IBMX activated LTCCs in the distant part of the cell in 
response to ISO, implicating a role of PDEs in defining local cAMP pools involved in 
the β-AR stimulation of LTCCs.34  These and subsequent findings suggest a differential 
expression of PDEs at the membrane and in the cytosol, establishing a model whereby 
PDEs prevent excessive cAMP accumulation upon β-AR stimulation by limiting the 
diffusion of the second messenger from the membrane into the cytosol.65   
The contribution of PDEs to cAMP compartmentalisation has become more intricately 
characterised with the more recent imaging approaches.41,66  As aforementioned, the 
stimulation of β-ARs in NRVMs was shown to generate localised increases in cAMP 
levels in correspondence of Z lines that could be directly imaged using a FRET 
reporter.40  These cAMP gradients were dissipated by application of the PDE inhibitor 
IBMX, demonstrating that PDEs play a key role in the formation of these restricted 
cAMP microdomains [Figure 1.4].40 
1.2.3 Functional roles of PDE2-4 
Interestingly, the relative activity of the different PDE subtypes seem to be highly 
dependent on the species investigated; in mouse and rat cardiac myocytes, PDE4 
represents the major cAMP-PDE, contributing to up to 60% of total cAMP-hydrolytic 
activity, whereas PDE3 accounts for 20-30%, and PDE1 and PDE2 representing the 
remaining activity.65,67-69  In contrast, PDE4 activity represents only 10% of the total 
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PDE activity in the human heart,69-72 while PDEs1-3 represent the vast majority of the 
hydrolytic cAMP activity.69,73,74 
Despite representing merely around 1% of the total PDE activity in the neonatal rat 
heart, PDE2 was found to be responsible for the degradation of a large proportion of the 
cAMP generated   by   β-AR stimulation.75  Moreover, it has been shown using a 
genetically encoded, fluorescent cAMP sensor that activation of PDE2 results in a rapid 
decrease of intracellular cAMP from high micromolar to the sub-micromolar range 
within a few seconds; indeed, the rate of cAMP hydrolysis by PDE2 was found to be 
greater than hormone-stimulated synthesis of the second messenger.76   Consistent with 
this, PDE2 has been found to tightly control the activity of LTCCs in a number of 
species 77-80.  For example, in frog cardiomyocytes, where it is the most abundant PDE 
subtype,81 PDE2 activation has been shown to decrease a local pool of cAMP in the 
vicinity of LTCCs and only a slight decrease in cAMP in the rest of the cell, implying 
the existence of a microdomain between the β-AR, LTCC and PDE2,77 consistent with 
observations in human atrial myocytes.82 
Similarly, selective inhibition of approximately 10% of the total PDE4 activity in 
neonatal mouse myocytes was demonstrated to result in a dramatic increase in cAMP.83  
The profound effect of PDE4 inhibition on the catecholamine-induced cAMP response 
suggests  a  tight  functional  coupling  of  PDE4  with  the  β-AR, consistent with a number 
of studies in adult ventricular myocytes from rats and mice indicating that while PDE4 
exerts little effect on basal cAMP levels, it becomes crucial for hydrolysing cAMP 
generated  during  β-AR stimulation and for the control of PKA phosphorylation of key 
proteins in ECC such as the LTTC,59,65 RyR284 and PLB.85-87  It was shown in a 
PDE4D-KO model that some of these changes in protein phosphorylation correlate with 
increases in cardiomyocyte shortening, Ca transients, Ca transient relaxation rates and 
SR Ca loads, corresponding with an enhanced both in vivo and ex vivo myocardial 
contractility.87  As a consequence, PDE4 inhibition strongly potentiates the inotropic 
effects  of  β-AR stimulation in these species.88-91   
On the contrary, despite PDE3 representing approximately 30% of the total PDE 
activity in the rodent heart, its role in cAMP compartmentalisation during   β-AR 
stimulation remains less clearly understood.  In neonatal mouse myocytes, PDE3 
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inhibition   seems   to   exert   only   a   marginal   effect   on   the   cAMP   response   to   β-AR 
stimulation, and appears to be comparable to the contribution of PDE4 only when all 
ACs are non-selectively activated by FRSK.83  However, it has been reported that PDE3 
as well as PDE4 activities are specifically coupled   to   the   β-AR, with their inhibition 
augmenting both subsarcolemmal [cAMP] and ICa,L, 92 while PDE3 has been shown to 
play a major role in modulating Ca entry consecutively to cAMP-dependent 
phosphorylation of the LTTC.93   Furthermore, PDE3 inhibition has been reported to 
mediate cardiac contractility and Ca cycling in mouse myocytes, with elevated levels of 
both PLB and RyR2.86  Interestingly, the role of PDE3 appears to supersede that of 
PDE4 in larger mammals; for example,  β-AR inotropic responses in human atrium are 
predominantly regulated by PDE3,94 while PDE3 inhibitors have been found to exert a 
potent positive inotropic effect in the dog heart.86 
1.2.4 cGMP-cAMP crosstalk  
Under basal conditions, PDE2 has similar affinity for cAMP and cGMP (Km cAMP = 
15 μmol/L, Km cGMP = 15 μmol/L) but its enzymatic activity is allosterically regulated 
by cGMP with positive cooperative kinetics.  Specifically, binding of cGMP to the 
regulatory GAF-B domain at the N-terminus of PDE2 increases the rate of cAMP 
hydrolysis by up to10-fold (GAF domains are found in mammalian cGMP-specific 
phosphodiesterases, cyanobacterial adenylate cyclases and Escherichia coli formate 
hydrogen lyase transcription activator FhlA).95-97  For this reason, PDE2 was first 
named cGMP-stimulated PDE (cGS-PDE).  Therefore, via the activation of PDE2, 
stimuli that elevate cGMP may attenuate cAMP signals, for example, following NO 
production.75,98  
In contrast, PDE3 has a similarly high affinity for cAMP and cGMP (Km cAMP = 0.2 
μmol/L, Km cGMP = 0.1 μmol/L) but a much higher catalytic rate for cAMP than for 
cGMP; cGMP therefore behaves as a competitive inhibitor of PDE3 [Figure 1.5].  As a 
consequence, PDE3 provides a means by which an increase in cGMP may lead to an 
increase in cAMP within the cell. 
Interestingly, the functional impact of cGMP signals on cAMP seems to be dependent 
on the intracellular concentrations of cGMP.  At low concentrations (<50 nmol/L), 
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cGMP exclusively inhibits PDE3, whereas at higher concentrations (200-500 nmol/L), 
cGMP also activates PDE2.99 
1.2.5 Intracellular localisation of PDE isoforms 
The inter-species differences in expression levels of the different PDE families could 
potentially complicate comparison of different studies.  However, a clear trend has 
emerged whereby the divergent effects of the different PDEs on the catecholamine-
induced cAMP increase could be attributed to the specific localisation of individual 
PDE subtypes, rather than the total expression level of the enzymes.  In support of this 
idea, immunostaining experiments have shown that individual PDE isoforms belonging 
to the different PDE subtypes are localised in distinct compartments within the cardiac 
myocyte, in accordance with their differential functional effects.  Interestingly, this 
scheme often seems to be species-dependent.    Specifically, PDE2 isoforms in rat and 
frog myocytes are found preferentially in microsomal fractions75,81 in association with 
functional membrane structures – plasma membrane, sarcoplasmic reticulum (SR), 
Golgi apparatus and nuclear envelope.52  Similarly, PDE3 isoforms can be either present 
in the cytosol or anchored to the aforementioned intracellular structures depending on 
the species52,100.  In the guinea pig and rat, PDE3 is mainly found in the soluble 
fraction;101-103 in contrast, PDE3 activity in the dog heart is found in the membrane 
fraction and associated with the SR membrane, where PDE3 inhibitors exert a potent 
inotropic effect.101,104,105  The multiplicity of the different PDE4 isoforms seems to 
favour a highly intricate differential expression within the rodent heart, which will be 
outlined in more detail in the next section [Section 1.2.4].  These findings indicate that 
different PDE isoforms are sequestered into defined intracellular locations and 
functionally coupled with the distinct pools of cAMP that are selectively activated in 
response  to  β-AR stimulation.   
The ability of PDE isoforms to be targeted to distinct intracellular regions is underlined 
by their structural features.  The enzymes possess a highly conservative (20-25% 
homology in isoforms belonging to different subtypes) C-terminal catalytic domain of 
approximately 270 aa that harbours the cyclic nucleotide binding site [Figure 1.5].  In 
contrast, the less-conserved N-terminal domain has a unique amino acid sequence 
within each PDE subfamily and contains domains responsible for targeting the 
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individual isozymes to discrete intracellular compartments, through either direct binding 
to membrane lipids or selective protein-protein interactions.106  Indeed, the partition of 
PDE2 and PDE3 isoforms between membrane structures and the cytosol in general 
seems to be highly dependent on the specificities of their N-terminal domains.52  Also 
located on the N-terminal are dimerisation domains, binding sites for specific regulators 
of PDE activity as well as phosphorylation sites targeted by protein kinases [Figure 
1.5].106  For example, it has been found that the two GAF domains, GAF-A and GAF-B, 
present on the N-terminal domain of the PDE2A subunit have distinct roles in 
dimerisation and cGMP binding,107 while PKA phosphorylation sites (in addition to 
those for a number of other kinases) have been identified on the long isoforms 
belonging to the PDE3 and PDE4 families.108,109   
1.2.5.1 Intracellular targeting of PDE4 isoforms 
Of all the currently identified PDE isoforms, those belonging to the PDE4 family seem 
to exhibit the most sophisticated control of cAMP signals, and studies on these variants 
have significantly enhanced our understanding of how individual PDE isoforms are 
physically constrained within defined intracellular locales.  PDE4 comprises the largest 
PDE family and consists of more than 20 distinct isoforms that are encoded by 4 highly 
similar subfamily genes (PDE4A-D) through alternative mRNA splicing coupled to the 
use of different promoters, although only PDE4A, PDE4B and PDE4D are expressed in 
cardiac tissue.56   
A constantly growing body of literature concerns the roles of PDE4D isoforms 
expressed in the heart, while less is known about PDE4A and PDE4B isoforms, yet they 
have been detected as active proteins in both rodent and human myocardium.69  These 
enzymes have a highly conserved catalytic core but each is characterised by a unique N-
terminal region.110,111  PDE4 isoforms are categorised into long, short, super-short or 
dead-short forms based on the presence or absence of the unique upstream conserved 
regions (UCR) 1 and 2 close to the N-terminus [Figure 1.5].111-113  The latter has a major 
functional role in regulating the maximal reaction rate (Vmax) of the PDE4 catalytic unit, 
particularly in integrating the effect of phosphorylation.  For instance, upon PKA 
phosphorylation, PDE4 activity can be increased by approximately 60% for a variety of 
long isoforms.109  It is thought that this scheme provides an important negative feedback 
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loop by which PKA limits excessive cAMP accumulation during β-AR 
stimulation.35,65,114  Intriguingly, dimerisation  has been shown to be a requisite for the 
activation of long PDE4 isoforms by PKA phosphorylation 115  
The use of a dominant negative approach, which exploits the overexpression of a 
catalytically inactive PDE isoform to displace its endogenous cognate and allows for the 
compartment- and subtype-specific blockade of PDE enzymatic activity,116,117 RNA 
silencing,118 in addition to the development of mice with ablation of PDE4A,87 B119 and 
D84 have facilitated dissection of the functional roles of the individual PDE4 isoforms.  
The picture that has gradually emerged is that individual PDE4 variants are localised to 
discreet cAMP microdomains to exert control on the activity of individual ECC 
proteins, with PDE4D5, PDE4D8 and PDE4D9 having been shown to interact directly 
or indirectly via β-arrestin with β-AR receptors in neonatal rat cardiomyocytes [Figure 
1.6].116,120,121  PDE4D could also coassemble with SERCA2a;86,87 similarly, both 
PDE4B and PDE4D have been found to associate with the LTCC in the mouse heart, 
although PDE4B seems to be predominantly responsible for mediating Ca current in 






Figure 1.6 The  PDE4  ‘interactome’.  
Some of the proteins and AKAPs currently known to interact with PDE4 isoforms to form 
signaling-specific signalling scaffold complexes that in certain instances are targeted to 
specific cellular regions. Such complexes underpin   ‘sink’   formation   and   the  
compartmentalisation of cAMP signalling [taken from 112]. 
Particularly intriguing is the ability of PDE4 isoforms to interact with AKAPs [Figure 
1.6].  Through binding of other components of the cAMP signalling pathways, 
including ACs,122,123 PDEs124,125 and phosphatases,126 AKAPs organise macromolecular 
signalling complexes where the signal is generated, modulated and relayed to the 
appropriate target.  Specifically, PDE4D3 has been demonstrated to interact directly 
with the mAKAP (which also binds PKA, Epac and the extracellular signal-regulated 
kinase 5 (ERK5)) via its unique 18 amino acid N-terminal domain.114  A sophisticated 
and multilayered control of local [cAMP] and PKA activation has been demonstrated to 
take place at the mAKAP signalling complex [Figure 1.7].  The basal activity of 
mAKAP-anchored PKA is kept under control by the anchored PDE4D3.114  Upon β-AR 
stimulation, cAMP concentration increases and the resulting PKA-mediated 
phosphorylation of PDE4D3 at Ser54 and Ser13 strengthens the interaction between 
mAKAP and PDE4D3 and increases PDE4D3 enzymatic activity to achieve more rapid 
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termination of the cAMP signal.127,128  Conversely, ERK5-mediated phosphorylation of 
PDE4D3 at Ser579 inhibits the enzyme, resulting in an increase in cAMP and triggers a 
signalling cascade initiated by Epac.63,109,129  The integration of the two signalling 
pathways allows the generation of local fluctuations of cAMP and pulses of PKA 
activity, as directly confirmed by imaging studies in live cells.130  Interestingly, the 
RyR2 has been found in a signalling complex with PDE4D3, PKA and mAKAP,131 with 
PDE4D3 potentially involved in regulating the function of the latter [Figure 1.6].84   
   
 
Figure 1.7 The mAKAP complex at the nuclear membrane of cardiomyocytes 
brings together three cAMP effectors: PKA, PDE4D3 and Epac1. 
Each of these enzymes is activated at different concentrations of cAMP and there is 
interaction between them.  As cAMP levels rise, activated PKA phosphorylates PDE4D3 
in the complex at two distinct sites (double red arrow).  Phosphorylation of Ser 13 
enhances the PDE affinity for mAKAP and phosphorylation of Ser54 increases the 
activity of the PDE.  This increase in activity depletes the local concentrations of cAMP 
and enables reformation of the inactive PKA holoenzyme.  As cAMP levels fall, the 
EPac1-mediated inhibition of ERK5 pathway is blocked and the consequent ERK 
phosphorylation (red arrow) of PDE4D3 decreases the PDE activity, enabling 
accumulation of more cAMP (taken from 25). 
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1.2.6 An evolving model of intracellular cAMP compartmentalisation 
Such a model of spatially confined PDE4 isoforms in determining local cAMP signals 
was further confirmed in a study in HEK293 cells using dominant-negative mutants to 
displace cognate endogenous active PDE isoforms,132 which disrupted the cAMP 
gradients generated by PGE1 activation.  Intriguingly, the investigators found cAMP 
levels to be higher in the membrane and nuclear compartments when compared to the 
cytosol,132 indicating that the cAMP gradient between the point of cAMP synthesis and 
the bulk cytosol was not uniform and therefore could not be attributed to an enzymatic 
PDE barrier, as postulated previously.  Rather, it was found that the specific spatial 
arrangement of PDE4B and PDE4D generates a pattern  of  local  ‘sinks’  that  drain  cAMP  
in defined locales, thus resulting in the generation of multiple gradients of cAMP.132   
Such a model implies that multiple cAMP gradients could be generated simultaneously 
in different cellular locations irrespective of their distance from the AC that generated 
the cAMP response, dependent instead on their proximity to the nearest PDE4 sink.  It 
is now thought that microdomains ensure that a range of [cAMP]i are made available to 
modulate the activity of high-affinity effectors such as PKA.133  In this way, cAMP 
concentrations can be increased sufficiently above the threshold of activation for cAMP 
effectors such as PKA or EPAC, except in   localised   PDE4   ‘hotspots’,   which  
presumably serve to protect against inappropriate activation.132  This notion has been 
supported by the most recent advance, which uses PDE isoforms themselves as cAMP 
reporters.  One approach to show that cAMP gradients form around PDE molecules 
involved monitoring the PKA phosphorylation of catalytically inactivated PDE4 
isoforms as an indicator of   ‘localised’   PKA   activity117 while the other used FRET 
reporters fused to individual PDEs.134  Computational approaches, using existing 
theoretical and experimental data on the kinetics of cAMP production, have also 
concluded that compartmentalised signalling intermediates, including PDE4, shape the 
cAMP response of the β1-AR.133,135   
1.2.7 Selective targeting of PDE isoforms: a novel therapeutic approach? 
It is now recognised that the cAMP pathway transduces signals in a compartmentalised 
manner such that individual stimuli only engage a subset of the pathway components 
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that are physically constrained within defined intracellular locales, thus resulting in a 
precise functional outcome.  The evidence outlined above provides a glimpse into the 
incredibly complex spatial organisation of this   pathway   in   response   to   β-AR 
stimulation.  To add to this complexity, there is now evidence to suggest that cGMP 
signals may also be compartmentalised136 and can selectively modulate local pools of 
cAMP by regulating the activities of PDE2 and PDE3 in a differential manner, thus 
giving rise to a crosstalk between the two signalling pathways99,137.  Furthermore, it is 
now appreciated that signal propagation is not only limited to undergo regulation in 
space, but could also be controlled temporally.138   
Finally, it must be emphasised that the compartmentalisation of PKA and cAMP signals 
is complemented by a number of other mechanisms that critically contribute to such 
spatial control. These include the intracellular confinement of AC isoforms associated 
with   β-AR stimulation139 and   the   β-AR itself140 into specialised membrane 
microdomains, including caveolae.141  In addition, the precise regulation of protein 
kinases and phosphatases is essential for the control of the phosphorylation state of 
PKA substrates.  In the heart, >90% of total phosphatase activity is contributed by the 
types 1 and 2A Ser/Thr PP-1 and PP-2A.  Specifically, PP-1 has been implicated in the 
regulation of cardiac β-AR responses and as a negative regulator of cardiac 
contractility,142-144 while PP-2A has been identified as an integral component of the 
mAKAP complex145 (see Section 1.2.5.1).  
Disturbance of such intricately organised compartmentalisation of cAMP signals is 
likely to contribute to pathological states if disturbed, as exemplified by the 
redistribution of β2-ARs in HF5 and the altered expression and activity of PDEs observed 
in both HF5,55 and arrhythmia119 models.  Indeed, in many pathologies including 
inflammation, cardiovascular diseases, neurodegenerescence and cancer, alterations of 
intracellular signalling related to PDE isozyme deregulation might contribute in 
explaining the difficulties observed in the prevention and treatment of these pathologies.  
The multiplicity of biochemical and structural properties of PDEs, their specific 
subcellular compartments, their transcriptional and post-transcriptional regulation raises 
the possibility that only the altered PDE isozymes are targeted, thus avoiding and/or 
decreasing the adverse effects induced by non-selective treatments.  This spatial and 
temporal control of local signalling to phosphorylation substrates is thus critical for the 
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contractile  response  to  β-AR stimulation.  ECC substrates introduced earlier include the 
sarcolemmal protein PLM, which is the main focus of this thesis.     
1.3  Phospholemman  
1.3.1 Expression and structure 
PLM is a sarcolemmal protein that is abundantly expressed in cardiac146-148 and skeletal 
muscle,149 and to a lesser extent in regions within the brain,150 kidney151 and smooth 
muscle.152  PLM is synthesised as a 92 amino acid peptide, with the 20 aa signal 
sequence at the N-terminus cleaved off during processing to form the mature protein 
containing 72 amino acid residues.153  Despite being initially characterised as a 15 kDa 
protein, the molecular weight of PLM is actually 8409Da,153 with the discrepancy 
between the two values reflecting the slow migration of PLM on SDS-PAGE, 
specifically by the transmembrane domain.154     
The amino acid sequence of mouse PLM (also known as FXYD1; see Section 1.3.3) as 
determined by Edman degradation is shown in Figure 1.8 and illustrates the amino, 
transmembrane and carboxyl regions of the mature protein, which are comprised of 17, 
20 and 35 amino acids respectively.153  The extracellular N-terminal domain is made up 
of amino acids 1-17, including the FXYD consensus sequence (see Section 1.3.3 for 
definition of FXYD proteins), has overall negative charge and is highly resistant to 
protease degradation.  The transmembrane domain comprises amino acids 18-37, which 
are uncharged and hydrophobic, and the cytosolic C-terminal domain is composed of 
amino acids 38-72, with an overall positive charge.  Sequence homology has been 
observed  between  PLM  and  the  γ-subunit of the NKA (see Section 1.4.1) and PLB.  The 
region of similarity in the latter (RSSIRRLST in PLM155 and RSAIRRAST in PLB156) 
contains serines and threnonines that are potential phosphorylation sites (see Section 





Figure 1.8 Amino acid sequence alignment of the seven currently known 
mammalian FXYD proteins.  
Conserved residues are in red. All except FXYD2 and FXYD7 contain a candidate 
cleavable N-terminal signal (in blue). The PKA/PKC multisite phosphorylation domain of 
phospholemman (PLM) is framed. All sequences are from human (taken from 157). 
Figure 1.9 shows the structure of PLM.  Infrared158 and nuclear magnetic resonance 
spectroscopy159,160 has revealed that the transmembrane domain of PLM reconstituted in 
liposomes is alpha-helical, with a maximum tilt of 15-17o.  Additionally, NMR 
spectroscopic studies of highly purified PLM in model micelles has shown that Helices 
1 (residues 12-17), 2 (residues 22-38) and 3 (residues 39-45) are rigidly connected and 
their relative orientations determined, with Helix 1 located in the extracellular N-
terminus and Helix 2 being the main transmembrane helix.159  Helix 4 (residues 60-68), 
located in the cytoplasmic region, is connected to Helix 3 by a long flexible loop and its 
relative orientation has not been pre-determined.  While PLM does not express splice 
variants, the PLM gene   is   alternatively   spliced   in   the   5’   untranslated   region,   which  
could potentially add another level of regulation to PLM expression.161  Human PLM 




Figure 1.9 Structure of PLM determined by combining the NMR constraints 
obtained in micelles with those obtained in lipid bilayers.  
The consensus phosphorylation sites, Ser63, Ser68 and Ser/Thr69 in the cytoplasmic 
helix of PLM are highlighted (adapted from 159). 
1.3.2 Kinase phosphorylation of PLM  
It was first demonstrated in 1985 that PLM phosphorylation occurs in response to both 
PKA163 and PKC,164 although the target residues were not identified at the time.  Amino 
acid sequence determination of PLM revealed four consensus phosphorylation sites 
located on its cytosolic C-terminal domain; Ser62, Ser63, Ser68 and Thr69 (Ser69 in 
mouse).153  PLM is unique within the FXYD family in that it possesses phosphorylation 
sites in the C-terminal domain that are conserved across all vertebrate sequences cloned 
to date.  It is interesting to note that Ser16 on PLB constitutes another key PKA 
phosphorylation target during β-AR stimulation,165 consistent with the aforementioned 




evidence generated from studies using synthetic peptides mimicking the cytoplasmic C-
terminal region of PLM,166,167 or in FRSK-146,168 or ISO-treated myocytes169,170 from a 
variety of species, that PKA phosphorylates PLM at Ser68.  It has been suggested that 
PLM as a PKA phosphorylation target is quantitatively comparable to cTnI and PLB, 
making it potentially one of the most important cardiac PKA phosphorylation targets 
upon  β-AR stimulation.153,163 
Peptide studies have also shown that PKC can phosphorylate PLM at both Ser63 and 
Ser68,166,167 which was later confirmed with PDBu-treated Xenopus oocytes168 and 
mouse ventricular myocytes.169,170  Although the peptide studies suggested that prior 
phosphorylation of Ser68 by PKA was able to hinder subsequent Ser63 phosphorylation 
by PKC,166,167 subsequent studies with native PLM demonstrated no difference in Ser63 
phosphorylation following sequential PKA and PKC stimulation in either order.168,170  
Similarly, an additive effect of sequential PKA and PKC stimulation on Ser68 
phosphorylation was observed, again independent of treatment order.168,170 
Furthermore, PLM has been shown to be phosphorylated at Ser63 and Ser68 in vivo in 
the absence of exogenous PKA and PKC stimulation, and this has been quantitatively 
estimated in cardiac tissue.  The basal phosphorylation levels of Ser63 and Ser68 have 
been estimated to be 16-30%,171,172 and 20-46%146,163,172,173 respectively in mouse and 
rat myocytes by a number of independent laboratories.  The variation in these values 
may be attributed to different methods of estimation used and the various assumptions 
made in each case, in addition to possible discrepancies between the basal adrenergic 
state of the animals used in each study immediately prior to tissue isolation.174  
However, it is likely to be predominantly due to the Ca content within the myocytes 
post-isolation, which is determined by how much basal PKC phosphorylation is present; 
indeed, variations in basal phosphorylation can been modulated by either using a low Ca 
incubation or with PKC inhibitors such as bisindolylmaleimide.171 In practice, the 
relatively high basal phosphorylation of PLM often poses a significant complication in 
the investigations into the relationship between PLM and the NKA.  This will be 




More recently, it was demonstrated in ARVMs that while Ser/Thr69 is barely 
phosphorylated under basal conditions; it is transiently phosphorylated in response to 
receptor-mediated PKC activation, in contrast to the sustained phosphorylation at Ser63 
and Ser68.171  In contrast, it is now appreciated that Ser62 is unlikely to be a target for 
phosphorylation.  Additionally, while PLM-Ser63 has been reported to be a substrate for 
NIMA kinase,166 there is no known functional connection between this kinase and the 
pump.      
1.3.3 PLM as FXYD1 
Based on electrical measurements on Xenopus oocytes in which PLM is over-expressed 
in artificial lipid bilayers, the function of PLM was initially proposed to facilitate the 
membrane flux of ions154 and/or serve as a hyperpolarisation-activated channel for 
taurine transport,156 ultimately contributing to the regulation of cell volume.175,176   
The role of PLM as a modulator of NKA function became clear once it was recognised 
as the first sequenced member of the FXYD family (FXYD1) in 2000.177 The FXYD 
family (named after a conserved Pro-Phe-X-Tyr-Asp motif in the extracellular N-
terminus domain) is comprised of single-span transmembrane proteins involved in 
tissue-specific regulation of the NKA [Figure 1.8].177  These small proteins are widely 
distributed in mammalian tissues, with predominant expression in tissues that carry out 
fluid and solute transport or that are electrically excitable, i.e. where the movement of 
Na across membrane has an important functional role.178  Importantly, FXYD proteins 
display a high level of tissue specificity [Figure 1.8], and it is now accepted that such 
exclusivity of expression allows most FXYD proteins to function as a tissue-specific 
regulatory subunit of the NKA, allowing the pump to meet the exact requirements of Na 
transport in the individual tissues.178   
1.4  The Na/K-ATPase 
Discovered in 1957 by Jens Christian Skou (who received a share of the Nobel Prize in 
Chemistry in 1997),179 the NKA is a highly conserved, heterodimeric membrane protein 
and is a member of the ubiquitous P-type ATPase family of cation pumps.  It is an 
extremely high capacity system that couples the hydrolysis of ATP to the movement of 
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Na and K ions across the plasma membrane of mammalian cells.180  The energy derived 
from the hydrolysis of one ATP molecule is used by the NKA to extrude three Na in 
exchange for two K against their electrochemical gradients, resulting in a net flux of one 
positive charge from the cell per cycle that generates a small outward membrane current 
(IP).181  The latter forms a significant part of the total net current during the cardiac 
action potential plateau phase.181  The NKA provides an indispensable means of active 
membrane transport in essentially every eukaryotic single and multi-cellular organism, 
and is the molecular target of the foxglove extracts digitalis and digoxin, having been in 
clinical use for treating HF since the eighteenth century.   
1.4.1 Structure  
The crystal structure of the NKA was solved in 1997 [Figure 1.10],182 with the pump 
comprising of two   essential   subunits,   α   and   β.     The   α-subunit is approximately 1000 
amino acid long and has a molecular weight of 112kDa.183  It is a multi-spanning 
membrane protein with intracellular amino and carboxyl termini, consisting of ten 
transmembrane domains.184  The   α-subunit is the catalytic core of the enzyme and 
contains binding sites for Na, K, ATP, Mg, inorganic phosphate and cardiac glycosides 
(a class of compounds that act as specific NKA inhibitors, including ouabain and 
digoxin).185  Currently, four  isozymes  of   the  α-subunit  have  been  identified  (α1,  α2,  α3 
and  α4), which display a tissue-specific pattern of expression that may be important in 
the maintenance and regulation of NKA activity.   
Specifically,  α1 and  α2 are expressed in mouse186 rat and guinea pig187 hearts  while  α1,  α2 
and  α3 are expressed in human heart.188  In practice, only α1 and α2 have been reported to 
be expressed at significant levels in cardiac myocytes.  Both the α1189 and α2186  subunits 
of the NKA have been found to be functionally linked to the NCX in ventricular 
myocytes, although the subcellular distribution of the two isoforms seems to be 
different, with the α2 subunit more concentrated in transverse (T)-tubular membranes.190  
This has led to some proposing different physiological roles for these two subunits; 
186,191 the current paradigm is that while both subunits are involved in the regulation of 
ECC,   α2-containing pumps are principally concerned with regulation of contractility, 
while  α1-containing pumps control both contractility and bulk intracellular Na.192    
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The latter is approximately 370 amino acids long and has a core molecular weight of 
around 35 kDa.193  This subunit is highly glycosylated and its actual molecular weights 
varies between 42 and 55 kDa depending on the extent of glycosylation.194  It is a 
single-spanning transmembrane protein with its amino terminal in the cytoplasm, and it 
interacts   with   the   α-subunit at the amino acid linker region between transmembrane 
domains 7 and 8 to form the functional pump unit.195  This obligatory association with 
the β-subunit is required for the assembly, trafficking and insertion of the pump in the 
plasma membrane, preventing its degradation close to the endoplasmic reticulum and 
therefore making the pump functionally active.196-198  Although the β-subunit is not 
necessary for specificity as it does not bind the substrates,199 it has previously been 
suggested to have a contribution to catalytic activity.200  Indeed, the affinity of the NKA 
for K has been shown  to  be  β  isozyme-dependent.200  There are strong bonds between 
the   α- and   β-subunits, and altering the conformation of either subunit will alter the 
affinity of the substrates and therefore pump activity.201  Three  β  isozymes  (β1,  β2 and 
β3) have been identified to date, and these are expressed in mouse, rat and human 
hearts.193,202  The principal β-subunit found in cardiac muscle is β1.  On the whole, the 
existence of  the  multiple  isoforms  of  the  α- and  β-subunits, and 7 FXYD proteins (see 
Section 1.3.3) in mammalian genomes can theoretically support the assembly of over 






Figure 1.10 Structure of the Na/K-
ATPase.   
The   α-,   β-subunits are coloured blue and 
wheat respectively.     Also   shown   is   the   γ-
subunit (FXYD2; coloured red), which is 
associated with the NKA in the kidney.  
The   β-ectodomain is shown by surface 
representation of the experimental 
electron density.  The transmembrane 
segments   of   the   α-subunit are numbered 
(in yellow) starting with the most N-
terminal.  The small C-terminal helix (S, 










1.4.2 Function  
The NKA provides the major route for cellular Na extrusion in mammalian cells and the 
activity of the NKA under normal conditions matches the cumulative activity of all the 
plasmalemmal transporters that lead to Na influx.203  It has been suggested that 
approximately 40% of the resting ATP consumption in cardiac myocytes could be 
attributed to NKA turnover,204 giving an indication of   the   pump’s   importance   for   the  
normal functioning of the heart.   
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Specifically, since [Na]i in cardiac myocytes is determined by a fine balance between 
Na influx and efflux, the NKA plays a crucial role in maintaining a low steady-state 
[Na]i (4 - 14 mmol/L compared with extracellular [Na] at approximately 140 mmol/L) 
at the expense of metabolic energy.203  The transmembrane Na gradient established by 
NKA activity is essential not only for generating the rapid upstroke of the action 
potential, but also for driving a number of ion exchange and transport processes critical 
for normal cellular function, ion homeostasis, and the control of cell volume.203   
Specifically, the steep electrochemical gradient provides the electromotive energy for a 
number of energetically unfavourable transmembrane transport processes involved in 
the movement of ions, substrates and amino acids (secondary active transport). 
Of particular relevance to the physiological functioning of the heart is the coupling of 
the sarcolemmal Na/Ca exchanger (NCX) to Na transport; by controlling steady-state 
[Na]i, the NKA determines the set-point for intracellular Ca via NCX, which in turn 
determines the SR Ca content.  NKA activity could therefore be regarded as an indirect 
regulatory mechanism of myocardial contractility.205  Functionally, this may have 
important consequences as the precise control of cytosolic and SR Ca concentrations is 
essential for maintaining cardiac output, with derangement of Ca handling being a 
primary cellular cause of contraction abnormalities and HF.203,206  Consequently, 
interventions that influence either the set-point of the NKA, or indirectly the 
transarcolemmal Na gradient, could profoundly affect myocardial function.   
1.4.3 Physical interaction between PLM and the NKA 
In addition to its regulation by a number of factors within the cellular environment 
(including intracellular [ATP], [Na]i, subsarcolemmal Na gradients and membrane 
potential (Em)),207 NKA   activity   is   also   functionally   coupled   to   the   β-adrenergic 
signalling system.  Specifically, there is considerable evidence indicating that PLM is an 
integral component of the cardiac NKA complex that serves to modulate the function of 
the pump upon kinase activation.  A physical association between PLM and NKA was 
first observed in Xenopus oocytes co-expressing rat NKA subunits and dog PLM 
cDNAs,208 and this interaction has also been observed with recombinant PLM in native 
heart (bovine) and skeletal (rat) muscle.208  Moreover, native PLM has been co-
immunoprecipitated with the NKA α1 in the heart.148  More recently, PLM has been 
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shown   to   be   in   close   proximity   to   the   α-subunit in detergent-solubilised membranes 
from HeLa cells expressing both proteins.209  
The  specific  association  of  PLM  with  the  α1 subunit of cardiac NKA has been supported 
by immunofluorescence studies in isolated guinea-pig myocytes, which illustrate that 
PLM  primarily  localises  with  the  NKA  α1-subunit  but  not  the  α2.146,148  As mentioned in 
Section 1.4.1, the distinct intracellular distribution of the α1 and α2 isoforms has led to 
the suggestion that the  two  α  isoforms possess distinct physiological roles.192While such 
observations initially led to the suggestion that PLM may exert isoform-specific 
regulation,146 it is now generally accepted that during when phosphorylated by either 
PKA or PKC, PLM  interacts  with  and  regulates  both  the  α1  and  α2  isoforms to a similar 
extent.210  
Despite much speculation on the nature of any potential interactions between PLM 
residues  and  the  α-subunit of the NKA,211 along with mechanisms for how the proteins 
interact to form the PLM-NKA complex,212the precise sites of interaction between PLM 
and  pump  α  subunits  remain  to  be  defined.   
1.4.4 PLM as regulator of kinase-mediated NKA activity 
It is now generally accepted that PKA phosphorylation of PLM, rather than direct 
phosphorylation of the NKA α subunit, is responsible for regulating activity of the 
pump.  The only well-characterised phosphorylation within the NKA α1 subunit is 
Ser943, present in a short helical segment between TM 8 and 9, and is thought to be a 
PKA site.  The consensus recognition sequence for PKA is Arg-Arg-X Ser/Thr-Phe, 
where X is any residue and Phe is a hydrophobic residue.  PKA has been shown to 
phosphorylate the residue, but only after SDS extraction.213,214  The expected 
localisation of the residue close to the cytoplasmic membrane interface and the 
detergent dependence led to scepticism of whether the observed phosphorylation is 
physiologically relevant.  The distinct lack of evidence for PKA-mediated 
phosphorylation of the intact NKA protein suggests that direct phosphorylation of Ser 
938 on the NKA α subunit occurs only when the protein is unfolded or at least partially 
denatured by detergents, as shown by later studies confirming the necessity of Triton X-
100 for PKA-mediated Ser938 phosphorylation to take place.215,216   
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1.4.4.1 Under basal conditions 
1.4.4.1.1 Measurements of pump current in single cells 
Despite the general agreement over the necessary role of PLM in regulating NKA 
function, some disagreement remains over the exact functional effect of PLM on the 
cardiac NKA under resting conditions, in part due to the variety of experimental models 
and approaches employed.   
Single-cell studies using cardiac myocytes from PLM-KO mice have revealed that 
maximal NKA rate is 20-30% higher in PLM-KO myocytes compared to their WT 
counterparts, despite NKA α-subunit expression being reduced in the former.169,170,217-
219  These studies demonstrate that unphosphorylated PLM inhibits NKA activity via a 
reduction in Na affinity169,219 and possibly also in Vmax,173,217,220   although this reduction 
in pump current is thought to be partially compensated for by a decreased membrane 
expression of the pump α subunit. In general, observations from our laboratory suggest 
that basal pump current is consistently higher in KO myocytes compared with WT, and 
therefore pump current per pump protein molecule is likely to be substantially 
increased.  Specifically, normalising the rate for equal subunit expression has 
demonstrated that the presence of PLM approximately halves the unitary NKA current 
rate in comparison to that observed in PLM-KO myocytes under basal conditions.218   
1.4.4.1.2 Measurements of in vivo contractility 
In contrast, the role of PLM  in modulating cardiac contractility in vivo remains 
somewhat less clear, possibly due to the effects of autonomic regulation which are 
absent in vitro.  In vivo conductance catheter measurements carried out by our 
laboratory revealed a mildly depressed cardiac contractile function in PLM-KO mice 
with congenic background (C57BL/6), which was associated with a mild cardiac 
hypertrophy218.  Biochemical analysis showed a significantly increased NKA activity in 
the crude ventricular homogenates from PLM-KO hearts, in agreement with the pump 
current measurements made on single cells mentioned above.218   The expression of the 
NKA α1-subunit was found to be decreased by ~25% in the PLM-KO hearts compared 
to the WT controls, although this difference was not statistically significant.218   
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The depressed cardiac contractility observed in vivo was exacerbated when hearts were 
isolated and Langendorff-perfused, and is consistent with the expectation that with relief 
of inhibition of the NKA, PLM-KO hearts should exhibit a lower (and unregulated) 
contractility (due to the presence a lower [Na]i) when compared with WT hearts.  The 
cardiac hypertrophy was not complemented by significant changes in action potential 
morphology in paced Langendorff-perfused hearts, suggesting that at 11 weeks, the 
hypertrophy remained a physiological adaptation to compensate for the depressed 
contractility.   
Similarly, a separate group has identified a mild cardiac hypertrophy in PLM-KO mice 
with mixed genetic background (C57BL/6 and 129/SvJ), but with an increased ejection 
fraction and a reduction in NKA activity.218,220 To complicate matters further, more 
recent observations in closed-chest catheterised mice show slightly increased baseline 
+dP/dt in congenic PLM-KO hearts.221  
Overall, these findings point to an important role of PLM in regulating cardiac 
contractility. However, the evidence outlined above suggests that PLM-KO hearts may 
contract at least as well as WT hearts under basal conditions, and the disparity within 
these findings may well reflect the different experimental conditions in the studies, 
including different genetic backgrounds, imaging/catheterisation procedures, 
anaesthesia and blood loss.  On the other hand, these observations may support a 
scenario whereby PLM is functionally quiescent at rest, as supported by similar [Na]i 
values observed between WT and PLM-KO myocytes,169,221 but becomes important 
under stressful conditions. 
1.4.4.2 During β-adrenergic receptor stimulation 
There is now considerable evidence indicating the functional importance of PLM in 
regulating   NKA   activity   upon   β-AR stimulation.  While treatment of guinea-pig 
myocytes with FRSK was shown to result in   an   increased   α1-subunit NKA current, 
Western blotting (WB) analysis   did   not   reveal   a   simultaneous   change   in   α1-subunit 
phosphorylation but rather an increased phosphorylation at Ser68 on PLM.146,148  This 
observation is consistent with the concurrent increase in NKA activity in PLM-WT 
myocytes treated with ISO observed in a number of studies, although this effect seems 
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to be also dependent on[Ca]i (See Chapter 4; Section 4.4 for reasoning).169,170,221  Of 
particular importance, there was an absence of ISO-mediated stimulation of the NKA in 
PLM-KO mice, with [Na]i remaining elevated in these animals,169,170,221 indicating that 
PKA-dependent phosphorylation of PLM, rather than the direct phosphorylation of the 
NKA   α-subunit, is responsible for mediating the   β-AR effects on NKA function. 
Similarly, PDBu-induced PKC activation increased NKA activity in PLM-WT 
myocytes, via an increase in maximal turnover rate but with no change in Na affinity, 
with this effect being absent in PLM-KO cells.170  This indicated that PKC-dependent 
regulation of NKA function is also modulated by PLM, as confirmed by an increased 
phosphorylation at Ser63 and Ser68 on the protein.170  Investigation into how PLM 
mechanistically inhibits the NKA and relieves this inhibition remains ongoing.  It has 
been demonstrated that only the intracellular (19 C-terminal residues) region of PLM is 
required to regulate the NKA.217  Co-immunoprecipitation (co-IP) experiments have 
shown that complete dissociation of the two proteins does not occur upon PKA and 
PKC phosphorylation,147,148 although FRET analysis suggests that the interaction 
between the α-subunit of NKA and PLM is altered upon Ser63 or Ser68 
phosphorylation.222  This functional scheme has been proposed to be analogous to the 
loss of inhibition seen in the sarcoplasmic/endoplasmic reticulum Ca ATPase (SERCA) 
following PLB phosphorylation.223  Recently, it has been shown that PLM could 
potentially regulate NKA activity via other mechanisms that are independent of 
phosphorylation, including palmitoylation and glutathionylation.207,224  These pathways 
will be discussed in more detail in Chapter 4 (Section 4.4).   
1.4.4.3 Functional consequences  
The most important functional consequence of PLM-modulated NKA activity may be 
the precise control of cytosolic and sarcoplasmic reticulum (SR) Ca content, which is 
essential for the maintenance of normal systolic and diastolic function.225,226  During  β-
AR stimulation, the increased Ca transients drive greater Ca extrusion via the NCX, 
which leads to increased Na influx at each beat, along with a more frequent and larger 
Na current via Na channels, thus resulting in a significant increase in [Na]i.3,226  The 
elevated [Na]   contributes   to   the   inotropic   response   of   β-AR stimulation by favouring 
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more Ca influx and less Ca efflux through the NCX, and is likely to be compensated for 
by an enhanced Na extrusion via the NKA.227-229   
A general hypothesis based on the above findings is that the association of PLM with 
the NKA provides the link between kinase activity and NKA modulation in a manner 
analogous to how PLB modulates SERCA, a P-type pump closely related to the NKA.  
That is, while unphosphorylated PLM inhibits NKA by primarily reducing its affinity 
for [Na]i,146,168,169,208 phosphorylation of PLM at Ser68 by PKA or Ser63 and Ser68 by 
PKC relieves this tonic inhibition and stimulates NKA activity by increasing its affinity 
for [Na]i, and perhaps Vmax.146,169,208  Figure 1.11 denotes a hypothetical relationship 
between PLM and NKA and suggests how NKA function could be altered by PLM 









Figure 1.11 The hypothetical relationship between phospholemman (PLM) and the  
Na/K ATPase a-subunit and alterations induced by PLM phosphorylation.   
(a) PLM is a single transmembrane spanning protein that inserts into the sarcolemma 
with its carboxy terminus on the cytoplasmic side of the membrane. The cytoplasmic tail 
of PLM contains three known phosphorylation sites at Ser63, Ser68 and Thr69 (Ser69 in 
mouse). (b) The helical structure of PLM [taken from 159] normally orientates with the 
cytoplasmic a-helix (H4) close to, or inserted into, the membrane 230. The basic nature of 
this region (+) means that it associates with the negatively charged phospholipids of the 
membrane. However, when PLM is phosphorylated at any or all of the phosphorylation 
sites indicated in Panel A (for example, by PKA: Panel B) the orientation of the 
cytoplasmic tail may shift altering its interaction with the Na/K ATPase a subunit and 
disinhibiting/stimulating ion transport [taken from 203]. 
Interestingly, it has been proposed more recently that PLM may physically associate 
with and directly modify the function of the NCX, with phosphorylation at Ser68 on 
PLM inhibiting NCX activity.172,231,232  However, much of the evidence supporting 
NCX modulation by PLM has not been reproduced by other groups and may merely be 
reflecting a secondary effect of   PLM’s   regulation   of   the   NKA   (PLM-mediated 
inhibition of the NKA results in reduced Na extrusion from myocytes, which will in 
turn reduce forward Na/Ca exchange).  Similarly, it has been demonstrated more 
recently in heterologous expression systems that PLM cooimmunoprecipitates with 
Cav1.2 channels from guinea pig myocytes, and may act as an endogenous regulator of 
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Cav1.2 channel gating.233  Collectively, these findings suggest that PLM is potentially a 
central player in the sympathetic response, playing a major role in the regulation of 
cardiac contractility under stressful conditions.206,234  Indeed, from a physiological 
perspective, limiting the rise in [Na]i at the expense of reduced inotropy has been 
suggested to prevent Ca overload in response to β-stimulation, prevent diastolic 
dysfunction and protect against arrhythmias.203,206,234,235  This model is consistent with 
the number of pathophysiological states found to be associated with altered cardiac 
NKA function, including HF,147,236 cardiac ischemia148 and post-MI.173 
1.5 Rationale, general hypothesis and aim of project 
It is now largely accepted that PDE activity is critical for spatial and temporal regulation 
of cAMP signal propagation.  PDEs are strategically distributed within the cell and 
selectively regulate cAMP signals triggered by individual GSPCRs, including the β-AR.  
Specifically, the evidence outlined above suggests the existence of multiple PDE 
variants with different catalytic and regulatory properties that permit the generation of 
tailored cAMP signals within distinct intracellular compartments in proximity to 
individual PKA substrates.  Since PLM is a major cardiac PKA phosphorylation target 
and resides in close proximity to the LTCC in the sarcolemma, we hypothesised that 
PDE activity is involved in modulating cAMP signalling signalling to PLM during  β-
AR stimulation.  Indeed, prior to the start of the PhD project, we have generated some 
preliminary data indicating the presence of an AKAP in the vicinity of PLM.  In 
voltage-patch-clamp (VPC) experiments, FRSK-induced NKA activation was shown to 
be blocked by Ht31 (a peptide that competes with endogenous AKAPs for binding to 
the R subunits of PKA) dissolved in the pipette solution, suggesting that AKAP binding 
of PKA is a requisite for PLM phosphorylation (unpublished data).  In support of this 
AKAP-based model, we have pilot data showing that PLM interacts with other 
membrane-bound and cytosolic proteins, suggesting that PLM may be a nodal point in 
signalling to cardiac transporters and integrates signalling from multiple pathways 
(unpublished data).  Interestingly, our group has shown that NKA activity and primarily 
the Ser68 phosphorylation residue on PLM are negatively modulated by the 
aforementioned PP-1 in resting cardiomyocytes, with this mechanism being sensitive to 
Inhibitor-1 (I-1).237  Moreover PLM-Ser68 phosphorylation was found to be markedly 
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diminished in failing human hearts, which is consistent with hyperactivated PP-1 and I-
1 deactivation previously observed in HF and may be involved in the pathogenesis of 
HF and arrhythmogenesis.   
Therefore, identifying the PDE subtype(s) involved in the regulation of cAMP 
signalling to PLM is a logical step that will shed light onto the functional link between 
β-AR stimulation and NKA activity.  Considering the importance of NKA in indirectly 
regulating myocardial contractility and the crucial role of PDEs in upholding normal 
cAMP signalling, in addition to the potential therapeutic use of PDE inhibitors as 
pharmacological agents, our findings may bear therapeutic potential for treating HF and 
other pathological conditions potentially involving PDE and NKA dysfunction.   
 
General hypothesis 
That one or more PDE subtypes contribute to the regulation of cAMP signalling to PLM 
and the NKA during  β-AR stimulation. 
Aim of project  
To identify the PDE subtype involved in regulating cAMP signalling to the PLM-NKA 
complex during β-AR stimulation and characterise its physical and functional 
associations with the complex using electrophysiological, biochemical and imaging 
approaches.   
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2 GENERAL METHODS 
Details of methodology relevant to more than one chapter are provided here.  Details of 
specific methodology and experimental groups are provided within the Specific Methods 
section of each chapter.   
2.1 Reagents 
All analytical-grade chemicals and consumables used were purchased from Sigma-
Aldrich or VWR unless otherwise indicated.  Purified water (Elgastat UHP, Elga Ltd.) 
at resistivity >18.2 MΩ was used to make up all solutions.     
2.2 Animals  
2.2.1 Principles 
The vast majority experiments described in the following chapters were carried out 
using ventricular myocytes from the adult rat.  Rat myocytes are generally more robust 
than mouse myocytes, which makes them more conducive to VPC studies.  
Additionally, due to the greater size of the heart in rat in comparison to the mouse, 
isolations generally yield a higher number of live cells, which facilitates WB studies by 
providing a strong protein signal, in addition to enabling multiple conditions to be tested 
using cells from a single heart.  This serves to reduce the number of animals culled for 
each experiment.    
2.2.2 Animal housing and handling  
Adult male Wistar rats (250 – 300 g; B & K Universal Ltd) were maintained on site 
(Biological   Services   Animal   Care   Facility,   King’s   College   London).  Animals were 
maintained   humanely   in   compliance  with   the   ‘Principles   of   Laboratory  Animal  Care’  
prepared   by   the  National   Society   for  Medical  Research,   and   the   ‘Guide   for Care and 
Use  of  Laboratory  Animals’  from  the  National  Academy  of  Sciences,  published  by   the 
National Institutes of Health (NIH Pub. No. 85-23, revised 1985).  All animals were 
kept in containment rooms maintained at 25oC with a 12-hour light-dark cycle; between 
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4 and 6 rats were housed in each cage, allowing free access to food and water.  All 
animal   protocols   were   approved   by   both   the   local   King’s   College   London   Ethical  
Review Process Committee and performed in accordance with the Home Office 
Guidelines on the Operation of the Animal Scientific Procedures Act (1986) published 
by  Her  Majesty’s  Stationary  Office,  London. 
2.3 ARVM isolation  
2.3.1 Isolation procedure 
ARVMs were isolated using a standard collagenase-based digestion protocol, yielding 
Ca-tolerant rod-shaped cells.  All the work described in Section 2.3.1 was undertaken by 
our  ‘in-house’  research  technician Dr Shiney Reji.   
Animals were anaesthetised by an intraperitoneal injection of sodium pentobarbitone 
(50 mg/kg; Sagatal, Rhone Merieux), followed by an injection of heparin (150 I.U; Leo 
Laboratories Ltd) into the femoral vein to prevent blood coagulation and clot formation 
in the excised heart.  Once the animal was unconscious, as determined by an absence of 
pedal and corneal reflexes, the abdominal cavity was opened just below the sternum and 
the heart exposed by removing the diaphragm and cutting laterally either side of the 
ribcage.  The chest wall was reflected and the heart gently lifted and rapidly excised 
with the proximal aorta and pulmonary trunk intact, and immersed in ice cold Ca-free 
modified  Tyrode’s  Solution (see Table 2.1 for composition).  After removal of excess 
thymus and fatty tissue, the aorta was cut just below the aortic arch and tied to a 
custom-made blunt stainless steel cannula and the aorta using 4/0 surgical silk (Johnson 
and Johnson).  Perfusion was commenced within 60 s of excision.     
Hearts were perfused at 37oC in the retrograde fashion though a modified Langendorff 
preparation for three sequential periods as follows: with  (1)  modified  Tyrode’s  solution  
containing 0.75 mmol/L CaCl2 (Solution A) for 4 min to clear the heart of blood and 
allow healthy stable contractions to be established; (2) Ca-free   modified   Tyrode’s  
solution containing 0.2 mmol/L EGTA (Solution B) for 4 min to arrest the heart; (3) 
modified   Tyrode’s   solution   containing   0.1   mmol/L   CaCl2 and 125 U/ml collagenase 
(Type II; Worthington Biochemical Corporation) for 7 min for enzymatic digestion of 
the heart tissue.  The coronary flow rate was maintained at 10 ml/min using a Gilson 
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Minipuls peristaltic pump, and all solutions were maintained at 37oC and gassed with 
100% O2 throughout the procedure.  The compositions of Solutions A-E are displayed in 
Table 2.2.  
After the perfusion protocol, the heart was removed from the cannula and the aorta, 
atrial and non-ventricular tissue carefully removed.  The right ventricle was then 
removed before the left ventricle was cut into fragments, first with sterile scissors and 
then using a sharp scalpel blade, before re-suspended in 20 ml of digestion buffer 
(Solution C).  The tissue fragments were then gently bubbled with 100% O2 for between 
15 and 20 min, and were subsequently carefully triturated using a 2 ml plastic dropping 
pipette to facilitate cell dispersion (<2min).  Digested cells were then filtered through a 
nylon mesh (200  μmol/L  pore  size).  The suspension was left to settle for 8 min to allow 
the cardiac myocytes to pellet.  The supernatant was then removed and the remaining 
live myocytes washed and re-suspended in warmed   modified   Tyrode’s   solution  
containing 0.5 mmol/L CaCl2 (Solution D).  After a further settling step lasting 8 min, 
the supernatant was removed and the myocytes washed and re-suspended in warmed 
modified  Tyrode’s   solution   containing  1  mmol/L  CaCl2 (Solution E), in order for the 
CaCl2 concentration to be increased to 1 mmol/L.  The cell suspension (>70% rod-
shaped as estimated by light microscopy) was maintained in Solution E in a water bath 
set at 35oC for approximately 2 hr prior to use in VPC experiments or maintained in 
culture at 37oC/5% CO2 for at least 2 hr prior to use in biochemical/adenoviral infection 










Table 2.1 Composition  of  modified  Tyrode’s  Solution  used  in  isolation  of  ARVMs.   
1x stock of the solution was prepared without glucose, which was added on the day of 
use.    The  solution  was  then  filtered  through  a  cellulose  acetate  filter  (0.2  μm  pore). 










*Added on day of use 
pH 7.3 at 37oC with NaOH  
 
Table 2.2 Composition of Solutions A – E used in isolation of ARVMs 
Solution Additions 
A 750  μmol/L  CaCl2 
B 100  μmol/L  EGTA 
C 100 CaCl2 & 0.5 mg/ml collagenase 
D 0.5 mmol/LCaCl2 




2.3.2 Cell viability 
Viable ARVMs were recognised as rod-shaped rectangular cells.  Healthy myocytes 
were identified by their defined edges and square ends.  Only isolations with viable cells 
equal to or in excess of 70% were used in experiments/maintained in culture.   
2.3.3  Post-isolation treatment of ARVMs 
As aforementioned, ARVMs were incubated/cultured for approximately 2 hr prior to 
experimentation to allow recovery from the isolation procedure.  Unpublished 
observations by our group suggest that the isolation procedure activates a number of 
stress kinases, which results in the hyper-phosphorylation of PLM.  Experimentally, this 
could potentially be problematic since a large proportion of our experiments are 
dependent upon agonists being able to stimulate PLM phosphorylation to a significant 
degree so that it is detectable by WB, and the corresponding changes in NKA current 
measured by electrophysiological means.   
If PLM is already maximally or close to being maximally phosphorylated, then any 
potential changes in PLM phosphorylation mediated by agonists and/or other 
pharmacological agents may remain undetected.  Therefore, with the aim of maximising 
the   ‘window’   for   detecting increases in PLM phosphorylation and NKA activity, our 
group has investigated the   ‘recovery   window’   (i.e.   the   time   required   for   PLM  
phosphorylation to significantly decrease and stabilise post-isolation).  Unpublished 
data generated by our group indicate that ARVM recovery and the decrease in PLM 
phosphorylation become stable after approximately 2 hr post-isolation.  By this time-
point, PLM phosphorylation is reduced by approximately 60% compared to freshly-
isolated ARVMs.  Further unpublished observations show that culturing ARVMs for 24 
hr significantly potentially reduces basal PLM phosphorylation by 80%.  However, a 
comparison of PLM phosphorylation responses to a range of ISO concentrations made 
between ARVMs left for 2 hr post-isolation and those cultured for 24 hr revealed 
similar results, with both experimental setups generating the same IC50 values. 
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2.3.3.1 Freshly-isolated ARVMs 
As outlined earlier, freshly isolated ARVMs were placed in a water bath heated to 35oC 
for 2 hr post isolation to allow recovery from the isolation procedure.  Myocytes were 
washed and re-suspended in an appropriate volume of modified Tyrode’s   solution 
(Table 2.1) after 2 hr to remove any dead cells prior to use in electrophysiological 
experiments. 
2.3.3.2 Short-term culture of ARVMs 
Laminin (2 ml  of  a  15  μg/ml  solution)  was  added   to  6- or 12-well plates, which were 
incubated at room temperature for 1.5 to 2 hr.  The laminin was then removed (and 
stored at -20oC for re-use up to 3 times) and the wells washed with 1-2 ml of sterile 
modified  Hank’s M199 culture medium (containing Hanks salts, 25 mmol/LHEPES, L-
glutamic acid and L-amino acids; Invitrogen; 500 ml bottle supplemented with 2 
mmol/L L-carnitine, 5 mmol/L creatine, 5 mmol/L taurine and 1% penicillin (100 
units/ml)   and   streptomycin   (100   μg/ml)).  The medium was aspirated from the wells 
prior to myocyte plating.     
After settling for approximately 1 hr post-isolation, modified   Tyrode’s   solution was 
aspirated from ARVMs isolated from a whole/half heart and the cells were washed at 
room temperature with approximately 30 ml M199 culture medium.  Cells were pelleted 
by centrifugation in a Heraeus Sepatech Megafuge 1.0R centrifuge at 300 rpm for 1 min 
at room temperature, the supernatant removed by aspiration and the cell pellet re-
suspended in an appropriate volume of pre-warmed M199 medium.  The myocytes were 
gently agitated to ensure equal suspension, before getting plated down in a volume of 1 
or 2 ml/well on pre-laminated 12- or 6-well culture plates respectively.  Throughout the 
culture process, the plated cells were kept in a humidified tissue culture incubator 
(37oC/5% CO2).  After 1.5 to 2 hr, the culture medium was exchanged for fresh media, 
in the process removing any dead myocytes that have not adhered prior to conduction of 
any biochemical/adenoviral infection experiments and/or further incubation of the cells 
overnight.  At the start of each experiment, the culture medium in each well was 
aspirated and 1 ml fresh medium added.   
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2.4 Pharmacological agents  
2.4.1 PDE inhibitors 
IBMX is a widely used non-selective inhibitor of all PDE subtypes, while EHNA, Cil 
and Rol are selective inhibitors of PDE2, PDE3 and PDE4 respectively.  IBMX was 
used  at  100  μmol/L while the subtype-selective inhibitors were used at 10 μmol/L (See 
Chapter 3; Section 3.4 for reasoning).  All PDE inhibitors were prepared as 1000x 
stocks in 100% DMSO.  In WB experiments, these stocks were diluted 1:10 in M199 
culture media to facilitate accurate loading into the wells.  See Table 2.3 for details of 
these compounds.          
2.4.1.1  IBMX 
Theophylline was the first PDE inhibitor to be described in the literature, in 1962.238  A 
decade later, a new xanthine analogue, IBMX, was shown to be 100-fold more potent 
than theophylline.239  Both IBMX240 and theophyline241 inhibit the PDEs belonging to 
the different families.  In the last decade, a large number of PDE inhibitors have been 
developed; some of them inhibit PDE activity very potently, in the nanomolar range, 
and are very specific for a single PDE family.  Therefore, in the span of several decades, 
the potency of PDE inhibitors has increased by 106 and the selectivity of some of them 
has increased by 104.   
2.4.1.2 EHNA 
There are many compounds which significantly interfere with PDE2, although many of 
them also inhibit other PDE subtypes.  EHNA (previously known as cGS-PDE or MEP 
1), has a very particular mechanism, and remains the only compound so far described 
that is able to inhibit PDE2 both basally (IC50 = 38 μmol/L) and when activated by 
cGMP242,243 (IC50 = 2 μmol/L).244  The precise mechanism of this inhibition is not 
entirely elucidated, since ENHA does not appear to displace cGMP from the regulatory 
site on PDE2.79  However, it is important to note that EHNA is also a potent adenosine 
deaminase inhibitor at lower concentrations245 (Ki = 10 nmol/L) and must therefore be 




Cil (also known as OPC-3689246) was the first potent and selective inhibitor of PDE3 
described.  It was the initially described as a platelet anti-aggregant.  PDE3 was 
considered as a cardiotonic target, with medicinal chemistry focusing on PDE3 
inhibitors, giving rise to amrinone, milrinone and enoximone.   
2.4.1.4 Rolipram 
PDE4 is characterised by its selective sensitivity to Rol (Ki value = 0.8 μmol/L), an 
antidepressant compound247 that was found to specifically bind with high affinity to 
membrane brain fractions and was shown to be a potent inhibitor of cAMP hydrolysis in 
brain homogenates.248  Accordingly, Rol became an archetype for the synthesis of new 
potent and selective PDE4 inhibitors.249  Importantly, there is now extensive evidence 
indicating a highly selective binding of Rol to PDE4 in a number of cell types250,251, 
including the myocardium.252-254  Rol binds to PDE4 at two sites, termed low-affinity 
rolipram binding site and high-affinity binding site.248,255    
2.4.2 Kinase agonists 
Further details of the kinase agonists used in our experiments are listed in Table 2.3. 
2.4.2.1 Isoprenaline hydrochloride  
Based on the chemical structure of noradrenaline, ISO is a potent, non-selective  β-AR 
agonist that increases [cAMP]i and induces PKA activation.  ISO was prepared fresh in 
distilled water before each experiment and stored away from light to prevent oxidation.  
The desired concentrations were obtained using serial dilutions. 
2.4.2.2 Phorbol-12-myristate-13-acetate  
PMA is a potent PKC agonist which directly activates the kinase due to the structural 
similarities between PMA and diacylglycerol (DAG, the endogenous PKC agonist).  
PMA was prepared in 100% DMSO as a 1000x stock.  In some of our experiments, 
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PMA was used as a positive control to maximally stimulate PLM phosphorylation at 
Ser63, Ser68 and Thr69.  This allowed us to access the approximate magnitude of 
maximal PLM phosphorylation at this site, which provides an insight into how reactive 
the myocytes are to an external agonist.   
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Table 2.3 Details of pharmacological agents used in experiments.   
Names, stock concentrations, appropriate vehicles used, suppliers and catalogue numbers. 
Compound Use Stock concentration  Vehicle Supplier Catalogue number 
 ISO β-AR agonist 5 mmol/L H2O Sigma Aldrich I5627 
FRSK AC activator 50 mmol/L DMSO Sigma Aldrich F6886 
 PMA PKC activator 300  μmol/L DMSO Sigma Aldrich  P8139 
 EHNA PDE2 inhibitor 10 mmol/L DMSO Sigma Aldrich E114 
 Cil PDE3 inhibitor 10 mmol/L DMSO Sigma Aldrich C7971 
Rol PDE4 inhibitor 10 mmol/L DMSO Sigma Aldrich R6520 




2.4.3 Storage of compounds and experimental conditions 
After desiccation, all compounds (apart from ISO, which was prepared immediately 
prior to experimental use) were stored in aliquots at -20oC.  As the majority of 
compounds were prepared in 100% DMSO, which may non-selectively activate several 
signalling pathways within the cardiac myocyte, care was taken during experiments to 
ensure that myocytes were exposed to no more than 0.1% DMSO during all treatment 
conditions, and that all treated wells were exposed to an equal amount of DMSO.  Any 
samples that have been treated with a maximal concentration of PMA but did not show 
the expected response were excluded from subsequent statistical analysis. 
2.5 SDS-PAGE/Western blotting 
2.5.1 Principles 
SDS-PAGE and WB represent two of the most widely-used biochemical techniques and 
when employed together allow quantification of the amount of one specific protein from 
within a cell/tissue sample.  SDS-PAGE separates all the proteins in a sample though a 
gel matrix according to their molecular weights.  Once separated the proteins can be 
transferred onto a supporting membrane and probed for binding to a specific antibody. 
2.5.2 Pharmacological treatment of ARVMs and sample preparation for SDS-
PAGE 
Cultured ARVMs were treated with various pharmacological agents including PDE 
inhibitors and kinase agonists.  The supernatant was subsequently removed and the cells 
lysed in 100 μl or 150 μl 2x sample buffer for 12-well or 6-well culture plates 
respectively.  The wells were scraped with a disposable cell scraper to ensure full cell 
lysis and maximise protein harvesting for biochemical analysis.  Samples were pipetted 
into 1.5 or 2ml Eppendorf tubes and stored at -20oC.  Prior to loading on a gel, samples 
were boiled at 95oC for 5 min (only if probing with anti-phospho Ser16 antibody; see 
Specific Methods of the relevant results chapters) and spun at 13,000 rpm for 5 min.  
Details of the compounds used are provided in Table 2.3, while the concentrations at 
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which they were used and durations of treatment are described in the Specific Methods 
of the relevant results chapters.     
2.5.3 SDS-PAGE 
Proteins were separated by SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
according to their molecular weight.  The gel matrix constituted of a lower resolving gel 
and a stacking gel into which wells were set for sample loading.  The 0.75 mm-thick 
resolving gels (see Table 2.4 for composition) were prepared first; 15% (v/v) 
acrylamide (Protogel, National Diagnostics; 37.5:1 acrylamide to bisacrylamide) gels 
were used to investigate PLM and PLB phosphorylation status and 10% (v/v) for that of 
larger proteins.  Water-saturated butanol was overlaid whilst the resolving gel 
polymerised to prevent drying; the butanol was then washed off and the 1.5 ml layer of 
stacking gel was prepared (see Table 2.4 for composition).  Toothed combs with 10-15 
wells were inserted into the stacking gel and removed after polymerisation to leave 














Table 2.4 Composition of stacking and running gels used in SDS-PAGE. 
 Resolving gel Stacking gel 
 10% 15%  
Tris HCL (mol/L)    
pH 8.8 0.38 0.38 - 
pH 6.8 - - 0.12 
Acrylamide (w/v, %) 10 15 4.5 
SDS (w/v, %) 0.1 0.1 0.1 
TEMED (v/v, %) 0.1 0.1 0.17 
APS (w/v, %) 0.09 0.09 0.11 
 
Samples and Precision Plus Protein TM Dual-Colour Standards (Bio-Rad; containing 
proteins ranging between 8 and 180 kDa in molecular weight) were loaded onto the 
stacking gel and immersed in running buffer (0.025M Tris-base, 0.19M glycine, 0.1% 
w/v SDS).  The markers were run in parallel to the samples on every gel to aid 
determination of transfer efficiency and to enable protein identification by molecular 
weight.  SDS-PAGE was carried out using the Mini protean III Tetra Cell system (Bio-
Rad) at 80 V (approximately 15 min) for protein migration through the stacking gel, and 
at 150-200 V until the bromophenol blue dye front reached the bottom of the resolving 
gel (approximately 45–60 min). 
2.5.4 Semi-dry electrophoretic transfer 
Polyvinylidene fluoride (PVDF) membranes (GE Healthcare) were cut to size and pre-
soaked in methanol, followed by transfer buffer (0.025 mol/L Tris-base, 0.19 mol/L 
glycine, 20% (v/v) methanol, 0.1% (w/v) SDS).  The membranes and resolving gels 
were sandwiched between six pieces of electrode paper, also pre-soaked in transfer 
buffer, and placed in a Hoeffer TE77 semi-dry transfer unit.  Transfer was carried out at 
10V for 35 min with the current limited to 250 mA per gel.  
2.5.5 Western blotting 
Following transfer, membranes were blocked against non-specific binding of antibodies 
by incubating in phosphate-buffered-saline-Tween (PBST) (5% (w/v) dried skimmed 
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milk powder (Marvel), 0.1% (v/v) Tween-20, in PBS) for ≥1 hr on an orbital shaker at 
room temperature.  Following a brief wash in PBST, membranes were incubated with 
the relevant primary antibodies (diluted in 5% (w/v) milk) in PBST).  The specific 
conditions for primary antibody incubations are detailed in Table 2.5.  Following 
antibody binding, membranes were washed repeatedly in PBST (4 – 6 times, 10 – 15 
min each) and then incubated with horseradish peroxidise (HRP)-conjugated secondary 
antibody (diluted in 5% (w/v) milk in PBST).  The specific conditions for secondary 
antibody incubations are detailed in Table 2.6. The membranes subsequently underwent 
4 – 6 washes in PBST for 10 – 15 min each before being prepared for enhanced 





Table 2.5 Details of primary antibodies used in Western blotting experiments. 
Antibody ID no. Dilution Origin Source Incubation conditions 
Anti-phospho PLM-Ser68*# Cp68 1:10,000 Rabbit J Randall Moorman, 
University of Virginia 
60 min; room temp. 
Anti-phospho PLM-Ser63 Cp63 1:10,000 Rabbit J Randall Moorman,  
University of Virginia 
60 min; room temp. 
Anti-phospho PLM-Ser/Thr69 T69 1:100 Sheep Raised 'in house' 
King's College London 
30 min; room temp. 
Anti-phospho PLB-Ser16# A010-12 1:5000 Rabbit Badrilla Overnight; 4oC 
Anti-phospho cTnI-Ser22/23 4004 1:5000 Rabbit Cell Signalling Overnight; 4oC 
Anti-total PLM (N-terminal 
domain) 
N1 1:100 Chicken Raised 'in house' 
King's College London 
60 min; room temp. 
Anti-total PLB A1 1:1000 Mouse Badrilla 60 min; room temp. 
Anti-total cTnI 4002 1:1000 Rabbit Cell Signalling Overnight; 4oC 
Anti-total actin JLA20 1:1000 Mouse Developmental Studies 
Hybridoma Bank 
60 min; room temp. 
Anti-GFP A11121 1:1000 Mouse Invitrogen Overnight; 4oC 
 
*This antibody has been shown to cross-react with PLB-Ser16.   
#Requires pre-boiling of samples at 95oC for 10 min to remove pentameric PLB.  
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Table 2.6 Details of secondary antibodies used in Western blotting experiments. 
Antibody ID no. Dilution Origin Source Incubation conditions 
Anti-Rabbit IgG HRP-linked NA934V 1:1000 Donkey GE Healthcare 60 min; room temp. 
Anti-mouse IgG HRP-linked NA931V 1:1000 Sheep GE Healthcare 60 min; room temp. 
Anti-chicken IgY HRP-linked G135A 1:1000 Rabbit Promega 60 min; room temp. 




2.5.6 Enhanced chemiluminescence and quantification of Western blots 
The ECL system (GE Healthcare) is a light emitting, non-radioactive technique used to 
detect an immune complex on a WB membrane through the binding of an HRP-
conjugated antibody.  Equal volumes of ECL Reagents A & B were mixed and 
membranes incubated in the resulting solution for up to 60 s.  Excess ECL was removed 
and the membranes placed within a plastic wallet inside a developing cassette.  
Hyperfilm ECL high performance X-ray film (GE Healthcare) was exposed to the 
membranes for approximately 30 s and developed using a Fuji RGII automatic 
processor (Fuji).  Exposed films were scanned into a computer using a flatbed scanner, 
and the intensity of protein bands quantified using a Bio-Rad GS800 densitometer and 
Quantity One software (Bio-Rad).  PVDF membranes were subsequently stained with 
Coomassie blue (2.4 mmol/L Coomassie Brilliant Blue R, 10% (v/v) acetic acid, 50% 
(v/v) methanol) for 30-60 min to stain the membrane for total protein, to confirm equal 
protein loading across samples and that protein transfer from the gel to the membrane 
had been successful.   
2.6 Statistical analysis 
Data are expressed as means ± SEM from at least six individual experiments performed.  
Statistical comparisons and curve-fitting were carried out using GraphPad Prism 
software; the Student’s t-test was used for comparing two groups (paired if both groups 
were from the same population) and one-way ANOVA followed  by  Bonferroni’s  post-
test was used for comparing three or more groups.  A value of p<0.05 was considered to 
be statistically significant.  
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As outlined in Chapter 1 (Section 1.2), PDEs restrict intracellular cAMP diffusion by 
degrading  the  second  messenger  to  5’-AMP, and there is increasing evidence to suggest 
that such a scheme plays a key role in the spatial and temporal control of cAMP signals 
within the cell.  The investigation into the functional roles of PDEs has been made 
possible by the introduction of broad-spectrum inhibitors that non-selectively inhibit all 
the known PDE families, such as IBMX, and selective inhibitors for individual PDE 
families, including EHNA for PDE2, Cil for PDE3 and Rol for PDE4.  Specifically, the 
use of family-selective inhibitors has allowed the functional roles of a particular PDE 
subtype to be assessed in combination with electrophysiological, biochemical and 
imaging techniques.  This has greatly enhanced our understanding of how individual 
PDEs contribute to modulating cAMP signalling. 
One drawback to the use of PDE inhibitors is the inherent difficulty in accurately 
assessing their pharmacological selectivity within an experimental system.  Although 
they are designed to be selective for each PDE subtype, it is thought that if used at too 
high a concentration, they may act to inhibit other PDE subtypes, while at too low a 
concentration, they may not be optimally effective for the targeted PDE subtype.  As 
such, using the inhibitors at an appropriate concentration constitutes an important 
experimental factor for consideration.  Another disadvantage is the fact that all the 
commercial PDE inhibitors available currently do not have the capability to distinguish 
between individual isoforms within a given PDE family.  Considering the emerging 
picture that individual PDE variants have differential, non-redundant functions, as 
delineated by methods such as PDE isoform ablation and RNA silencing, data generated 
from PDE inhibitors may not reflect the full complexity of the manner in which PDEs 
contribute to the intracellular regulation of cAMP signalling, and therefore more 
intricate delineation is often necessary.   
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Nonetheless, it must be emphasised that the use of PDE inhibitors has without any 
doubt provided some of the most important insights into the functional effects of several 
of the major cardiac PDE subtypes.  In this study, we therefore decided to use the 
inhibitors as tools for identifying the PDE subtype(s) that have a functional contribution 
to   cAMP   signalling   to   PLM   during   β-AR stimulation.  As the basal phosphorylation 
level of PLM is relatively high, this set of experiments involved using a submaximal 
[ISO] so that any effects induced by PDE inhibition in the presence of ISO could be 
observed.  
The primary aim of the experiments presented in this chapter was to characterise the 
effects of PDE inhibition on the phosphorylation status of PLM .  We hypothesised that 
inhibition of PDE2, PDE3 or PDE4 in the absence of ISO would induce no significant 
effect on the phosphorylation of PLM by either PKA or PKC.  In contrast, in light of the 
considerable evidence suggesting a key role of PDE4 isoforms in regulating cAMP 
signalling   to   a   number   of   cardiac   substrates   during   β-AR stimulation, including PLB 
and SERCA, we hypothesised that selective inactivation of PDE4 in the presence of ISO 
would significantly increase the amplitude of cAMP signals to PLM and therefore the 
phosphorylation status of PLM specifically at Ser68, the PKA consensus site.  As PDE4 
selectively degrades cAMP, we hypothesised that PDE4 inhibition would induce 
significant intracellular cAMP accumulation in both the absence and presence of ISO.  
The specific hypotheses and objectives of the studies described in this chapter are 
outlined below.   
3.1.2 Specific hypotheses 
 That pharmacological inhibition of PDE2, PDE3 or PDE4 in the absence of ISO 
would induce no effect on PLM phosphorylation at Ser68, Ser63 or Thr69 as 
basal phosphorylation appears predominantly mediated via PKC 
phosphorylation.   
 
 That pharmacological inhibition of PDE4 in the presence of a submaximal 
concentration of ISO would selectively induce a significantly increase in the 




 That pharmacological inhibition of PDE4 also influences PLB-Ser16 and cTnI-
Ser23/24 in the absence and/or presence of ISO. 
 
 That pharmacological inhibition of PDE4 in both the absence and presence of 
ISO results in significant intracellular cAMP accumulation.   
3.1.3 Specific objectives 
1. To generate a concentration response curve to a range of ISO concentrations in 
order to identify a suitable submaximal [ISO]. 
 
2. To investigate the effects of PDE2, PDE3 and PDE4 inhibition on the 
phosphorylation status of PLM-Ser68, PLM-Ser63 and PLM-Thr69 in the 
absence and presence of ISO. 
 
3. To investigate the effects of PDE4 inhibition on the phosphorylation status of 
PLB-Ser16 and cTnI-Ser23/24 in the absence and presence of ISO.   
 
4. To investigate the effects of PDE4 inhibition on total intracellular cAMP 














3.2.1 Isolation and culture of ARVMs 
The experiments in this chapter were performed using ARVMs isolated from the hearts 
of adult (250 – 300 g body weight) male Wistar rats (B & K Universal), as described in 
Chapter 2 (Section 2.3.1).  Cells were maintained in culture at 37oC/5% CO2 for 2 hr 
prior to use in biochemical experiments, as described in Section 2.3.3.2. 
3.2.2 Pharmacological treatment of ARVMs and sample preparation for SDS-
PAGE 
For generation of an individual ISO concentration-response curve for PLM 
phosphorylation using SDS-PAGE/WB, 10 concentrations of ISO were tested (1 
nmol/L, 3 nmol/L, 10 nmol/L, 30 nmol/L, 100 nmol/L, 300 nmol/L, 1 μmol/L,   3 
μmol/L, 10 μmol/L and 30 μmol/L).  For assessment of PDE2-4 inhibition on the 
phosphorylation levels of PLM, PLB and cTnI,  100  μmol/L  IBMX,  10  μmol/L  EHNA,  
10  μmol/L Cil  and  10  μmol/L  Rol  alone  or   in  combination  with   ISO,  DMSO  (vehicle  
control), 10 nmol/L ISO alone in addition to PMA (positive control) were added to 
individual wells.  Treated myocytes were incubated for 10 min at 37oC/5% CO2; the 
reactions were stopped by addition of 2x SDS sample buffer to the myocytes and the 
proteins subsequently scraped off the wells as described in Section 2.5.2.  All wells 
contained 0.1% DMSO.   
3.2.3 SDS-PAGE/Western blotting  
SDS-PAGE/WB was used to probe for phosphorylation levels of PLM-Ser68, PLM-
Ser63, PLM-Thr69, PLB-Ser16 and cTnI-Ser23/24, in addition to total actin levels, as 
described in Chapter 2 (Section 2.5).  In addition, total levels of PLM, PLB and cTnI 
were probed for to ensure equal protein loading between samples, but only total actin 
levels were used for data normalisation.  The incubation times for each of the primary 
and secondary antibodies used are listed in Tables 2.5 and 2.6 respectively. 
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3.2.4 Total intracellular cAMP enzymeimmunoassay  
3.2.4.1 Principles 
The cAMP  Biotrak™  competitive enzymeimmunoassay (EIA) system (GE Healthcare; 
catalogue number: RPN2251) enables a simple, direct measurement of total [cAMP]i to 
be made using novel lysis reagents to facilitate simple and rapid extraction of cAMP 
from cell cultures.  The requirement for traditional, time-consuming extraction 
procedures and the need for removal of extraction reagents prior to measurement are 
therefore obviated.  The assay combines the use of a peroxidase-labelled cAMP 
conjugate, a specific antiserum which can be immobilised on to pre-coated microplates, 
and a one-pot stabilised substrate solution. 
3.2.4.2 Pharmacological treatment of ARVMs and sample preparation for total 
[cAMP]i measurements  
Sample preparation for the cAMP EIA was carried out according to the manufacturer’s  
instructions.  The 96-well microplate provided (coated with donkey anti-rabbit IgG) was 
set up to enable the running of all blanks, standards and samples in duplicates as 
required.  ARVMs that have been cultured for 24 hr as described in Chapter 2 (Section 
2.3.3.2) were  treated  with  10  μmol/L  Rol in the absence and presence of 10 nmol/L ISO 
for 10 min.  Reactions were quenched through the aspiration of the culture medium 
followed by the rapid lysis/agitation and scraping  of  the  myocytes  in  100  μl  lysis buffer.  
Samples were subsequently stored on ice prior to evaluation using the cAMP EIA kit.   
3.2.4.3 Assessment of total [cAMP]i 
The cAMP EIA was  carried  out  according  to  the  manufacturer’s  instructions.  Briefly, 
all reagents were equilibrated to room temperature prior to use and the temperature was 
maintained at 4oC by incubation on crushed ice/ in refrigerator throughout the duration 
of the assay.  100  μl  of  antiserum  was  subsequently  added  to  each well of the microplate 
and the plate was incubated at 4oC for 2 hr.     This  was   followed  by   addition  of  50  μl  
cAMP-peroxidase conjugate to the wells and 1 hr incubation at 4oC.  The solutions were 
then aspirated and the wells thoroughly washed (6 x with wash buffer) and dried prior to 
the   addition   of   150   μl enzyme substrate into all wells.  The plate was left on a 
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microplate shaker for 30 min at room temperature before the reaction was halted by 
pipetting 100 μl   of   1.0   M   sulphuric   acid   into   each   well.      The   optical   density   was  
immediately determined in a microplate reader at 450 nm.   
For data processing, the mean optical density for each set of replicate wells was first 
calculated, followed by the percent bound for each standard and sample using the 
following equation: 
%B/B0 = [(standard or sample OD-NSB OD) x 100]/(zero standard OD-NSB OD) 
An 8-point standard curve was subsequently generated by plotting the% B/B0 as a 
function of the log[cAMP], which allowed the fmol/well values for each sample to be 
determined. 
3.2.5 Post-statistical analysis issues 
For a number of data sets, large increases in phosphorylation level were observed in 
response to PDE inhibitors that were nevertheless found to be not statistically 
significant.  Therefore, it was decided that changes that had a statistical significance of 
p>0.05 but < 0.1 or with a magnitude of 3-fold or greater would be referred to as having 
‘a  trend  for  a  change’ in the Results and Discussion sections of this chapter.  In addition, 
for several of these data sets, a power calculation was carried out to determine how 
many samples would theoretically be required for a change of the observed magnitude 









3.3 Results  
3.3.1 Identification of a suitable submaximal [ISO] 
To identify a suitable submaximal [ISO] for investigating the functional effects of PDE 
inhibition on PLM phosphorylation, an individual concentration response curve for 
PLM-Ser68 to a range of [ISO] was constructed.  Our decision to investigate the effects 
of ISO on PLM-Ser68 was based on the fact that it represents to date the only known 
PKA phosphorylation site on PLM,146 and our hypothesis was based on the notion that 
PDE inhibition is likely to mediate its effects on PLM phosphorylation through cAMP 
and PKA signalling.  The curve demonstrated that the relationship between [ISO] and 
the phosphorylation status at PLM-Ser68 in ARVMs is sigmoidal, with the 
phosphorylation level reaching a peak of approximately 2.5-fold increase in response to 
100 nmol/L ISO, and subsequently reaching a plateau in response to the higher ISO 
concentrations tested [Figure 3.1].  This is wholly consistent with published studies 
establishing that agonist-induced phosphorylation of PLM in rat ventricular muscle 
generally elicits only a two- to three-fold increase in phosphorylation at Ser68, 
corresponding to the relatively  high basal phosphorylation of PLM  in rat ventricular 
myocytes (~40%) in comparison with other classical cardiac proteins such as PLB.  It 
has been shown that this basal phosphorylation is mostly contributed to by PKC 
activity, consisting of a rapid turnover of phosphorylation and dephosphorylation,171 




























Figure 3.1 PLM-Ser68 phosphorylation 
levels in response to treatment with a 
range of [ISO]. 
(A) ISO concentration-response curve for 
PLM-Ser68 phosphorylation levels.  ARVMs 
were treated with a range of [ISO] (0.1 nmol/L, 
0.3 nmol/L, 1 nmol/L, 3 nmol/L, 1 nmol/L, 30 
nmol/L, 100  nmol/L,  300  nmol/L,  1  μmol/L  &  3 
μmol/L)   for   10   min   and   PLM-Ser68 
phosphorylation levels were analysed by SDS-
PAGE (15% gel) and WB analysis using an 
anti-phospho PLM-Ser68 antibody.  Addition of 
0.1% DMSO only was used as a negative 
control while positive controls comprised of 
ARVMs challenged with 50 μmol/L FRSK or 
300 nmol PMA (not shown).  ARVMs in all 
treatment groups were exposed to 0.1% 
DMSO.  Samples were subjected to 
complementary WB analysis using anti-total 
actin and anti-total PLM antibodies, to 
demonstrate equal protein loading between 
samples.  Membranes were subsequently 
stained with Coomassie Blue to demonstrate 
equal protein loading and transfer.  
Densitometry values for PLM-Ser68 were 
normalised to those for total actin and 
subsequently normalised to the control to 
generate fold values.  Data are expressed as 
means ± SEM.  (n=6)  Mean data were fitted 
with a sigmoidal concentration response curve 
(variable slope).  (B) Representative blot of 
PLM-Ser68 phosphorylation levels in response 






A suitable submaximal [ISO] was defined as a concentration of the agonist that resulted 
in an increase in PLM-Ser68 phosphorylation quantitatively large enough to be detected 
by SDS-PAGE/WB, but small enough as to provide a sufficiently large window for any 
subsequent increases induced by PDE inhibition to be detected.  After careful 
consideration, 10 nmol/L ISO was selected as the ideal submaximal concentration.  At 
this concentration, the corresponding increase in PLM-Ser68 phosphorylation was 
found to be situated at the bottom of the steep part of the curve [Figure 3.1], indicating 
that while the response was relatively small, it was quantifiable, with a 0.5-fold increase 
in PLM-Ser68 phosphorylation compared with the control that was found to be 
statistically significant [Figure 3.2; Panel A].  This helped to confirm 10 nmol/L ISO as 
a submaximal concentration   with   a   small   but   ‘real’   effect   on   PLM-Ser68 
phosphorylation rather than a subthreshold concentration.   
As discussed above, 10 nmol/L ISO was subsequently used in all biochemical PDE 
inhibition experiments; in contrast to our previous observations, we found that in these 
experiments, 10 nmol/L ISO exerted no apparent effect on the phosphorylation level of 
PLM-Ser68 [Figure 3.2; Panel B].  This discrepancy may be attributed to the presence 
of a mixture of phosphorylated and unphosphorylated PLM in the rat heart under basal 
conditions, with the phosphorylated portion being critically influenced by the adrenergic 
state of the heart when myocytes are prepared predominantly through PKC activation 
(See Chapter 1, Section 1.3.2 for reasoning).    Indeed,  ‘resting’  PLM  phosphorylation  is  
likely to vary between laboratories, and as may be the case here, even from day to day 
within the same laboratory.  In some ways, this finding was unexpected because 
previous unpublished observations from our laboratory suggested that in comparison to 
freshly-isolated myocytes, basal PLM-Ser68 phosphorylation is reduced to normal 
levels (~40%) when cultured myocytes have been allowed to recover from the stresses 
of isolation via incubation at 37oC/5% CO2 for approximately two hours (see Chapter 2; 
Section 2.3.3.2).  One would therefore have expected these cells to be accordingly more 
responsive in terms of fold changes in phosphorylation following agonist application.  
Our finding highlights how using a submaximal concentration of ISO carries with it an 
inherent danger of its relatively small effect on PLM-Ser68 phosphorylation (previously 
determined to be an approximately 50% increase) being undetectable on top of the 
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Figure 3.2 Changes in PLM-Ser68 phosphorylation level in response to treatment 
with 10 nmol/L ISO  
ARVMs were treated with 10 nmol/L ISO for 10 min in (A) individual concentration-
response curve or (B) PDE inhibition experiments and PLM-Ser68 phosphorylation 
levels were analysed by SDS-PAGE (15% gel) and WB analysis using an anti-phospho 
PLM-Ser68 antibody.  Addition of 0.1% DMSO only was used as a negative control 
while positive controls comprised of ARVMs challenged with 50 μmol/L FRSK or 300 
nmol PMA.  ARVMs in both treatment groups were exposed to 0.1% DMSO.  Samples 
were subjected to complementary WB analysis using anti-total actin and anti-total PLM 
antibodies, to demonstrate equal protein loading between samples.  Membranes were 
subsequently stained with Coomassie Blue to demonstrate equal protein loading and 
transfer.  Densitometry values for PLM-Ser68 were normalised to those for total actin 
and subsequently normalised to the control to generate fold values.  Statistical 
comparisons  were  made  using  paired  Student’s  t-test and data are expressed as means 






3.3.2 Effects of PDE2-4 inhibition on PLM-Ser68 phosphorylation in the 
absence and presence of a submaximal [ISO] 
In order to assess the functional roles of PDE2-4 in regulating PKA phosphorylation of 
PLM, ARVMs were challenged with the broad-spectrum PDE inhibitor IBMX and 
selective inhibitors for the individual PDE subtypes.  Upon treatment with the broad-
spectrum PDE inhibitor IBMX, we observed an approximately 3-fold increase in PLM-
Ser68 phosphorylation compared with control myocytes [Figure 3.3; Panel A].  
Similarly, exposure to IBMX in the presence of 10 nmol/L ISO resulted in an 
approximately 3-fold increase in phosphorylation level at this site compared with 
myocytes treated with ISO alone [Figure 3.3; Panel A].  However, these changes were 
found to be not statistically significant. 
On the other hand, treatment with the PDE2 inhibitor EHNA or PDE3 inhibitor Cil was 
found to exert no effect on PLM-Ser68 phosphorylation in both the absence and 
presence of 10 nmol/L ISO [Figure 3.3; Panels B & C].  However, selective inhibition 
of PDE4 with Rol, whilst exerting no apparent effect on PLM-Ser68 phosphorylation 
under basal conditions, was found to induce an approximately 5-fold increase in PLM-
Ser68 phosphorylation in the presence of 10 nmol/L ISO [Figure 3.3; Panel D].  This 
difference did not reach statistical significance, but did show a trend for a change (p = 

































           




Fold PLM-Ser68 phosphorylation  
Figure 3.3 PLM-Ser68 phosphorylation levels 
in response to PDE inhibition in the absence 
and presence of a submaximal [ISO]. 
ARVMs were treated with (A) 100 μmol/L  IBMX; 
(B) 10 μmol/L  EHNA;;  (C) 10  μmol/L  cilostamide  
or (D) 10   μmol/L   rolipram   alone   or   in  
combination with 10 nmol/L ISO.  Negative and 
positive controls comprised of ARVMS 
challenged with 0.1% DMSO and (E) 300 nmol/L 
PMA respectively.  ARVMs in all treatment 
groups were exposed to 0.1% DMSO.  SDS-
PAGE (15% gel) and WB analysis was used to 
analyse PLM-Ser68 phosphorylation levels 
using an anti-phospho PLM-Ser68 antibody.  All 
samples were subjected to complementary WB 
analysis using anti-total actin and anti-total PLM 
antibodies, to demonstrate equal protein loading 
between samples.  Membranes were 
subsequently stained with Coomassie Blue to 
demonstrate equal protein loading and transfer.  
Densitometry values for PLM-Ser68 were 
normalised to those for total actin and 
subsequently normalised to the DMSO control to 
generate fold values.  Statistical comparisons 
were   made   using   paired   Student’s   t-test and 
data are expressed as means ± SEM (n=8).   
**p   ≤   0.01      (F) Representative blot of PLM-
Ser68 phosphorylation levels in response to 





3.3.3 Effects of PDE2-4 inhibition on PLM-Ser68 phosphorylation under Ca-
free conditions 
The discrepancy observed between the effects of 10 nmol/L ISO on PLM-Ser68 
phosphorylation in the two sets of experiments mentioned above indicates that the mean 
basal phosphorylation of PLM in the myocytes used in the PDE inhibition experiments 
could have been higher than normal.  Since basal phosphorylation is extremely sensitive 
to the resting cellular Ca load, this carried the possibility that the discrepancy could be 
attributed to the Ca content within the cells.  Basal PLM phosphorylation can be 
substantially reduced either by lower extracellular Ca or by treating cells with 
bisindolylmaleimide (BIS) implicating the Ca-activated PKCs in this basal tone.   
This prompted us to assess the effects of PDE inhibition on PLM-Ser68 
phosphorylation in myocytes that have been cultured using a Ca-free protocol, in which 
myocytes were cultured in Ca-free  Tyrode’s  Solution  instead of standard M199 media.  
Unexpectedly, usage of this protocol did not result in an augmented response upon 
treatment with the individual PDE inhibitors.  Rather, the reduction in extracellular Ca 
seemed to have negated the effects observed in myocytes that had undergone the 
standard culturing protocol [Figure 3.4: Panels A-D].  Specifically, none of the 
inhibitors were found to induce differences in PLM-Ser68 phosphorylation under basal 
conditions; in the presence of 10 nmol/L ISO, inhibition of PDE2-4 had no effect on the 
phosphorylation level at this site.  Although inhibition of total PDEs with IBMX was 
found to exert a 2-fold increase in phosphorylation, (in contrast to the 3-fold increase in 
the previous experiment), this was found to be not statistically significant [Figure 3.4; 
Panel A].    
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Figure 3.4 PLM-Ser68 phosphorylation levels 
in response to PDE inhibition in the absence 
and presence of a submaximal [ISO] under 
Ca-free conditions.    
ARVMs cultured in Ca-free   Tyrode’s   Solution  
were treated with (A) 100 μmol/L   IBMX; (B) 10 
μmol/L  EHNA;;   (C) 10  μmol/L  cilostamide  or   (D) 
10  μmol/L  rolipram  alone  or  in  combination  with  
10 nmol/L ISO.  Negative and positive controls 
comprised of ARVMS challenged with 0.1% 
DMSO and 300 nmol/L (E) PMA respectively.  
ARVMs in all treatment groups were exposed to 
0.1% DMSO.  SDS-PAGE (15% gel) and WB 
analysis was used to analyse PLM-Ser68 and 
PLB-Ser16 phosphorylation levels using an anti-
phospho PLM-Ser68 antibody (samples were 
pre-boiled at 95oC for 10 min to remove 
pentameric PLB).  All samples were subjected to 
complementary WB analysis using anti-total 
actin and anti-total PLM antibodies, to 
demonstrate equal protein loading between 
samples.  Membranes were subsequently 
stained with Coomassie Blue to demonstrate 
equal protein loading and transfer.  
Densitometry values for PLM-Ser68 were 
normalised to those for total actin and 
subsequently normalised to the DMSO control to 
generate fold values.  Statistical comparisons 
were   made   using   paired   Student’s   t-test and 
data are expressed as means ± SEM (n=6).   
(F) Representative blot of PLM-Ser68 
phosphorylation levels in response to 
pharmacological treatment. 
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3.3.4 Effects of PDE2-4 inhibition on PLM-Ser63 phosphorylation in the 
absence and presence of a submaximal [ISO] 
Challenge with IBMX under either basal conditions or β-AR stimulation had no effect 
on PLM-Ser63 phosphorylation, even though an approximately 2-fold increase in 
phosphorylation was observed in the presence of 10 nmol/L ISO [Figure 3.5; Panel A].  
Treatment with EHNA, Cil or Rol was found to exert no effect on phosphorylation at 





































Figure 3.5 PLM-Ser63 phosphorylation levels 
in response to PDE inhibition in the absence 
and presence a submaximal [ISO].    
ARVMs were treated with (A) 100 μmol/L  IBMX; 
(B) 10 μmol/L  EHNA;;  (C) 10  μmol/L  cilostamide  
or (D) 10   μmol/L   rolipram   alone   or   in  
combination with 10 nmol/L ISO.  Negative and 
positive controls comprised of ARVMS 
challenged with 0.1% DMSO and (E) 300 nmol/L 
PMA respectively.  ARVMs in all treatment 
groups were exposed to 0.1% DMSO.  SDS-
PAGE (15% gel) and WB analysis was used to 
analyse PLM-Ser63 phosphorylation levels 
using an anti-phospho PLM-Ser63 antibody.  All 
samples were subjected to complementary WB 
analysis using anti-total actin and anti-total PLM 
antibodies, to demonstrate equal protein loading 
between samples.  Membranes were 
subsequently stained with Coomassie Blue to 
demonstrate equal protein loading and transfer.  
Densitometry values for PLM-Ser63 were 
normalised to those for total actin and 
subsequently normalised to the DMSO control to 
generate fold values.  Statistical comparisons 
were   made   using   paired   Student’s   t-test and 
data are expressed as means ± SEM (n=8).   
***p  ≤  0.001     (F) Representative blot of PLM-
Ser63 phosphorylation levels in response to 
pharmacological treatment.       
        E                                          F 
          





Fold PLM-Ser63 phosphorylation  
Chapter 3 
92 
3.3.5 Effects of PDE2-4 inhibition on PLM-Thr69 phosphorylation in the 
absence and presence of a submaximal [ISO] 
None of the PDE inhibitors tested exerted any statistically significant changes in PLM-
Thr69 phosphorylation in both the presence and absence of 10 nmol/L ISO [Figure 3.6; 
Panels A-D].  Interestingly, while the addition of IBMX induced an approximately 1.5-
fold increase in PLM-Thr69 phosphorylation under basal conditions, the 
phosphorylation level at this site was found to be reduced in the presence of 10 nmol/L 







































Figure 3.6 PLM-Thr69 phosphorylation levels in 
response to PDE inhibition in the absence and 
presence of a submaximal [ISO].    
ARVMs were treated with (A) 100 μmol/L  IBMX; 
(B) 10 μmol/L  EHNA;;  (C) 10  μmol/L  cilostamide  
or (D) 10   μmol/L   rolipram   alone   or   in  
combination with 10 nmol/L ISO.  Negative and 
positive controls comprised of ARVMS 
challenged with 0.1% DMSO and (E) 300 nmol/L 
PMA respectively.  ARVMs in all treatment 
groups were exposed to 0.1% DMSO.  SDS-
PAGE (15% gel) and WB analysis was used to 
analyse PLM-Thr68 phosphorylation levels using 
an anti-phospho PLM-Thr69 antibody.  All 
samples were subjected to complementary WB 
analysis using anti-total actin and anti-total PLM 
antibodies, to demonstrate equal protein loading 
between samples.  Membranes were 
subsequently stained with Coomassie Blue to 
demonstrate equal protein loading and transfer.  
Densitometry values for PLM-Thr69 were 
normalised to those for total actin and 
subsequently normalised to the DMSO control to 
generate fold values.  Statistical comparisons 
were   made   using   paired   Student’s   t-test and 
data are expressed as means ± SEM (n=8).      
*p  ≤  0.05    (F) Representative blot of PLM-Thr69 
phosphorylation levels in response to 
pharmacological treatment.   
       E                                        F 
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3.3.6 Effects of PDE2-4 inhibition on PLB phosphorylation  
Since PDE4 activity influences PKA phosphorylation of a number of ECC components 
in the heart, including PLB and cTnI, we decided to investigate the effect of PDE4 
inhibition on the phosphorylation status of PLB-Ser16, as well as that of cTnI-Ser22/23.  
As mentioned in Chapter 1 (Section 1.3.2), Ser16 represents the primary PKA 
phosphorylation site on PLB and has been reported to be sufficient in mediating the 
latter’s  maximal  cardiac  responses  to  β-agonists.165  Similarly, cTnI-Ser22/23 represents 
another established PKA phosphorylation target in the rodent heart, and 
phosphorylation of these serine residues leads to a reduction of myofilament Ca 
sensitivity and shifts the force-pCa relationship rightwards.256,257   
PLB-Ser16 phosphorylation was augmented by a statistically significant margin 
(approximately 40-fold compared with control mycoytes) in response to treatment with 
IBMX [Figure 3.7; Panel A], while also exerting a 2-fold increase in the presence of 10 
nmol/L ISO [Figure 3.7; Panel A].  Treatment with EHNA or Rol also significantly 
increased PLB-Ser16 phosphorylation (approximately 2-3-fold compared with control 
myocytes) [Figure 3.7; Panels B & D], but quantitatively comparable responses were 
observed when the inhibitors were added in the presence of 10 nmol/L ISO [Figure 3.7; 
Panels B & D].  The effect of Cil on PLB-Ser16 phosphorylation was augmented in the 
presence of ISO but the inhibitor did not significantly increase phosphorylation at this 




































Figure 3.7 PLB-Ser16 phosphorylation levels 
in response to PDE inhibition in the absence 
and presence of a submaximal [ISO].   
ARVMs were treated with (A) 100 μmol/L  IBMX; 
(B) 10 μmol/L  EHNA;;  (C) 10  μmol/L  cilostamide  
or (D) 10   μmol/L   rolipram   alone   or   in  
combination with 10 nmol/L ISO.  Negative and 
positive controls comprised of ARVMS 
challenged with 0.1% DMSO and (E) 300 nmol/L 
PMA respectively.  ARVMs in all treatment 
groups were exposed to 0.1% DMSO.  SDS-
PAGE (15% gel) and WB analysis was used to 
analyse PLB-Ser16 phosphorylation levels using 
an anti-phospho PLB-Ser16 antibody.  All 
samples were subjected to complementary WB 
analysis using anti-total actin and anti-total PLB 
antibodies, to demonstrate equal protein loading 
between samples.  Membranes were 
subsequently stained with Coomassie Blue to 
demonstrate equal protein loading and transfer.  
Densitometry values for PLB-Ser16 were 
normalised to those for total actin and 
subsequently normalised to the DMSO control to 
generate fold values.  Statistical comparisons 
were   made   using   paired   Student’s   t-test and 
data are expressed as means ± SEM (n=7).   
*p  ≤  0.05; ***p ≤ 0.001  (F) Representative blot 
of PLB-Ser16 phosphorylation levels in 
response to pharmacological treatment.     
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3.3.7 Effects of PDE2-4 inhibition on PLB-Ser16 phosphorylation under Ca-
free conditions  
In contrast to PLM-Ser68 phosphorylation, it was found that the effects of IBMX 
treatment on PLB-Ser16 phosphorylation under Ca-free conditions was augmented, with 
profound increases at this site in both the absence and presence of 10 nmol/L ISO 
(approximately 500- and 5-fold increases) [Figure 3.8; Panel A].  Similarly, addition of 
Rol significantly increased basal PLB-Ser16 phosphorylation (approximately 100-fold 
increase) but in this case, also led to a statistically significant effect under β-AR 
stimulations (approximately 5-fold increase) [Figure 3.8; Panel D].  On the other hand, 
challenge with EHNA did not result in a statistically significant change in basal PLB-
Ser16 phosphorylation, in contrast to our observations under Ca-containing conditions 
[Figure 3.8; Panel B].  Indeed, both EHNA and Cil did not significantly alter PLB-







































Figure 3.8 PLB-Ser16 phosphorylation levels 
in response to PDE inhibition in the absence 
and presence of a submaximal [ISO] under 
Ca-free conditions.    
ARVMs cultured in Ca-free   Tyrode’s   Solution  
were treated with (A) 100 μmol/L   IBMX; (B) 10 
μmol/L  EHNA;;   (C) 10  μmol/L  cilostamide or (D) 
10  μmol/L  rolipram  alone  or  in  combination  with  
10 nmol/L ISO.  Negative and positive controls 
comprised of ARVMS challenged with 0.1% 
DMSO and 300 nmol/L PMA  (E) respectively.  
ARVMs in all treatment groups were exposed to 
0.1% DMSO.  SDS-PAGE (15% gel) and WB 
analysis was used to analyse PLM-Ser68 and 
PLB-Ser16 phosphorylation levels using an anti-
phospho PLM-Ser68 antibody (samples were 
pre-boiled at 95oC for 10 min to remove 
pentameric PLB).  All samples were subjected to 
complementary WB analysis using an anti-total 
actin and anti-total PLB antibodies, to 
demonstrate equal protein loading between 
samples.  Membranes were subsequently 
stained with Coomassie Blue to demonstrate 
equal protein loading and transfer.  
Densitometry values for PLM-Ser68 were 
normalised to those for total actin and 
subsequently normalised to the DMSO control to 
generate fold values.  Statistical comparisons 
were   made   using   paired   Student’s   t-test and 
data are expressed as means ± SEM (n=6). 
*p  ≤  0.05; **p  ≤  0.01  (F) Representative blot of 
PLM-Ser68 phosphorylation levels in response 
to pharmacological treatment. 
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3.3.8 Effects of PDE2-4 inhibition on cTnI-Ser22/23 phosphorylation 
cTnI-Ser22/23 phosphorylation was found to be increased in response to addition of 
IBMX in the absence of ISO (approximately 75- fold increase ), although this was not 
observed in the presence of ISO[Figure 3.9; Panel A].  Challenge with EHNA did not 
exert any effect on basal cTnI-Ser 22/23 phosphorylation, although the effect of ISO 
was found to be decreased in the presence of EHNA.  This difference was found to be 
not statistically significant, although there was a trend for a change (p = 0.0873) [Figure 
3.9; Panel B].   
Treatment with Cil was found to exert an increase in cTnI-Ser22/23 phosphorylation 
level under both basal conditions and β-AR stimulation (approximately 30- and 270-
fold increases respectively) [Figure 3.9; Panel C], while addition of Rol resulted in 
similarly increased phosphorylation levels at this site under both basal and ISO-
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Figure 3.9 cTnI-Ser22/23 phosphorylation 
levels in response to PDE inhibition in the 
absence and presence of a submaximal 
[ISO].   
ARVMs were treated with (A) 100 μmol/L  IBMX; 
(B) 10 μmol/L  EHNA;;  (C) 10  μmol/L  cilostamide  
or (D) 10   μmol/L   rolipram   alone   or   in  
combination with 10 nmol/L ISO.  Negative and 
positive controls comprised of ARVMS 
challenged with 0.1% DMSO and 300 nmol/L 
PMA (E) respectively.  ARVMs in all treatment 
groups were exposed to 0.1% DMSO.  SDS-
PAGE (15% gel) and WB analysis was used to 
analyse cTnI-Ser22/23 phosphorylation levels 
using an anti-phospho cTnI-Ser22/23 antibody.  
All samples were subjected to complementary 
WB analysis using anti-total actin and anti-total 
cTnI antibodies, to demonstrate equal protein 
loading between samples.  Membranes were 
subsequently stained with Coomassie Blue to 
demonstrate equal protein loading and transfer.  
Densitometry values for cTnI-Ser22/23 were 
normalised to those for total actin and 
subsequently normalised to the DMSO control to 
generate fold values.  Statistical comparisons 
were   made   using   paired   Student’s   t-test and 
data are expressed as means ± SEM (n=5).   
(F) Representative blot of cTnI-Ser22/23 
phosphorylation levels in response to 
pharmacological treatment. 
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3.3.9 Generation of standard curve for total [cAMP]i measurements 
To obtain further insights into the mechanism of action underlying PDE4 inhibition, we 
examined its effect on total [cAMP]i in ARVMs.  The standard curve depicted in Figure 
3.10 is illustrative of the cAMP EIA measurements carried out for this chapter.  As a 
result of the complete lysis of the samples prior to measurement with the EIA system, 
the increase in total [cAMP]i within the cell could be detected.  
   












Figure 3.10  Representative standard curve generated for total intracellular [cAMP] 
measurements. 
Identification of total intracellular cAMP levels regulated by PDE4 activity was measured 
via inhibition using rolipram.  Known standards (12.5, 25, 50, 100, 200, 400, 800, 1600 
and 3200 fmol) were added to individual wells, and a standard curve was generated by 
plotting the percent bound for each standard as a function of the log cAMP 
concentration per well (See Section 3.2.4.3 for equation).  Similarly, the percent bound 
for each sample was calculated and the fmol/well value could subsequently be 






3.3.10 Effects of PDE4 inhibition on total [cAMP]i 
As depicted in Figure 3.11, the total [cAMP]i in ARVMs was significantly augmented 
upon treatment with Rol in both the absence and presence of ISO when compared with 
the DMSO control and 10 nmol/L ISO respectively. 
 









Figure 3.11 Total intracellular cAMP concentration in response to PDE4 inhibition 
in the absence and presence of a submaximal [ISO].   
ARVMs  were   treated  with  0.1%  DMSO,  10  nmol/L   ISO,  10  μmol/L  Rol  and  10  μmol/L  
Rol in combination with 10 nmol/L ISO for 10 min and total [cAMP]i was analysed using 
the   cAMP   BiotrakTM   Enzymeimmunoassay   System   according   to   the   manufacturer’s  
instructions.   All treated myocytes were exposed to 0.1% DMSO.  Measurements were 
taken in duplicate. Statistical comparisons were made  using  paired  Student’s  t-test and 
data are expressed as means ± SEM (n=6).  *p ≤ 0.05   The fmol/well value of samples 









3.4 Discussion  
There is now considerable evidence indicating a key role of PDEs in tailoring specific 
cAMP signals to control PKA phosphorylation of individual cardiac proteins in 
response  to  β-AR stimulation (See Chapter 1; Section 1.2.4).  In our study, we used the 
broad-spectrum PDE inhibitor IBMX as well as the family-selective PDE inhibitors 
EHNA, Cil and Rol to assess the respective roles of PDE2-4 in the regulation of cAMP 
signalling to PLM under both basal conditions   and   during   β-AR stimulation.  
Specifically, we compared the effects of selective PDE inhibition on PLM 
phosphorylation status at the three consensus sites on the protein: Ser68, Ser63 and 
Thr69. 
The vast majority of studies on PDE function in the heart have been carried out in 
myocytes isolated from the rat or mouse heart.  The PDE-inhibition experiments in our 
study were carried out exclusively in ARVMs because as described in Chapter 2 
(Section 2.2.1), the adult rat heart produces a consistently greater cell yield when 
compared to the adult mouse heart; additionally, the individual myocytes are generally 
more resistant to apoptosis in comparison with the latter.  These features assist in the 
generation of a more robust response as detected by WB.  Despite the relative activity of 
individual PDE families being similar between ARVMs and NRVMs, we opted to use 
myocytes from the adult rat heart as opposed to its neonatal counterpart for practical 
reasons. 
As with any pharmacological inhibitors, the relative selectivity of the commercial PDE 
inhibitors is highly dependent on the concentrations at which they are used.  A possible 
limitation of the present study is the reliance on pharmacological inhibitors to analyze 
the mechanisms involved in PDE inhibition-induced consequences.  For our 
experiments, we selected the optimal working concentrations of the PDE inhibitors 
based on the literature.  IBMX, EHNA, Cil and Rol are undoubtedly among the most 
frequently used agents for inactivating total PDEs, PDE2, PDE3 and PDE4 respectively 
(see Chapter 2; Section 2.4) .  Several internationally-renowned groups within this field, 
including those led by Manuela Zaccolo and Rudolph Fischmeister, have carried out a 
large number of comparable PDE inhibition experiments using IBMX at 100 μmol/L, 
and the family-selective inhibitors at 10 μmol/L.43,59,65,83  We were aware that Cil and 
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Rol have been used at a lower concentration (25 nmol/L – 1  μmol/L) in some studies; 
however, the majority of published data are derived from experiments using these 
particular family-selective inhibitors at 10 μmol/L.  To quantitatively confirm the 
selectivity of the compounds, we calculated their relative selectivity for the individual 
PDEs based on their estimated inhibition constant (Ki) values.  Therefore, at the 
concentrations used herein these pharmacological compounds have been widely used 
and probed to be valid tools; however, as with any pharmacological agents, the 
possibility of undesired non-selective effects cannot be completely ruled out.   
Table 3.1 Relative selectivity of PDE inhibitors for PDEs 2-4 used in experiments.       
Inhibitor Inhibition constant (Ki) (μmol/L) 
 PDE2 PDE3 PDE4 
IBMX 0.50 0.18 1.00 
EHNA ≤  0.01 1.00 1.00 
Cilostamide 0.19 5.25x10-4 1.00 
Rolipram 1.00 1.00 3.80 x 10-3 
 
Our hypotheses were based on the assumption that PDEs are involved in the regulation 
of  cAMP  signalling  to  PLM  specifically  during  β-AR stimulation.  In order to stimulate 
the  β-AR pathway in ARVMs, we used the classical non-selective  β-AR agonist ISO in 
our experiments.  For any effect of PDE inhibition in the presence of ISO on PLM to be 
observed,  the  effect  of  ISO  alone  must  be  minimal  as  to  provide  as  large  a  ‘window’  as  
possible in order for further increases in the level of PLM phosphorylation to be 
detected.  As such, we generated a concentration-response curve to quantify the 
phosphorylation status at PLM-Ser68 in response to a range of [ISO].  This allowed us 
to determine the submaximal concentration of the agonist (10 nmol/L) that produced a 
response situated at the bottom of the steep part of the curve.   
In our PDE inhibition experiments, we found that 10 nmol/L ISO selectively induced a 
small increase in PLM-Ser68 phosphorylation level.  This observation is consistent with 
previous work in our laboratory demonstrating that 10 nmol/L ISO could induce 
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increases in PLM-Ser68 phosphorylation, although the differences were not statistically 
significant (unpublished data).  This suggests that at 10 nmol/L, ISO is sufficient to 
increase the activity of AC localised in membrane to bring the cAMP concentration 
above threshold for cAMP-dependent phosphorylation of PLM at Ser68.  The effect of 
this submaximal concentration of ISO on PLM-Ser68 was more modest in comparison 
with those on PLB-Ser16 and cTnI-Ser22/23.   
There are at least two potential explanations for this.  One is that the basal level of 
PLM-Ser68 of the ARVMs used in our experiments was higher than that of PLB and 
cTnI, which made it more difficult to augment with a low [ISO], as addressed earlier  
The other possibility is that PLM, PLB and cTnI are located in distinct compartments 
within the cell, and therefore are differentially regulated by distinct pools of cAMP and 
PKA.  Hence addition of ISO would not induce an equal effect on the phosphorylation 
levels of these proteins, as activation of the β-AR system might not have induced 
identical changes in cAMP-PKA signalling within these compartments.  Thus our 
findings may reflect a compartmentalised model of cAMP/PKA signalling, which 
would be entirely consistent with data generated with cAMP sensors reported in the 
literature, and which we have attempted to address in Chapter 5.      
As described in Chapter 1 (Section 1.3.2), PLM-Ser68 phosphorylation in ARVMs has 
been estimated by our group to be ~40% at rest.146  In practice, this value is likely to be 
significantly higher immediately after myocyte isolation due to the activation of stress 
kinases initiated by the isolation procedure, as described in Chapter 2 (Section 2.3).  
Unpublished findings from our group suggest that culturing myocytes for 2 hr at 35oC 
consistently decreases PLM-Ser68 phosphorylation to a stable level of approximately 
40% compared to freshly-isolated cells by reducing PKC phosphorylation of PLM-
Ser68 induced by Ca.  We therefore opted to culture ARVMS in Ca-containing medium 
for at least 2 hr prior to their use in PDE-inhibition experiments.  In consideration of 
these preliminary findings, this duration of culture suggests that basal PLM-Ser68 
phosphorylation   in   our   experiments   was   physiologically   ‘normal’   and   comparable to 
that measured in vivo, and therefore sufficiently low for experimentally investigating 
increases in the phosphorylation level at this site upon treatment of ARVMs, as 
confirmed by treatment with a maximal concentration of PMA.  A 24 hr culturing 
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period could potentially further reduce PLM-Ser68 phosphorylation, although our group 
had previously found no significant differences between the two durations of culture on 
PLM-Ser68 phosphorylation.   
It is therefore logical that the PKA phosphorylation of PLM-Ser68  basal PLM-Ser68 
phosphorylation could theoretically be further reduced by incubation in Ca-free media, 
and this has been previously by our laboratory to be the case, even if this may be 
unrepresentative of the normal physiological situation.  However, in these experiments, 
the Ca-free protocol did  not  seem  to  enhance  the  phosphorylation  ‘window’  for  PLM-
Ser68.   We found that this lack of Ca-driven effect on basal PLM-Ser68 
phosphorylation surprising, since the removal of Ca and the resulting decrease in PKC 
phosphorylation under basal conditions imply that any PKA-mediated effects would be 
more readily observed.  We considered the possibility that the Ca removal protocol 
failed to work, although the augmented effects of IBMX and rolipram on PLB-Ser16 
phosphorylation in the presence of ISO under Ca-free conditions as compared to Ca-
containing conditions point to a possible reduction of basal PLB-Ser16 phosphorylation.  
Thus it remains unclear as to why this reduction in Ca concentration within the culture 
medium did not also result in a reduced PLM-Ser68 phosphorylation under basal 
conditions.  The most likely explanation is that the removal of Ca was not sufficient to 
adequately reduce basal PKC phosphorylation of PLM-Ser68, and theoretically, also at 
Ser63 and Thr69.  One can only assume that the basal PKC phosphorylation of these 
sites was higher than ideal under our experimental conditions.   
Investigating the effects of PDE inhibition on top of a submaximal concentration of ISO 
has been attempted previously.59,83  As mentioned in Section 3.2.5, a recurring feature 
of my findings in this chapter is that many observed effects of the PDE inhibitors in the 
presence of ISO stimulation, in particular those with   IBMX  and  rolipram,  are  large  (≥  
3x) and/or close to statistical significance (p > 0.05 but < 0.1) but found to be not 
statistically significant.  As such, I have referred to such differences as ‘displaying a 
trend towards an increase’ throughout this chapter.  A potential explanation for this is 
the large discrepancy between responses across the sample group.  Therefore, a power 
calculation was carried out for these data points to determine the maximum number of 
samples that would theoretically be required for a difference of this magnitude to be 
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statistically significant.  From this, we estimated that statistical significance should be 
achieved if the sample number is doubled. 
Our finding that treatment with IBMX induced a trend for an in increase in basal PLM-
Ser68 phosphorylation suggests that in our preparations, there was a substantial basal 
activity of AC that determined a basal cAMP synthesis, and that there was a significant 
basal PDE activity which limits the degree of cAMP-dependent phosphorylation of 
PLM.   
In contrast, treatment of ARVMS with EHNA, Cil or Rol were found to induce no 
significant effect on basal PLM-Ser68 phosphorylation, suggesting that inhibition of a 
single cardiac PDE subtype is insufficient to raise intracellular cAMP concentration to 
the threshold concentration necessary for PLM phosphorylation.  The likely explanation 
for this finding is that other PDE subtypes accounted for cAMP hydrolysis under basal 
conditions, with the individual PDEs possessing sufficient enzymatic activity to fully 
hydrolyse the cAMP produced by the basal activity of ACs.  This suggests a scenario 
whereby PLM phosphorylation in quiescent ARVMs is regulated by PDE subtypes 2-4 
functioning in tandem, with the rate of cAMP turnover being low enough such that the 
activity of the individual PDE subtypes becomes functionally redundant.   
Interestingly, it has been reported that basal PDE4 activity is not as prominent in adult 
rodent myocytes (~40%) and is closely matched by that of PDE3 (~30%), while PDE2 
activity is significantly lower.35,69  On addition of EHNA, it could therefore be 
conjectured that PDE2 activity is easily compensated for by the activities of PDE3 
and/or PDE4.  On the other hand, our data suggest that upon treatment with Cil, PDE4 
activity had to be increased by at least two-fold in order to compensate for the absence 
of PDE3 activity, and vice versa on the addition of Rol.  To test this idea of functional 
redundancy of different PDE subtypes, there is the possibility in future experiments to 
inhibit the activity of two PDE subtypes simultaneously using combinations of PDE 
inhibitors and observe their effects on PLM-S68 phosphorylation.  Considering that 
PDE2 activity is significantly less than that of PDE3 and PDE4 in the rat heart, it is 
tempting to speculate from the above that the concomitant inhibition of PDE3 and 
PDE4 would result in a significant increase in the phosphorylation status of PLM-S68, 
although we currently have no direct evidence to confirm this.   
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In contrast, inhibition of PDE4 was found to selectively exert a pronounced stimulation 
of PLM-Ser68 phosphorylation after application of 10 nmol/L ISO, with the effect 
being very close to being statistically significant.  This enhancement was not observed 
upon treatment with EHNA or Cil, suggesting that PDE4 is the predominant PDE 
subtype  involved  in  regulating  cAMP  signalling  to  PLM  during  β-AR stimulation.  Thus 
while a functionally redundant hydrolytic system comprised of PDE2-4 may serve to 
prevent intracellular cAMP from rising immoderately to exert an effect on PLM-Ser68 
phosphorylation in the absence of NA, PDE4 becomes determinant in regulating PLM-
Ser68 phosphorylation when   the   cell   is   challenged  by   a   stimulus   activating   the  β-AR 
pathway.  Importantly, this effect was found to be quantitatively greater than that 
induced by IBMX in combination with ISO, which is unexpected considering the notion 
that PDEs 2-4 represent the main PDE subtypes in the heart, and that IBMX should 
inhibit all the known PDE isoforms.  As such, one would expect the effect of IBMX to 
be quantitatively equal to that induced by the sum of EHNA, cilostamide and rolipram.  
As addressed earlier, comparing the effects of different pharmacological inhibitors is 
highly dependent on the concentration at which they are used, and considering the 
prominent effect of rolipram, it is possible that IBMX might not have been inhibiting 
PDE4 to an equal degree, and therefore any residual PDE4 activity could have reduced 
the overall effect of IBMX.  Similarly, it is possible that there are PDEs present in the 
cell whose activities are not affected by IBMX.  Admittedly, these two scenarios are 
highly unlikely given the standard use of IBMX as a non-selective PDE inhibitor and 
our current understanding of cardiac PDE subtypes.  It is also possible that the 
discrepancies observed may reflect differences in permeability levels of these PDE 
inhibitors, or could be attributed to different levels of sensitivity of the cells to the 
inhibitors.  However, these would imply that a fair comparison between these PDE 
inhibitors cannot be made and the multitude of published studies investigating the 
effects of these inhibitors in cohort refutes this.  The most plausible explanation could 
well be due to intra-sample discrepancy.  However, as mentioned earlier, power 
calculations suggest that the observed effects of IBMX and rolipram are likely to reflect 
genuine changes, and it is possible that when the number of samples is doubled (i.e. n = 
12), the changes induced by these two inhibitors may match each other more closely.   
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When considering the manner in which cardiac contractility is regulated and maintained 
upon sympathetic activation, it is interesting to note some of the similarities that PLM 
shares with PLB and cTnI from both a regulatory and functional viewpoint.  The former 
is underlined by their specific dependency on PKA in determining their phosphorylation 
status  during  β-AR activation.  Meanwhile, the latter could be attributed to the indirect 
role of PLM in maintaining optimum [Ca]i and hence cardiac contractility in synergy 
with the ECC proteins, a reflection of the interplay between Na and Ca transport within 
the cardiac myocyte. Intriguingly, while PDE2-4 inhibition was found to exert little 
effect on basal phosphorylation levels of PLM-Ser68, PLB-Ser16 phosphorylation was 
found to be significantly increased in response to treatment with IBMX, or with either 
EHNA or rolipram when under Ca-free conditions.  Similarly, a trend for an increase in 
cTnI-Ser22/23 phosphorylation was observed in response to inhibition of PDE3 or 
PDE4. 
Indeed, selective PDE4D gene deletion in the mouse myocardium was found to result in 
increased basal PLB phosphorylation,87 and our findings are also consistent with a 
previous report concluding that PLB-Ser16 phosphorylation level is augmented upon 
the combined inhibition of PDE3 and PDE4 (because the authors found that the effect 
could only be obtained by the addition of Cil and Rol in combination).258  Likewise, it 
has been shown that cTnI-Ser22/23 phosphorylation may also be modulated by PDE3 
and PDE4,258 and that these PDE families are responsible for regulating basal ICa,L in 
ARVMs, with PDE4 becoming predominantly involved in the control of the LTTC 
during  β-AR stimulation.59   
Our findings raise the possibility that for proteins with an intrinsically lower basal 
phosphorylation level, individual PDE subtypes may be determinant in regulating their 
phosphorylation status as they are able to sufficiently raise intracellular cAMP levels 
above the threshold.  This may also explain why the effects of total PDE inhibition with 
IBMX is apparently more pronounced than observed with PLM-Ser68 phosphorylation. 
However, our findings may also reinforce the notion that PDEs may regulate different 
PKA substrates in distinct ways, reflecting a possible effect of cAMP 
compartmentalisation.  Thus the functional redundancy underlying PLM-Ser68 
phosphorylation may reflect the intrinsically high phosphorylation level of the protein 
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under basal conditions and/or differential regulation of individual PKA substrates by 
PDEs.   
Under ISO-stimulated conditions, the picture is less clear.  The pattern of PDE 
inhibition in the presence of ISO for PLB-Ser16 seems to largely correspond with  that 
for PLM-Ser68.  Under Ca-free conditions, addition of IBMX or rolipram in 
combination with ISO was found to significantly augment PLB-Ser16 phosphorylation, 
and despite the lack of statistical significance, we obtained a similar pattern of response 
with PLM-Ser68 phosphorylation under Ca-containing conditions.  It must be 
emphasised that the mechanism underlying the more pronounced increases in PLB-
Ser16 phosphorylation upon addition of IBMX or rolipram observed under Ca-free 
condition remains unclear.  While we hypothesised that a removal of Ca would reduce 
basal PKC phosphorylation of PLM-Ser68, we expected this protocol to induce no 
effect on PLB-Ser16 phosphorylation, since there are no published reports to date 
suggesting a regulation of the latter via PKC phosphorylation.  Interestingly, PLB is 
also phosphorylated by CamKII (at Thr17), which is Ca-dependent, and the question 
remains whether the Ca-free protocol could have altered the basal PLB-Ser16 
phosphorylation via a mechanism involving CamKII phosphorylation?   
Meanwhile, it is difficult to draw firm conclusions from the effects of PDE inhibition on 
cTnI-Ser22/23 in the presence of ISO.  We observed no changes in phosphorylation at 
this site upon treatment with IBMX, and while the addition of cilostamide or rolipram 
resulted in approximately two-fold increases, they could not be regarded as trends 
towards an increase and may not represent genuine changes.  Interestingly, for both 
PLB-Ser16 and cTnI-Ser22/23, addition of EHNA in the presence of ISO was observed 
to reduce phosphorylation level at this site, which could potentially be attributed to a 
cGMP-mediated effect.  As aforementioned, besides inhibiting PDE2, EHNA is also a 
potent inhibitor of adenosine deaminase.  It has been suggested that this mechanism 
could potentially result in an accumulation of intracellular cGMP.  As  detailed in 
Chapter 1 (Section 1.2.4), an increase in [cGMP] leads to a greater rate of cAMP 
hydrolysis by PDE2, and it is therefore possible that inhibition of adenosine deaminase 
underlies the observed decreased phosphorylation of cTnI-Ser22/23 observed in the 
presence of EHNA and ISO.  Future experiments could directly address the changes in 
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intracellular [cGMP] in response to addition of EHNA, which may clarify this potential 
limitation of using the latter as a PDE2 inhibitor.    
From the findings discussed so far, it could be envisaged that the distinct effects of ISO 
and of the individual PDE inhibitors on basal phosphorylation of PLM, PLB and cTnI 
may not only reflect different levels of basal protein phosphorylation, but also possibly 
a scenario whereby the PDEs 2-4 are regulating cAMP signalling to these PKA 
substrates in a differential manner.  During β-AR stimulation, PDE4 becomes primarily 
responsible for regulating cAMP signals to PLM and PLB (and possibly for cTnI, 
although this remains unclear).   
However, there is also the possibility (which happens to constitute the simplest 
explanation for our findings) that our observed patterns of PLM-Ser68 phosphorylation 
may simply reflect the total intracellular activity of PDE2-4 in ARVMs rather than 
compartmentalised cAMP signalling.  It has been suggested that PDE4 isoforms may 
collectively regulate bulk cAMP levels within the rodent heart;69 since PDE4 activity 
represents the dominant fraction quantitatively in the rodent heart,65,69,92 the fact that it 
induces a prominent effect on the phosphorylation levels of PLM, PLB and cTnI may 
therefore be simply be reflecting its high levels of abundance.  On the other hand, the 
low relative activity of PDE2 in ARVMs92 could potentially limit its effects on 
downstream targets.  Such a model is likely to be overly simplistic, however, given our 
observations that PDE2, PDE3 and PDE4 seem to differentially regulate PLM-Ser68, 
PLB-Ser16 and cTnI-Ser23/24 phosphorylation levels, as detailed earlier.   Our results 
therefore suggest that the regulation of cAMP signalling to cardiac proteins by PDEs is 
highly multifaceted and complex, and PDEs may contribute to the regulation of cAMP 
signalling to a number of cardiac proteins in a differential manner.  
Our finding that PDE4 inhibition resulted in an increase in total [cAMP]i is consistent 
with our current understanding of how PDE4 regulates cardiac cAMP signalling.  Under 
normal circumstances, cAMP-PDEs continually hydrolyse cAMP; inhibition of their 
activity should therefore result in an immediate and significant increase in global cAMP 
levels inside the cell.  Since PDE4 activity comprises the predominant cAMP-hydrolytic 
fraction in the rodent heart, its inactivation is therefore expected to lead to a 
significantly accumulation of cAMP within the cell.  It is interesting to note that this 
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increase in cAMP did not translate into a significant augmentation of PLM-Ser68 
phosphorylation.  There remains some controversy surrounding the basal [cAMP]i in the 
rodent heart.  It has been demonstrated using a cytosolic cAMP sensor that the basal 
concentration of total cAMP in intact guinea pig ventricular myocytes could be as high 
as 1.2   μmol/L.133  On the other hand, traditional radioimmunoassay (RIA) 
measurements in mouse ventricular myocytes have shown that basal [cAMP]i is in the 
fmol range and that 10   μmol/L Rol induced a 2.5-fold increase in total cAMP levels 
after 10 min.68  At the same time-point, we observed a comparable increase of 
approximately 2-fold in cAMP accumulation, in line with the possibility that basal 
PDE4 activity is often greater in neonatal rodent myocytes (~60%).68,83   
Our results additionally provide clues into the downstream mechanisms of cAMP.  The 
effect exerted on PLM phosphorylation by PDE4 inhibition seems to be specifically 
modulated via the actions of PKA, as treatment of Rol in the presence of ISO did not 
lead to an augmented phosphorylation level of PLM-Ser63 or PLM-Thr69, the 
consensus PKC sites on PLM.  This suggests that PKA plays a key role in the regulation 
of cAMP signalling to PLM by PDE2-4  under  basal  conditions  as  well  as  during  β-AR 
stimulation .  PKA is a major cardiac effector of cAMP and one would therefore expect 
its inactivation to completely abolish any cAMP-mediated signals.  Indeed, our findings 
are consistent with imaging experiments using the AKAR PKA probe confirming the 
functional influence of PDE4 inhibition on PKA activity.44  The role of PKA in 
regulating the activities of PDEs themselves should also be considered, as PKA 
phosphorylation has been shown to increase the activities of PDE3A259and the long 
PDE4 isoforms,57,109 suggesting that PKA activity could serve as a negative feedback 
regulator on PDE4 to   functionally   ‘match’   PDE   activity   to   the   intracellular cAMP 
concentration.  Since PDE4 inhibition induced such a dramatic effect on PLM 
phosphorylation in the presence of ISO, this implies that PDE4 activity is highly 
pronounced   during   β-AR stimulation, consistent with the notion that PKA 
phosphorylation of several long PDE4 isoforms could potentially increase their activity 
by up to 60%,109 and therefore cannot be compensated for by the activities of the 
remaining PDEs.  On the whole, our findings are consistent with the notion that PDE4 is 
cAMP-specific and therefore selectively influences downstream PKA signalling. 
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In conclusion, the work described in this chapter suggests that in the adult rodent heart, 
PDE4 becomes functionally important specifically in response to stimulatory hormones.  
Overall, these findings support our model of PDE4-mediated PKA phosphorylation of 
PLM; under basal conditions, the combined activities of PDE3 and PDE4 (and possibly 
PDE2) are required to regulate basal PKA phosphorylation of PLM in a functionally 
redundant manner, possibly due to the high basal phosphorylation level of PLM.  The 
latter could be further explored in future experiments whereby  the effects of combined 
PDE inhibition are investigated.   On the other hand,  upon  β-AR activation, our findings 
suggest that PDE4 becomes determinant in regulating cAMP signalling to this protein, 
as supported by intracellular cAMP measurements.  Intriguingly, this pattern of PDE 
regulation contrasts with those for PLB and cTnI, suggesting that PDE4 plays extensive 
yet differential roles in the regulation of cAMP signalling in the rodent heart.  Together, 
our data have revealed insights into the regulation of PLM phosphorylation by PDE4 
under neurohormonal stimulation.    
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In the previous chapter, we presented data suggesting a specific role of PDE4 in 
regulating PKA phosphorylation of PLM-Ser68   during   β-AR stimulation.  It is now 
generally accepted that PLM serves as the functional link between kinase activation and 
NKA activity upon sympathetic stimulation, with PKA phosphorylation at PLM-Ser68 
mediating the increase in NKA activity.  As mentioned in Chapter 1 (Section1.4.3), 
such a scheme has been hypothesised to be physiologically important in limiting the 
detrimental effects of Na (and indirectly Ca) overload  upon  β-AR stimulation.  Given 
the well-characterised functional association between PLM and NKA, we proceeded to 
use whole-cell VPC to investigate the functional impact of PDE inhibition on NKA 
activity.  
We hypothesised that changes in NKA activity upon PDE inhibition would correspond 
to the pattern of PLM phosphorylation, with inactivation of PDE2, PDE3 or PDE4 
under basal conditions having little effect on Ip density while in the presence of ISO, 
pharmacological inhibition of PDE4 would lead to a significant increase in NKA 
activity.  This series of experiments would shed further light onto the functional 
association between PLM and the NKA, in addition to the role of PDE4 in the 
regulation of downstream cAMP targets in the heart.  The specific hypotheses and aims 
of the studies described in this chapter are outlined below.   
4.1.2 Specific hypotheses 
 That pharmacological inhibition of PDE2, PDE3 or PDE4 in the absence of ISO 
would induce no significant effect on Ip.   
 
 That pharmacological inhibition of PDE4 in the presence of a submaximal 
concentration of ISO would selectively induce a significant increase in Ip.   
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4.1.3 Specific objectives 
1. To generate a concentration response curve to a range of ISO concentrations in 
order to identify a suitable submaximal [ISO]. 
 
2. To investigate the effects of PDE2, PDE3 and PDE4 inhibition on Ip in the 


















4.2.1 Isolation and culture of ARVMs 
The experiments in this chapter were performed using ARVMs isolated from the hearts 
of adult (250 – 300 g body weight) male Wistar rats (B & K Universal), as described in 
Chapter 2 (Section 2.2.1) Cells were maintained in suspension at 35oC for 2 hr prior to 
use in electrophysiological experiments, as described in Section 2.3.3.2. 
4.2.2 Voltage-patch-clamping 
4.2.2.1 Principles 
In 1952, prior to the discovery of ion channels and ion transport mechanisms, Hodgkin 
and Huxley used crude glass electrodes to record Em in squid giant axon.260-262  The 
development of voltage-clamp unfolded in an almost contemporary manner,263 although 
the application of voltage-clamp in single cells using micropipettes for intracellular 
recording was not applied for a further 26 years, when voltage-clamp was used in either 
two-electrode mode264 or single-electrode mode.265  The first recording of the single 
channel activity of native ion channels in biological membranes (muscle nicotinic 
acetylcholine receptors) were made by Erwin Neher and Bert Sakmann in 1976 using an 
innovative modification of the voltage-clamp method.266  This technique, now known as 
patch-clamp, used blunt-tipped glass pipettes that, when pressed gently against the cell 
membrane isolated a small membrane area.  A further modification of this technique is 
now widely used and involves measuring whole-cell  current  by  completely   ‘breaking’  
the patch of membrane underneath the electrode tip (the ruptured-patch conformation) 






4.2.2.2  Pulling and filling of pipettes 
Pipettes for patch-clamping were made from thin-walled (1.5 mmol/L outer diameter, 
1.17 mm inner diameter) borosilicate glass capillaries (Harvard Apparatus Ltd).  These 
were pulled and fire-polished using a 3-stage electrode puller (DMG Universal Puller, 
Zeitz-Instrumente Vetriebs GMBH).  Puller settings were adjusted to give a consistent 
open pipette resistance (Rpip) of 1-2  MΩ  when  back-filled with pipette solution and a tip 
shape to encourage successful whole-cell current recording in the perforated-patch 
configuration. 
4.2.2.3 The amplifier circuit 
Back-filled pipettes were placed on a stripped and chloride end of Teflon-coated silver 
wire (Advent Research Materials Ltd) which was connected to the amplifier head-stage 
(Model CV 201, Axon Instruments Inc).  The CV 201 is dedicated to the Axopatch 200 
patch-clamp amplifier (Axon Instruments).  An integrated Ag/AgCl electrode placed in 
the superfusing solution downstream of the cells provided the reference electrode. 
Voltage protocols were generated and data acquired using pClamp software (Version 
10, Axon Instruments) on a Dell personal computer via a 16-bit analogue/digital 
converter data acquisition system (ModelDigidata 1440A, Axon Instruments).  The 
amplifier was also connected in parallel to an oscilloscope (Gould Instrument Systems 
Ltd) and a chart recorder (Model RS3200, Gould Instrument Systems). 
4.2.2.4 Whole-cell perforated voltage-patch-clamping 
A small volume of cell suspension (~0.5 ml) was placed in a purpose-built perfusion 
bath on an inverted light microscope (Nikon Diaphot, Nikon).  The bath was 
constructed from Perspex with a glass cover-slip base, allowing solution warmed to 
35oC to flow over the cells, past the reference electrode and out into a waste reservoir.  
The flow rate was ~2-3 ml/min and solution height was maintained by a tissue-paper 
wick drawing solution towards the waste pipette.  Cells were viewed from beneath and 
continuously imaged using a CCD camera (IonOptix Myocam, InoOptix Corporation) 
and monitor.  The microscope, bath, head-stage and micromanipulator were all placed 
on an anti-vibration air-table (Ealing Electro-Optics Ltd). 
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Electrophysiological experiments were carried out using the whole-cell perforated-patch 
technique at 35oC to record whole-cell Ip.  The perforated patch-clamp technique is a 
less invasive method of Ip as the intracellular content is not dialysed by the pipette 
solution, as occurs in the ruptured method.  On the other hand, whilst this may limit the 
dialysis of small soluble signalling molecules and important cytosolic factors, a 
disadvantage is poorer control of intracellular and specifically subsarcolemmal [Na]i. 
Cells were left to settle on the glass base for 1-2 min before superfusion  with  Tyrode’s  
solution [Table 4.1] at 2-3 ml/min.  The pipette tip was lowered into the superfusing 
solution using the coarse setting on the micromanipulator (Patchman, Eppendorf).  The 
fine setting was then used to position the pipette tip close to a single, well-isolated 
myocyte.  At this stage any junction potential between the pipette solution and the 
superfusing solution was compensated at the amplifier.  A 20 mV alternating voltage-
step protocol was generated (from 0 mV holding potential) and the size of the response 
was indicative of the open Rpip,   as   described   by   Ohm’s   Law.      This   was   generally  
between 1 and 1.5 MΩ.     
Upon initial contact between the pipette tip and the cell membrane, Rpip increased 
slightly and very gentle negative pressure (~5 cm H2O) was manually applied through 
the pipette holder from an air-filled syringe.  A tight seal between the cell membrane 
and the microelectrode tip was subsequently established and considered adequate when 
this  reached  gigaohm  (GΩ)  values.     After  GΩ  seal  formation,  negative  pressure  in   the  
pipette was allowed to slowly dissipate.  At this point, the series resistance of the 
electrode tip and the cell membrane (Rtip) was very large.  A voltage protocol which 
held the cell at -80 mV and stepped to and from -75 mV was then used to track changes 
in seal resistance (Rs)  by  Ohm’s  Law  (RS = V/ I).   
Amphotericin B dissolved in the pipette solution slowly permeabilised the patch of 
membrane underneath the electrode tip (by forming monovalent cation-selective pores) 
and induced a progressive reduction in Rtip.  Hence, access resistance (Racc) 
progressively decreased and was monitored with repeated 5 mV depolarising steps as 
described above (sampling frequency of 100 Hz).  Typically, Racc fell to ~10  MΩ within 
10-15  min.    After  the  establishment  of  a  1  GΩ  seal,  the  superfusate  was  switched  to 5 
mol/L K-Test solution.  After the access resistance had fallen to ~2 MΩ and stabilised, 
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pump current measurements were made.  With  a   typical  400pA  current  and  a  10  MΩ 
access resistance, the voltage error is 4 mV.  With a holding current of 0 mV, this 
voltage error should not affect the current recorded as the I-V relationship around 0 mV 
is relatively stable.   
4.2.2.5 Recording the whole-cell current 
At this stage, a voltage protocol constructed using pClamp software, could be executed 
in the presence of different extracellular (superfusing) and intracellular (pipette) 
solutions [Table 4.1].  The electrophysiological equipment was set up to measure and 
record the current between the recording electrode and reference electrode during the 
voltage protocol.  Under steady state conditions (equilibrium), this current equals the 
sum of all currents passing through two parallel resistances: (i) the cell membrane and 
(ii) the pipette seal.  Both these resistances were considered to be in series with the 
resistance afforded by the pipette tip. 
During episodic current recordings (square-step protocols), signals were sampled at 5 
Hz and filtered at 1 kHz (low-pass filter).  For continuous gap-free current recordings, 
signals were sampled at 10 Hz and filtered at 1 Hz.  In all experiments, signals were 
sampled at a rate at least three times that of the filter setting to avoid signal aliasing. 
4.2.2.6 Experimental solutions 
For all electrophysiological recording of Ip, experimental solutions were superfused 
over the myocytes at 35oC.  Experimental solutions were similar to those described by 
Shattock and Masuura267 and were adapted from the method described by Gadsby and 
co-workers.268  In combination with a specific voltage protocol, experimental 
intracellular and extracellular solutions [Tables 4.1 and 4.2] were designed to block or 
avoid activation of any current other than the Ip.  Inward ICa,L were avoided by using Ca-
free test solutions (in which Ba ions replaced Ca).  K current was blocked by replacing 
intracellular K with pipette Cs (125 mmol/L) and with 1 mmol/L Ba in the extracellular 
solution.  The NCX was inhibited with 2 mmol/L NiCl2 in the extracellular 
solutions.269,270  2 mmol/L NiCl2 also completely blocked L-type current thus 
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preventing Ba currents through these channels.267  Na channel currents were eliminated 
by recording at a holding voltage of 0 mV. 
The pipette solution contained 30 mmol/L [Na] to allow changes in NKA activity 
resulting from either a change in Km or Vmax to be observed.  For all VPC experiments, 
amphotericin B was added to the pipette solution on the day of use.  A small quantity of 
amphotericin B was reconstituted in DMSO (Hybri-max, Sigma) in an opaque 
microcentrifuge tube to a concentration of 30 mg/ml and vortexed thoroughly.  The 
solution was then added to the pipette solution and vortexed to give a final 
concentration  of  amphotericin  B  in  the  pipette  solution  of  225  μg/ml,  with  [DMSO]  of  

















Table 4.1 Composition of extracellular experimental test solutions used in voltage-
patch-clamp experiments. 
Compound Tyrode's (mmol/L) K-Test (mmol/L) K-free (mmol/L) 
NaCl 137 140 140 
KCl 5.4 5 - 
MgCl2 0.4 1 1 
CaCl2 1 - - 
NiCl2 - 2 2 
BaCl2 - 1 1 
Glucose 10 10 10 
HEPES 10 10 10 
 
     pH 7.4 at 35oC with CsOH 
 
Table 4.2 Composition of intracellular (pipette) experimental test solution used in 
voltage-patch-clamp experiments. 
 











4.2.2.7 Measuring Ip 
The NKA was activated by perfusion with 5 mmol/L K-test solution and inhibited in a 
reversible manner by perfusion with K-free test solution (0 mmol/L K), which had 
previously shown to be identical to that sensitive to 10 mmol/L ouabain.146  The 
removal of extracellular K was chosen as opposed to the use of ouabain since the 
washout time for ouabain is relatively long compared to the rapid reversal of K-free 
pump inhibition (ouabain is reported to still affect inotropy and intracellular Na for 
more than 30 min after washout in cardiac tissue).  The Ip was continuously recorded 
whilst the myocyte was held at 0 mV using a continuous, gap-free recording protocol.  
A stable current recording was established in K-test solution before the protocol was 
stopped, and the cell perfused with K-free solution.   Ip was subsequently defined using 
the reversible inhibition of the NKA by perfusion with K-free solution (see Section 
4.2.2.8.2). 
4.2.2.8 Pump current analysis 
4.2.2.8.1 Calculating cell capacitance and seal resistance  
Capacitors have the ability to store electrical charge upon a change of voltage.  The 
most effective capacitors are parallel conducting plates of large surface area separated 
by a thin sheet of insulator.  This is an excellent approximation of the membrane lipid 
bilayer.  The magnitude of this capacitance is proportional to the area of the capacitance 
‘plates’   (the   surface   area   of   the   cells)   and   it   can   therefore   be   used   as   an   indirect  
quantitative measure of cell surface area.  Multiple capacitors in parallel are 
electronically equivalent to a single large capacitor, hence membrane capacitance 
increases with cell size and is usually  expressed  as  a  value  per  unit  area  (pF/μm2).  As a 
rough  approximation   the  capacitance  of   the  membrane   is  approximately  1  pF/μM2.  If 
current is applied to the membrane it first charges the membrane capacitance before 
changing the Em. 
In order to obtain an approximation of cell size, a standard protocol was used at the 
beginning and end of each VPC experiment.  A step depolarisation from -80 mV to -75 
mV lasting 25 ms gave typical recordings (200 kHz sampling frequency), showing a 
positive deflection at the start of the voltage step, a negative capacitance spike at the end 
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and a maintained rise in the whole cell current for the duration of the step.  The upward 
and downward spike deflections are associated with the charging and dissipation of 
membrane capacitance.  The area under the capacitance spike is proportional to the 
capacitance of the cell membrane (Cm).   
4.2.2.8.2 Calculation of Ip  
Ip was defined as the current sensitive to the removal of extracellular K, and was 
identical to that sensitive to 10 mmol/L ouabain (unpublished data).  Subtraction of 
traces recorded in the presence and absence of extracellular K was carried out ‘offline’ 
using Clampfit software (Version 10, Axon Instruments) analysis functions and further 
analysis using Microsoft Excel and GraphPad Prism software.  Results were collated 
and normalised to cell capacitance.  The use of cell membrane capacitance to represent 
the membrane area is well documented271-273 and such normalisation allows study of Ip 
density, rather than the whole-cell current which would inevitably vary from cell to cell 
according to cell size. 
Ip was defined as the difference between the stable currents measured in the presence 
and absence of extracellular K, rather than the peak of the overshoot current after the 
reintroduction of K, as for example, used by Bers and co-workers.  The overshoot 
observed when K is reintroduced is a product of Na accumulation inside the 
subsarcolemmal during the period of pump inhibition and inadequate control of 
intracellular Na by pipette dialysis.  While the overshoot is related to the activity of the 
NKA, it is also influenced by several other factors, which make it a less accurate 
method of quantifying NKA activity.  These factors include the access resistance 
between the pipette solution and the cell, the Na leak into the cell, in addition to the 
time during which Na can accumulate within the subsarcolemmal space – i.e. the time 
period during which the cell is perfused with K-free solution.   
4.2.2.9 Exclusion criteria  
Cells were excluded from further analysis if the capacitance protocol was not carried 
out successfully both at the beginning and end of the experimental protocol.  If Rs was 
poor, then the cell was also excluded.  An experimental protocol was not started until 
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Racc was  <15  MΩ,  with  most  cells  stabilising  at  around  10  MΩ.  Cells which failed to 
maintain a good seal or give adequate Racc were discarded.  Furthermore, cells were 
excluded if the perforated-patch confirmation spontaneously changed to the ruptured-
patch conformation which was evident from a significant decrease in Racc (from ~10 to 
3-4   MΩ).      Failure   to   complete   the   full   experimental   procedure   also   resulted   in  
experimental exclusion while cells where were found to be spontaneously contracting, 
had indistinct cross striations or membrane blebs were also excluded. 
4.2.3 Pharmacological treatment of ARVMs  
For generation of a cumulative ISO concentration-response curve for Ip density using 
VPC, 10 concentrations of ISO were tested (1 nmol/L, 3 nmol/L, 10 nmol/L, 30 nmol/L, 
100 nmol/L, 300 nmol/L, 1 μmol/L,   3 μmol/L, 10 μmol/L and 30 μmol/L).  The 
individual concentrations of ISO were added to the K-test solution and exposed to 
myocytes for approximately 10 min, when a steady-state effect (plateau) has been 
established.  For assessment of a single submaximal concentration of ISO on Ip, 
myocytes were treated with 300 nmol/L ISO for 10 min.  For assessment of PDE2-4 
inhibition on Ip,  myocytes  were  treated  with  100  μmol/L  IBMX,  10  μmol/L  EHNA,  10  
μmol/L   Cil   and   10   μmol/L   Rol   alone   or   in   combination   with   300 nmol/L ISO for 
approximately 10 min, when a steady-state effect has been established.  For all 
treatments, myocytes were exposed to 0.1% DMSO (in both K-test and K-free 
solutions) throughout the entire experimental procedure.   
4.2.4 Experimental protocols 
Panel A of Figure 4.1 outlines the VPC protocol used for assessing the effect of PDE 
inhibition on Ip density in the absence and presence of ISO while Panel B of the same 
figure outlines a separate protocol used for assessing the effect of ISO on Ip.   
We had initially designed a protocol that enabled the measurement of the responses 
generated upon treatment with PDE inhibitors under basal conditions, ISO alone and 
PDE inhibition in combination with ISO in sequential order on a single myocyte.  
However, the inability  to  ‘wash  out’  the  effects  of  ISO  in  our  system  during  preliminary  
experiments meant that it was necessary to divide this protocol into two mini-protocols 
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[Figure 4.1; Panels A & B].     This  lack  of  a  sufficient  ‘wash-out’  meant  that  it  became 
preferable to analyse the PDE inhibition-induced effects on Ip density under basal 
conditions and in the presence of ISO using different statistical methods.  Another 
consequence of this is that in contrast to our initial plans, only the amplitude of the Ip 
response (and not its temporal profile) could be accurately determined, as the transient 








Figure 4.1 Experimental protocols used in voltage-patch-clamp studies.  
The cell was initially superfused with K-test solution prior to switching to K-free solution to reversibly inhibit NKA activity.  Upon 
reperfusion with K-test solution, the current was allowed to reach a steady-state level (plateau), defined as the baseline, after 
which (A) PDE inhibitors in the absence and presence of 300 nmol/L ISO were added sequentially to the K-test solution or (B) 300 
nmol/L ISO alone was added to the K-test solution.  Cells were first treated with PDE inhibitors for 10 min, unless a steady-state 
effect had been attained earlier, followed by treatment with 300 nmol/L ISO for a further period of up to 10 min.  The cell was 
subsequently perfused with K-free solution to ensure Rs had remained stable throughout the experiment.  Any alterations in the 
current recorded in K-free solution resulted in the exclusion of the experiment for data analysis. 
 
Representative trace of a single experiment is shown; all measurements were made using the perforated configuration of VPC 
(pipette [Na] 30 mmol/L); Ip was defined as the difference between the stable currents measured in the presence and absence of 
extracellular K.  Results were collated and Ip values normalised to cell capacitance to generate Ip density values.   
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Importantly, in order to ensure that any changes in Ip observed could be directly 
attributed   to   the   treatments   applied   and   not   a   result   of   any   inherent   ‘drifting’   of   the  
pump current, which constitutes a major practical complication of any VPC 
experiments, we carried out time-matched control experiments interspersed in a random 
manner throughout the series of PDE inhibition experiments to check that Ip typically 
remained stable throughout the duration of the protocol (typically within 30 – 40 min).  
In general, we observed that the Ip generated by myocytes remain stable for 
approximately 60 min, thus eliminating the possibility of the observed changes in 
response to the different pharmacological treatments arising from alterations in the 
baseline Ip during the experimental procedure.  Additionally, it must be noted that while 
a  ‘run-down’  of  Ip is a recognised complication with the VPC procedures (usually more 
pronounced with the ruptured patch variation in comparison to the perforated method, 
due to a greater extent of dialysis of intracellular components and earlier cell death with 
the former), it is rarer to observe a gradual  ‘drift-up’  of  the  current,  although  a  gradual  
decrease in Rs over time could lead to an increase (albeit often a sudden shift) in current 












4.3 Results  
4.3.1 Identification of a suitable submaximal [ISO] 
A cumulative concentration response curve for Ip density to a range of [ISO] was first 
generated to allow identification of a submaximal [ISO] that was deemed suitable for 
investigating the functional effects of PDE inhibition on Ip during  β-AR stimulation.  In 
contrast to biochemical PDE inhibition experiments, where an individual concentration 
response curve was generated, a cumulative curve in an electrophysiological setting 
enabled the measurement of multiple concentrations of ISO on a single myocyte, which 
eliminated the necessity of testing each concentration on an individual cell.  The 
relationship between [ISO] and Ip density in ARVMs was found to be apparently 
biphasic, with a two-phase relationship [Figure 4.2], but with a significant amount of 
variability, consistent with previous observations from our group (unpublished data), 
and is also in agreement with the relationship between [ISO] and PLM-Ser68 
phosphorylation (See Chapter 3, Section 3.3.1).      The   saturating   [ISO],   3   μmol/L  
induced a peak increase in Ip by approximately 0.5 pA/pF, while the [ISO] needed for 
half-activation of Ip is approximately 1 μmol/L  [Figure  4.2].   
A suitable submaximal [ISO] was defined as a concentration of the agonist that 
produced an increase in Ip density that was quantitatively large enough to be detected by 
VPC,   but   sufficiently   small   as   to   provide   an   adequate   ‘window’   for   any   subsequent  
increases induced by PDE inhibition to be detected.  We therefore selected 300 nmol/L 
ISO, which was found to induce an Ip response that was situated at the bottom of the 
slope of the curve [Figure 4.2].  As this effect was extracted from a cumulative 
concentration response curve, and individual responses have been influenced by 
preceding treatment, we investigated the effect of an individual treatment with 300 
nmol/L ISO on the Ip response.  The resulting increase in Ip density was found to be 
smaller than the effect observed within the concentration-response curve [Figure 4.3; 
Panel A], as expected, although it did reach statistical significance when analysed using 
the   paired   Student’s   t-test [Figure 4.3; Panel B].  Therefore, 300 nmol/L ISO was 
selected as an appropriate concentration for studying the effects of PDE inhibition on Ip 
during submaximal β-AR stimulation.  Importantly,   the   inability   to   ‘wash   out’   the  
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effects of ISO meant we had to characterise the response of 300 nmol/L ISO alone on Ip 
(see Section 4.2.4).    
 


















Figure 4.2 Cumulative ISO concentration-response curve for Ip.   
ARVMs were superfused with K-test solution and challenged sequentially with 10 
nmol/L,   30   nmol/L,   100   nmol/L,   300   nmol/L,   1   μmol/L,   3   μmol/L,   10   μmol/L   and   30  
μmol/L   for   10  min.  All treated myocytes were exposed to 0.1% DMSO.  Perforated 
whole-cell VPC was used to determine Ip before and after treatment by switching to K-
free solution to reversibly inhibit NKA activity.  Ip values were subsequently normalised 
to cell capacitance to generate Ip density values.  Pipette [Na]: 30 mmol/L.  Data are 
expressed as means ± SEM (n=7).  Mean data were fitted with a hyperbolic two-site 





































Figure 4.3 Changes in Ip in response to treatment with 300 nmol/L ISO.  
ARVMs were superfused with K-test solution and treated with 300 nmol/L ISO for 10 
min in (A) cumulative concentration-response curve or (B) single-concentration 
experiments.  All treated myocytes were exposed to 0.1% DMSO.  Perforated whole-
cell VPC was used to determine Ip before and after treatment by switching to K-free 
solution to reversibly inhibit NKA activity.  Ip values were subsequently normalised to 
cell capacitance to generate Ip density values.  Pipette [Na]: 30 mmol/L.  Data are 
expressed  as  means  ±  SEM  (n=12).  ***p  ≤  0.001  (paired  Student’s  t-test) 
4.3.2 Effects of PDE2-4 inhibition on Ip under basal conditions 
Due to the nature of the protocols used (see Section 4.2.4), it was deemed most 
scientifically valid to compare the effects of PDE inhibition on Ip under basal conditions 
and in the presence of ISO using different statistical methods.  It could be observed 
from Figure 4.4 that steady-state baseline Ip ranges from approximately 0.5 pA/pF to 2 
pA/pF.  Upon treatment with each of the PDE inhibitors under basal conditions, we 
observed a significant increase in Ip from  the  baseline  using  the  paired  Student’s   t-test 















Figure 4.4 Changes in Ip in response to PDE inhibition under basal conditions.   
ARVMs were superfused with K-test solution and challenged with (A) 100  μmol/L IBMX, 
(B) 10  μmol/L  EHNA,   (C) 10  μmol/L  Cil   or   (D) 10  μmol/L  Rol   for   10  min.     All   treated  
myocytes were exposed to 0.1% DMSO.  Perforated whole-cell VPC was used to 
determine Ip before and after treatment by switching to K-free solution to reversibly 
inhibit NKA activity.  Ip values were subsequently normalised to cell capacitance to 
generate Ip density values.  Pipette [Na]: 30 mmol/L.  Statistical comparisons were made 
using   paired  Student’s   t-test and data   are   expressed   as  means   ±  SEM   (n=10).   **p   ≤  












































































4.3.3 Effects of PDE2-4 inhibition on Ip under ISO-stimulated conditions 
As mentioned, since the effects of PDE inhibition on Ip density in the presence of ISO 
were tested on a separate batch of cells to those that have been treated with ISO alone, 
the mean changes in Ip density for the two treatment groups were quantitatively 
compared  using  the  unpaired  Student’s  t-test in order for a valid comparison to be made 
without resolving to plotting fold changes, which artificially removes any variation in 
the baseline values [Figure 4.5; Panels A-D].  The mean change in Ip density under 
basal conditions was also plotted, although not used in statistical analysis as they had 
already  been  assessed  quantitatively  using   ‘before-after’   line  plots   [Figure 4.4; Panels 
A-D].    
As depicted in Figure 4.5, challenge with the non-selective PDE inhibitor IBMX in 
combination with ISO was found to significantly increase the Ip density by 
approximately 0.25 pA/pF when compared to treatment with 10 nmol/L ISO alone 
[Figure 4.5; Panel A].  Similarly, treatment with EHNA or Rol in the presence of ISO 
resulted in a significant increase of approximately 0.15 pA/pF and 0.1 pA/pF 
respectively compared to treatment with ISO alone [Figure 4.5; Panels B & D].  In 
contrast, exposure to either Cil or Rol in combination with ISO did not further augment 













Increase in Ip (pA/pF)




Increase in Ip (pA/pF)





Increase in Ip (pA/pF)











Figure 4.5 Increases in Ip in response to PDE inhibition in the absence and 
presence of a submaximal [ISO].   
ARVMs were superfused with K-test solution and challenged with (A) 100  μmol/L  IBMX,  
(B) 10   μmol/L   EHNA,   (C) 10   μmol/L   Cil   or   (D) 10   μmol/L   Rol   in   the   absence   and  
presence of 300 nmol/L ISO for 10 min.  All treated myocytes were exposed to 0.1% 
DMSO.  Perforated whole-cell VPC was used to determine Ip before and after treatment 
by switching to K-free solution to reversibly inhibit NKA activity.  Ip values were 
subsequently normalised to cell capacitance to generate Ip density values.  Pipette [Na]: 
30 mmol/L.  Statistical  comparisons  were  made  using  paired  Student’s   t-test and data 








4.4 Discussion   
Following on from the experiments outlined in the previous chapter, which primarily 
focused on the effects of PDE inhibition on the phosphorylation status of PLM-Ser68, 
the series of experiments described within the present chapter was aimed at 
characterising the effects of PDE inhibition on NKA activity.  The latter was 
quantitatively assessed by taking advantage of the asymmetrical transport mechanism of 
the NKA, which governs the outward transport of three Na ions and the inward transport 
of two K ions for each ATP molecule hydrolysed, up to a hundred times per second, 
generating a measurable outward current if assayed in millions of pumps (Shattock and 
colleagues have estimated the presence of approximately ten million pumps per rabbit 
myocyte274).   
Specifically, we made use of the perforated-patch version of the VPC technique, in 
combination with extracellular and intracellular solutions designed to block any 
contaminating currents, to measure the Ip response to treatment with different PDE 
inhibitors in the absence and presence of ISO in freshly-isolated ARVMs.  We used a 
relatively low [Na] in the pipette solution at 30 mmol/L, which has previously been 
shown by our laboratory to be situated at the foot of the Na activation curve for Ip; 
therefore changes in NKA activity resulting from either a change in Km or Vmax of the 
pump could be detected.  
A study by Stimers and Dobretsov in 1997 reported that the myocyte isolation 
procedure does not impair mechanisms   linking   β-ARs with the NKA, in guinea pig 
myocytes maintained in short-term culture.275  As outlined earlier, the perforated patch 
method was selected as baseline Ip was found to remain in steady-state for a 
substantially greater duration than when using the ruptured patch method.  This is 
consistent with the general notion that rupturing a section of the cell membrane results 
in a greater degree of dialysis of cytosolic components necessary for cell survival in 
comparison with membranes that are perforated but remain essentially intact.  The 
subsequent  reduction  in  the  duration  in  which  the  cell  remains  ‘healthy’  and  viable  for  
experimental   use   is   reflected   by   the   gradual   irreversible   ‘run-down’   in   Ip after 
approximately 20 min in ruptured patch mode, as opposed to the steady-state current 
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lasting for up to 60 min which we found to be typical in untreated cells that have been 
patched onto using the perforated-patch technique.   
The perforated-patch method does have its drawbacks, however, the most significant 
being a less decisive control of intracellular Ca, and as such, there is the possibility that 
changes in Ip density may or may not be reflective of genuine underlying physiological 
changes.  Indeed, the addition of ISO was found to elicit an increase in Ip density that 
was not time-dependent, consistent with their perceived roles in responding to acute 
stimuli   of   the   pathway.      Given   the   unlikelihood   that   this   inability   to   ‘wash   out’   the  
effects of ISO constitutes a genuine physiological phenomenon, the lack of a temporal 
profile detected may therefore represent an artefact that could be attributed to the 
inherent nature of the perforated patch method, which somehow prevents the activated 
β-AR pathway   from   ‘switching   off’.      Certainly, previous work in our laboratory 
corroborates with this possibility, with the perforated-patch method generally displaying 
highly variable time courses, while the ruptured-patch method was shown to clearly 
demonstrate a differential response to ISO and FRSK.  Upon challenging with ISO, Ip 
returned to baseline levels within 2 min, while exposure to FRSK resulted in an 
augmentation of Ip that remained for an indefinite period of time (data not shown).   
Interestingly, the control of [Ca]i may effect other important consequences concerning 
the stimulation of NKA activity by ISO.  In isolated cardiac myocytes, ISO has been 
shown to stimulate the pump by several authors227,276-278 but having an inhibitory278-280 
or no effect281 by others in both rat and guinea pig myocytes.  In the present study, we 
found that ISO induced an increase in Ip density in a concentration-dependent manner in 
ARVMs, consistent with the majority of reports.  Importantly, it was determined that 
while 300 nmol/L ISO is a submaximal concentration in a VPC setting, it represents a 
maximal concentration as detected by SDS-PAGE/WB (See Chapter 3; Section 3.3.1).  
This emphasises the inherent characteristics of different experimental techniques and 
hence the necessity of individually characterising the parameters for each set of 
experiments.   
The reasons underlying the disparate observations on the effects of ISO on Ip remain 
somewhat controversial, although attempts have been made in recent years to delineate 
these issues.275  It is now generally accepted that the most plausible explanation for 
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these seemingly contradictory findings may at least partially reside in the complexity of 
the adrenergic stimulation of the NKA, in particular its dependence on [Ca]i.  In guinea 
pig myocytes, it was determined by Gao and colleagues in 1991 that with low [Ca]i 
(<150 nmol/L), ISO inhibited Ip, while at high [Ca]i (>150 nmol/L), ISO stimulated 
Ip.277  Subsequent studies reproduced this disparity, with PKA-dependent activation of Ip 
in the presence of ISO corresponding with a clamping of [Ca]i to physiological or 
slightly supraphysiological concentrations,276,278 while PKA-dependent inhibition 
corresponding with a subphysiological [Ca]i.278,279  In general, it seems that laboratories 
reporting pump inhibition by PKA buffer [Ca]i below 100 nmol/L280 while those 
reporting pump activation by PKA do not buffer [Ca]i.146,169,171  This effect of Ca 
buffering on PKA-mediated NKA activation is consistent with the observation that 
elevated Na affinity of the NKA in PLM-KO myocytes is dependent on pipette [Ca], 
with this effect being negated when [Ca] is buffered below approximately 10 nmol/L.282  
Indeed, [Ca] has been reported to modify the effect of PKA activation on pump activity 
in an identical fashion in tissues other than the heart.283   
Whether this effect of Ca represents merely a biophysical phenomenon or a genuine 
physiological means to switch the pump from a PKA-inhibitable to a PKA-activatable 
state remains unclear.  Since the average intracellular Ca levels, which are dependent on 
heart rate and adrenergic tone, would likely exceed the 101-150 nmol/L threshold above 
which PKA stimulates the pump,277,278 PKA inhibition of the pump could potentially be 
of limited biological relevance in cardiac muscle under normal circumstances, but may 
become important when intracellular Ca levels fall below normal levels in certain 
pathologies, and also in other cardiac cell types with an intrinsically lower [Ca]i.  The 
potentially high basal phosphorylation level of PLM-Ser68 (discussed in Chapter 3; 
Section 3.4) is indicative of a high Ca load in the myocytes used in our experiments, 
which is consistent with PKA activation of the NKA.  Indeed, our results are entirely 
consistent with the extensive evidence suggesting that phosphorylation of PLM-Ser68 
by PKA is required for augmenting NKA activity.   
Interestingly, Ishizuka and Berlin reported an absence of ISO stimulation on Ip in rat 
ventricular myocytes, which may be reflective of the particular experimental condition, 
in which Ip reactivation currents, rather than steady-state currents were measured.281  As 
detailed in Section 4.2.2.8.2, we chose to employ a K-removal protocol for Ip 
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measurement in our VPC experiments, whereby steady-state currents measured in K-
test and K-free solutions were subtracted to generate Ip values that were subsequently 
normalised to cell capacitance to allow a quantitative evaluation of Ip density.  In our 
experience, analysis of steady-state currents surpasses measurement of Ip reactivation 
currents in both accuracy and reliability, as the overshoot instilled by the reactivation of 
the NKA by the reintroduction of K is more variable in our hands (See Section 
4.2.2.8.2).  Thus the disparity between our findings and those by Ishizuka and Berlin 
may reflect a continuum of NKA transport that is modulated by experimental 
conditions.   
While the ISO-induced increase in NKA activity is matched by a corresponding 
increase in PLM-Ser68 phosphorylation level, attempts to link the effects of PDE 
inhibition on NKA activity with those on PLM-Ser68 phosphorylation seem to be more 
complex.  The large body of evidence establishing the functional association between 
PLM and the NKA during β-AR stimulation has already been outlined in detail in 
Chapter 1 (Section 1.4.3) and we therefore expected a close correlation between the WB 
and VPC data sets, as highlighted by our initial hypothesis.  As discussed in Chapter 3, 
treatment of myocytes with PDE inhibitors in a biochemical setting provides evidence 
for PDE4 being the predominant PDE subtype involved in regulating PKA 
phosphorylation   of   PLM   during   β-AR stimulation.  In contrast, exposure to these 
inhibitors in an electrophysiological setting suggests that PDE2 constitutes the major 
PDE  subtype  contributing   to   the   regulation  of  NKA  activity  during  β-AR stimulation, 
with PDE4 inhibition also exerting a statistically significant effect. 
It is important to emphasise here that the duration of treatment with PDE inhibitors in 
the biochemical/Western blot experiments differed to that in the VPC study.  In the 
biochemical experiments, cells were exposed to the PDE inhibitors for 10 min 
simultaneously, while in the electrophysiological experiments, cells were first treated 
with PDE inhibitors for 10 min, which were left on for a further 10 min in the presence 
of ISO, and therefore the cell had been exposed to the inhibitor for 20 min in total.  We 
admit that the two protocols do not directly correspond with each other, but this 
experimental design in the VPC study was unavoidable.  Considering the relatively 
quick onset of action of these inhibitors, and their cell permeability, a difference of 10 
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min in duration seems unlikely to significantly affect their activities under these 
experimental conditions.   
Since PDE2 appears to play such a prominent role in regulating Ip despite having only a 
small effect on PLM phosphorylation, this observation raises the possibility that PDE2 
may selectively affect NKA activity via a mechanism that is independent of PLM 
phosphorylation.  One such mechanism is S-palmitoylation, which is the reversible 
covalent post-translational attachment of the fatty acid palmitic acid to the thiol group 
of cysteine via an acyl-thioester linkage.284  In recent years, protein S-palmitoylation has 
gradually emerged as an important and common post-translational modification in a 
variety of tissues,285 and has been found to exert a variety of functions, including the 
regulation of ion channel/transporter activity, stability, or subcellular localisation.285,286  
Importantly, it was recently shown that PLM can be palmitoylated at two intracellular 
cysteines, C40 and C42, just beyond the transmembrane domain to exert an overall 
inhibitory effect on the pump.287  Interestingly, PLM palmitoylation is directly 
influenced by its phosphorylation status, such that phosphorylation of PLM-Ser68 by 
PKA increases PLM palmitoylation.287  Hence, one post-translational modification of 
PLM that activates the NKA serves to promote a second that inhibits it.   
Another mechanism thought to regulate cardiac NKA activity is glutathionylation of the 
pump’s   α   subunit.288  Glutathionylation of the pump occurs in the basal state, and is 
promoted during cardiac hypoxia, causing profound pump inhibition.  Since 
glutathionylation and palmitoylation may competitively influence the same cysteine 
residues, it is possible that dynamic regulation of the pump may occur independently of 
PLM phosphorylation.  However, it must be emphasised that both of these mechanisms 
have been shown to result in inhibition rather than stimulation of the NKA; as such, 
palmitoylation and glutathionylation of PLM is unlikely to explain our findings, which 
indicate an increase in NKA activity.  Therefore, PDE2 would have  to selectively 
reduce PLM palmitoylation or glutathionylation, in order to result in an increase in Ip 
without affecting PLM phosphorylation.    Theoretically, this is possible, although it is 
equally likely that another yet-unidentified mechanism could be involved.   
Additionally, as discussed in Chapter 1; (Section 1.4.3), while it is theoretically possible 
that PKA can directly phosphorylate the NKA (which would provide an alternative 
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explanation for our findings), the kinase signalling pathways that lead to cardiac NKA 
activation are now almost universally acknowledged to terminate at PLM.  Although it 
has been suggested that direct   phosphorylation   of   the   α   subunit   of   the  NKA  may   be  
important for regulating   the   latter’s   activity   in   certain   cell   types, the lack of evidence 
supporting such a model within the heart suggests that it is highly unlikely to play an 
important role in specifically regulating cardiac NKA activity.   
The PLM phosphorylation-independent regulation of NKA function may be 
functionally important under basal conditions.  Our results suggest that PDE2-4 
individually contribute to the regulation of cAMP signalling to the NKA at rest, in 
contrast to the notion that these PDE subtypes only exert a small effect upon PLM-
Ser68 during basal conditions, possibly due to the intrinsically high basal 
phosphorylation level at this site (See Chapter 3; Section 3.4.  What also remains 
unclear is how the observed effects of PDE inhibition on Ip under basal conditions relate 
to   those  during  β-AR stimulation.  Our findings suggest a scenario whereby PDE2 is 
primarily important for regulating cAMP signalling to the NKA under both basal 
conditions  and  during  stimulation  of  β-ARs.  On the other hand, PDE3 seems to be only 
necessary for modulating NKA activity at rest.  In light of previous reports on the 
effects of PDE inhibition on ICa,L, which demonstrated that selective inhibition of a 
single PDE subtype was insufficient to significantly raise basal ICa,L, PDE4 becomes 
predominant   in   modulating   cAMP   signalling   to   the   LTTC   during   β-AR activation.59  
Indeed, it seems logical that a particular PDE becomes functionally important when 
intracellular cAMP levels are elevated, as supported by augmentation of PDE4 activity 
via PKA phosphorylation.109  Our findings are therefore at variance with this model in 
suggesting  a  selective  ‘switching  off’  of  PDE3  function  upon  sympathetic  activation.   
On the whole, the potential functional implications of our findings are intriguing.  The 
predominant cAMP-hydrolytic activity of PDE4 in the rodent heart, and its role in the 
regulation of several key components of ECC is well established in both an in vitro and 
in vivo setting.  Thus the idea that PDE4 influences cAMP signalling to the NKA by 
mediating PKA phosphorylation of PLM-Ser68 lies well within the current context in 
which PDE4 action is thought to unfold.  What is perhaps more intriguing is the idea 
that PDE2 seems to play a role in regulating cAMP signalling to the NKA.  As detailed 
in Chapter 1 (Section 1.2.3), there is evidence for PDE2 regulating cAMP levels in 
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response  to  β-AR stimulation.75  Importantly, as this particular PDE subtype constitutes 
a much lower percentage of total PDE activity in comparison to PDE3 or PDE4, our 
findings suggest that the action of PDE2 in relation to the NKA may be 
compartmentalised, with PDE2 preferentially regulating a local cAMP pool in the 
vicinity of PLM/NKA.   As detailed in Chapter 1 (Section 1.2.5), there is now an 
extensive body of evidence indicating that individual PDE isoforms are likely to be 
located in distinct intracellular compartments of the cell, with tethering of the PDE 
variants directly to cardiac proteins or indirectly via AKAPs to facilitate this local 
regulation of cAMP signalling.  Previous reports have demonstrated a tight control of a 
local pool of cAMP in the vicinity of LTCCs by PDE2 in a number of species; 
considering the role of NKA in indirectly regulating [Ca]i,77,78,80 our findings are 
therefore in line with this possible scenario of cAMP compartmentalisation involving 
PDE2.  
In conclusion, the effects of pharmacological inhibition of PDE2-4 on NKA activity as 
assessed by measurement of Ip density using VPC suggests that PDE2 plays a 
significant role in regulating cAMP signalling to the NKA.  This is in addition to our 
finding that PDE4 seems to be primarily responsible for regulating PKA 
phosphorylation of PLM-Ser68, indicating a possible scenario whereby PDE2 regulates 
cAMP signals in the vicinity of PLM/NKA in a compartmentalised manner via a 
mechanism independent of PLM phosphorylation by PKA.       
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5 CHARACTERISATION OF A NOVEL FRET-
BASED CAMP SENSOR 
5.1 Introduction 
5.1.1 Background 
5.1.1.1 Measurement of intracellular cAMP levels 
Despite the notion of intracellular compartmentalisation having been proposed early on 
in the study of cAMP signalling,11,289 the lack of high-resolution sensors for monitoring 
cAMP at the single-cell level has served as a significant obstacle in the experimental – 
and conceptual – exploration of the spatiotemporal dynamics of intracellular cAMP 
changes.  Measurements of cAMP levels within the cell had traditionally been limited to 
biochemical antibody-based techniques, such as enzyme immunoassays290 and RIAs,291 
whereby only total and not free cAMP levels in batches of cells or tissue samples 
(including those molecules bound to proteins and sequestered in cells) can be measured.  
Furthermore, the destructive nature of these in vitro assays means that cAMP levels 
cannot be determined with any spatial resolution, in sharp contrast to the concept of 
cAMP compartmentalisation that has emerged over the past few decades, which 
suggests that different cAMP concentrations are present in distinct intracellular 
compartments.  A further limitation is that such methods only enable static samples to 
be taken, thus providing little information on the temporal profile of the responses.   
Although such cell population assays are simple, economical and continue to be 
extremely useful in well-defined situations where spatiotemporal dynamics or 
individual cellular variation is not a consideration, cAMP compartmentalisation and 
dynamics are increasingly being recognised as an intrinsic and regulated part of the 
cellular management of cAMP.  As such, there has been a significant development in 
novel techniques that can resolve the real-time dynamics of cAMP signalling in living 
cells and tissues with high temporal and spatial resolution to address these issues.   
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5.1.1.2 Live-cell imaging of cAMP dynamics 
The first breakthrough came in the early 1990s with the development of a fluorescent 
sensor  termed  ‘FICRhr’  (pronounced  ‘flicker’)  and  this  advance  has  been  followed by a 
wave of genetically encoded sensors.292  The currently available single-cell biosensors 
for measuring cAMP are all based on downstream targets of the second messenger, 
including PKA,40,292,293 CNGCs294,295 and Epac.30,296,297  These sensors can be used with 
microscopic techniques to precisely report physiologically relevant free intracellular 
cAMP levels that are present in the cytosol and capable of activating effector proteins.  
Moreover, they are capable of reporting rapid changes in cAMP at a higher temporal 
resolution and spatially resolve intracellular signalling at the subcellular level.   
5.1.1.3 The principle of FRET 
The majority of these biosensors are fluorescently tagged molecules that rely on the 
application of FRET, a quantum mechanical phenomenon first discovered in the late 
1940s that occurs between a fluorescence donor and a fluorescence acceptor in 
molecular proximity of each other if the emission spectrum of the donor overlaps with 
the excitation spectrum of the acceptor.298  In this approach, the sensor is attached to a 
pair of fluorophores with overlapping spectra.  Typically, the green fluorescent protein 
(GFP) variants: cyan fluorescent protein (CFP) and yellow fluorescent proteins (YFP) 
are used.  For these constructs, binding of cAMP to the cAMP-responsive protein 
generates a conformational change and a consequent decrease in FRET signal as the 
distance between the CFP and YFP moieties is increased.  Specifically, excitation of 
CFP, which is best achieved with light of a wavelength of 436 nm, normally leads to 
emission of the typical cyan fluorescence, with a peak at a wavelength of 480 nm.  If 
however, a second fluorophore such as YFP is close by, then – under appropriate 
circumstances – energy can be transferred to YFP (which has excitation and emission 
maxima of 514 and 527 nm respectively) and a yellow emission from YFP occurs that 
has a peak wavelength of 535 nm.  In this transfer of energy, CFP acts as the donor and 





Figure 5.1 Principle of FRET using CFP and YFP as a donor–acceptor pair.   
FRET occurs when the donor (CFP) is close enough (<10 nm) to the acceptor (YFP), so 
that upon excitation of CFP (with light at a wavelength of 436 nm), energy is transferred 
to YFP and causes yellow emission (at 535 nm); at the same time, cyan emission (at 
480 nm) decreases (adapted from 38). 
Importantly, real-time FRET measurements can be made in a number of different cell 
types, provided that the cells can be efficiently transfected with the CFP- and YFP-
tagged cAMP sensor molecules.  Further development over the past few years has 
introduced several modifications to the parent cAMP probes, generating an array of 
cAMP sensors with improved sensitivity, signal-to-noise ratio, dynamic range and 
spatiotemporal resolution.  Key advances have been driven by the enhanced efficiency 
of the newer FRET sensors, the targeting of variants of classical cAMP sensors to 
specific sites within the cell and most recently, the ability to produce transgenic animals 
expressing genetically encoded FRET-based sensors.  
5.1.1.4 FRET-based cAMP sensors derived from Epac 
cAMP biosensors based on the exchange protein directly activated by cAMP (Epac) are 
among the newest additions to the cAMP sensor collection.  Figure 1.3 [Panel C] shows 
how a generic Epac-based cAMP sensor functions according to the principle of FRET 
mentioned above.   Epac represents an important intracellular effector for cAMP and 
appears to account for many of its effects.299  Epac consists of a regulatory binding site 
and a catalytic domain, which has the function of GTP loading of the small G protein 
Rap1 and maintaining its active state.  In vitro studies have shown that cAMP is 
absolutely required for the activation of Epac.300  In support of the unfolding model, 
Chapter 5 
143 
cAMP binding to the regulatory domain results in a significant conformational change 
of the protein that leads to a reduction of the FRET signal, compatible with an increased 
distance between the CFP and YFP moieties [Figure 5.2].299   
 
Figure 5.2 Model for the conformational change of Epac following binding of 
cAMP to the regulatory domain of the protein.   
Following cAMP binding, the VLVLE sequence can interact with the regulatory domain, 
release the inhibition of the GEF domain by the REM domain.  FRET between the CFP 
and YFP tags allows detection of this conformational change (taken from 297).   
In 2004, the generation of several FRET-based cAMP sensors containing Epac1 and 
Epac2 was reported almost simultaneously by three independent groups.30,296,297  The 
unimolecular Epac-based probes, in which CFP and YFP are attached to opposite ends 
of a single effector molecule, increase FRET efficiency and the signal-to-noise ratio 
compares very favourably with that of the multimolecular PKA-based sensors.297  PKA 
has a complex mechanism of activation (cooperative cAMP binding to four 
interconnected sites of different affinities) and it has been demonstrated that the 
activation kinetics of several cytosolic Epac-based probes is faster than that of the 
relatively slowly dissociating PKA-based counterparts.30  Additionally, Ponsioen and 
colleagues reported an extended dynamic range for their Epac-based sensor as 
compared with the PKA-based FRET sensor.297  More recently, Epac-based constructs 
have been generated that are selectively localised to the plasma membrane, as well as 
other variants that are targeted to the nucleus and the mitochondria, thereby enabling 
cAMP signals in discrete intracellular compartments to be compared.296     
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5.1.1.5  A novel FRET-based cAMP sensor derived from Epac 
We generated a variant of the widely-used Epac1-based cAMP sensor Epac1-camps30 
(camps for cAMP sensor) by conjugation with the full-length human PLM sequence in 
collaboration with Baillie and co-workers (unpublished data).  Specifically, this 
modified sensor comprises human PLM at the N-terminus, and Epac1-camps as the C-
terminal tag, thereby producing PLM-Epac1-camps.  Due to the presence of PLM, this 
sensor should in theory be selectively targeted to the plasma membrane of cardiac 
myocytes, in contrast to Epac1-camps, which has been shown to be distributed within 
the bulk cytosol of HEK293 cells.30  As a result of the distinct localisation patterns of 
the two sensors, we proposed that they will provide novel insights into the 
spatiotemporal  and  regulatory  patterns  of  β-AR-mediated response of cAMP signalling 
to PLM.   
Specifically, the potential for delineating whether cAMP signalling to PLM is 
modulated by PDE4 in a compartmentalised manner, in support of the emerging model 
of physical association of PDE4 with cardiac substrates in distinct cAMP 
microdomains, or globally within the bulk cytosol during sympathetic activation is of 
particular relevance to this project.  We had outlined in Chapters 3 and 4 the evidence 
indicating PDE4 as the predominant PDE subtype in regulating PKA phosphorylation of 
PLM  during  β-AR stimulation.  Preliminary co-IP experiments suggest that individual 
PDE4 isoforms could either be tethered to PLM or exist in the immediate vicinity of the 
protein, giving rise to the possibility that the local regulation of cAMP signals by PDE4 
in close proximity to PLM is responsible for our findings [see Appendices I and II].  
The use of PLM-Epac1-camps in conjunction with its non-targeted counterpart, Epac1-
camps could contribute to delineating between these two potential mechanisms by 
allowing us to assess whether cAMP levels increase locally in the vicinity of PLM or 
globally within the bulk cytosol upon pharmacological inhibition of PDE4 in the 
presence of ISO.     
To facilitate effective transfection of these sensors into cultured ARVMs, we first 
incorporated the sensors into an adenoviral vector.  This series of experiments involved 
characterisation of the sensors in HEK293 cells, incorporation of the constructs into 
recombinant adenoviruses and subsequent investigation of the functional capabilities of 
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these sensors in ARVMs.  We hypothesised that the presence of the PLM sequence on 
PLM-Epac1-camps would result in the selective targeting of this sensor to the 
sarcolemmal membrane of ARVMs (in contrast to Epac1-camps, which remains in the 
cytosol), with its functional characteristics remaining unaltered.  The specific 
hypotheses and objectives of the studies described in this chapter are outlined below.   
5.1.2 Specific hypotheses 
 That PLM-Epac1-camps is targeted to the membrane regions of HEK293 cells 
and ARVMs. 
 
 That Epac1-camps is not specifically localised but rather expressed within the 
bulk cytosol of both cell types. 
 
 That both PLM-Epac1-camps and Epac1-camps display similar functional 
characteristics, with both being suitable for use in FRET-based experiments  
5.1.3 Specific objectives 
1. To characterise the molecular weights and intracellular expression patterns of 
the plasmid constructs encoding for Epac1-camps and PLM-Epac1-camps in 
HEK293 cells. 
 
2. To incorporate the genes of interest into an adenoviral vector to facilitate 
transfection into ARVMs. 
 
3. To characterise the molecular weight of the gene products, and the expression 
patterns and functional characteristics of the recombinant adenoviruses in 
ARVMs. 
 
4. To use these characterised sensors to probe the local intracellular cAMP 









5.2 Methods  
5.2.1 Generation of cAMP sensors 
The construction of Epac1-camps is outlined in detailed by Nikolaev and co-workers.30  
Briefly, the DNA construct encoding for the nucleotide binding sequence of Epac1-
camps (E157-E316) was generated by PCR using human Epac1 (GenBankTM accession 
number AF103905) as a template.  GFP variants were amplified with standard primers 
from pEYFP and pECFP (Clontech) and fused to the N-and C-termini of the gene 
construct.  The construct was cloned into a pcDNA3 vector (Invitrogen) for transient 
expression in mammalian cells.  PLM-Epac1-camps was constructed by fusing the full-
length human PLM sequence (1-92 aa) to YFP on Epac1-camps.   
All of the work detailed Section 5.2.1 was undertaken by our PhD project collaborator 
Dr George Baillie (University of Glasgow). 
5.2.1.1 Generation of recombinant plasmids 
5.2.1.1.1 Restriction enzyme digestion of plasmid DNA and shuttle vector 
The pcDNA3 plasmid containing the GOI was digested with 5U each of HindIII and 
Not1  in  1x  NEBuffer  2  and  BSA  to  a  final  concentration  of  100  μg/ml,  for  2  hr  at  37oC.  
500 ng of the viral shuttle vector, pShuttle-CMV [Figure 5.3] was also digested with the 
same restriction enzymes.   
5.2.1.1.2 DNA gel electrophoresis 
DNA was visualised following restriction enzyme digestion (and other molecular 
biology techniques) by electrophoresis at 100 V on a 1% agarose TAE-gel.  1 g agarose 
dissolved in 100 ml 1 x TAE (50x TAE: 2 mol/L Tris base, 64 mmol/L EDTA, 17.5% 
acetic acid), by melting in a microwave, and then cooled, 10000x GelRed (Cambridge 
Biosciences) was added at a dilution of 1:10000.  DNA was visualised by exposure to 




5.2.1.1.3 Gel purification 
The required insert and vector bonds were excised from the gel and purified using the 
Roche  DNA  purification  kit  according  to  the  manufacturer’s  instructions.  Briefly, 300 
μl  binding  buffer  was  added  to  each  100  mg  agarose  and  incubated  for  10  min  at  56oC 
until   completely   dissolved.      150   μl   isopropanol  was   added   for   each   100  mg   agarose.    
The sample was mixed, applied to the column and centrifuged for 1 min at 13,000 x g.  
Flow-through  was  discarded  and  the  column  washed  twice  with  500  μl  and  then  200  μl  
wash   buffer   before   elution   in   50   μl   elution   buffer   by   centrifugation   into   a   fresh  
Eppendorf tube at 13,000 x g for 1 min.  All centrifugation steps were carried out in an 
Eppendorf bench-top centrifuge (5417R) at room temperature.   
5.2.1.2 Quantification of plasmid DNA 
Eluted  DNA  concentration  was  determined  by  dilution  of  1  μl  purified  plasmid  DNA  in  
99  μl  ddH2O  and  measurement  of   absorbance  at  λ  260  nm  using a spectrophotometer 
(Eppendorf BioPhotometer).  Protein contamination of the purified DNA sample was 
assessed through measurement of absorbance at λ   280   nm,   and   was   considered  
acceptable if the 260/280 ratio of absorbance was equal to or greater than 1.8. 
5.2.1.2.1  Ligation of insert 
The insert was ligated into the digested pShuttle-CMV shuttle vector using the 
Fermentas Rapid DNA Ligation Kit.  The required volume of insert DNA for a 3:1 
insert to vector molar ratio was calculated using the following formula (100 ng vector 
DNA was used): 
[(ng vector) x (size of insert (kb) x molar ratio)]/(size of vector) = ng insert 
The required volumes of vector and insert DNA were mixed, and ligation carried out 
using 5U T4 DNA ligase and 1x Rapid Ligation Buffer in a total volume  of  20  μl   at  





5.2.1.2.2 Transformation  of  chemically  competent  E.  coli  DH5α  cells 
Chemically competent E. coli DH5α   cells   (Subcloning   Efficiency,   Invitrogen)   were  
transformed with plasmid DNA.  Competent cells stored at -80oC were gently thawed 
on ice and 50 μl aliquoted into pre-chilled 1.5 ml Eppendorf tubes on ice.  Plasmid 
DNA (5 ng) was added to cells, gently mixed and incubated on ice for 30 min.  Cells 
were heat-shocked at 42oC for 20s and incubated on ice for 2 min.  Preheated (37oC) 
SOC  medium  (250  μl;; 8.5 mmol/L NaCl, 2.5 mmol/L KCl, 20 g/L tryptone, 5 g/L yeast 
extract, 20 mmol/L glucose, pH 7.0) was added to each reaction and cells were 
incubated at 37oC for 1 hr, shaking at 250 rpm.  All of the transformation reaction was 
spread out onto LB-agar (10 g/L NaCl, 10 g/L tryptone, 5 g/L yeast extract, 15 g/L agar) 
plates  containing  the  appropriate  antibiotic  for  the  plasmid  encoded  resistance  (50  μg/ml  
kanamycin) and incubated overnight at 37oC.   
5.2.1.2.3 Isolation and purification of plasmid DNA 
Well-isolated colonies of transformed cells were inoculated into 3 ml LB-Kan and 
grown at 37oC overnight, shaking at 250 rpm.  Plasmid DNA was isolated using the 
QIAprep Spin Miniprep Kit (Qiagen).  All centrifugation steps were carried out in an 
Eppendorf bench-top centrifuge (5417R) at room temperature. 
1.5 ml of bacterial cells were pelleted by centrifugation at 5000 rpm for 5 min, the 
supernatant removed by aspiration, and a further 1.25 ml of bacterial cells added to the 
same Eppendorf tube and pelleted by centrifugation at 5000 rpm for 5 min.  The 
supernatant  was  removed  by  aspiration  and  the  cell  pellet  resuspended  in  250  μl  chilled  
buffer  P1  by  vortexing.     250  μ  buffer  P2  was   added   to   lyse   the  cells,   and   tubes  were  
inverted   to  mix.     350  μl  buffer  N3 was added to neutralise the cell lysates, and tubes 
were inverted to mix.  Cell debris was pelleted by centrifugation at 13,000 rpm for 10 
min.  The supernatant was applied to a QIAprep column and centrifuged at 13,000 rpm 
for 1 min.  The flow-through was  discarded  and  the  column  washed  with  500  μl  buffer  
PB and centrifuged at 13,000 rpm for 1 min.  The flow-through was discarded and the 
column  washed  with   750  μl   buffer  PE   and   centrifuged   at   13,000   rpm   for   1  min.     To  
ensure removal of residual wash buffer, the flow-through was discarded and the empty 
column centrifuged for 13,000 rpm for 1 min.  The column was transferred into a clean 
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Eppendorf  tube  and  DNA  was  eluted  by  addition  of  50  μl  double  distilled  H2O (ddH2O, 
resistance 18.2 mΩ) to the column and centrifugation at 13,000 rpm for 1 min. 
The remaining 0.25 ml bacterial cells that were not subjected to DNA isolation, were 
added to 0.25 ml 50% (v/v) glycerol and stored at -80oC as glycerol stocks, and used in 
future experiments if large scale amplification   of   the   DNA   was   required.      3   μl   of  
plasmid DNA was digested with HindIII and NotI and the digestion products run on a 
1% agarose gel to check that the GOI had been successfully cloned into the pShuttle-
CMV shuttle vector, as previously.   
5.2.2 Generation of recombinant adenoviruses 
Recombinant adenoviruses are replication-deficient adenoviral vectors that are 
commonly used as a gene delivery tool.  Adenoviruses contain a linear, dsDNA genome 
between 26 and 45 kbp in length that is able to replicate in the nucleus of mammalian 
cells   using   the   host   cell’s   DNA   replication  machinery.      Generation   of   an   adenoviral  
vector using the AdEasy system301 involves subcloning the gene of interest (GOI) into a 
small shuttle plasmid, followed by the introduction of the linearised shuttle vector into a 
strain of BJ5183 cells that harbours the supercoiled backbone vector (AdEasier cells).  
BJ5183 bacterial cells are deficient in certain enzymes that mediate recombination in 
bacteria but still permit efficient generation of stable homologous recombinants.  The 
PacI-digested recombinant adenoviral DNA is then transfected into HEK293 cells and 
viruses are harvested 14-20 days later.   The individual steps will be outlined in more 
detail below.     
All   of   the   work   detailed   in   Section   5.2.2   was   undertaken   by   our   ‘in-house’   virus  
technician Dr Elizabeth Kemp.   
5.2.2.1 Cloning of GOI into pShuttle-CMV 
The pShuttle-CMV plasmid (Stratagene) was used as a shuttle vector into which the 
GOI was subcloned, before homologous recombination was carried out between 
pShuttle-CMV-GOI and pAdEasy-1, to create recombinant viral DNA, rAd5-GOI.  The 
plasmid contained the kanamycin (KanR) cassette, conferring resistance to the antibiotic, 
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kanamycin, in bacteria expressing the plasmid.  A vector map of pShuttle-CMV is 
shown in Figure 5.3.  
 
Figure 5.3 Vector map of pShuttle-CMV adenoviral shuttle vector utilised for the  
generation of recombinant viruses.   
The GOI was cloned into the pShuttle-CMV at the MCS using the NotI and HindIII sites.  
The KanR confers resistance to the antibiotic, kanamycin, in bacteria expressing this 




5.2.2.2 Homologous recombination between shuttle vector and the viral backbone 
DNA 
Approximately   1   μl   of   the   pShuttle-CMV shuttle vector containing the GOI was 
linearised using 3U PmeI in 1x NEBuffer 4 and BSA to a final concentration of 100 
μg/ml   in   a   total   volume   of   20   μl,   for   2   hr   at   37oC.  An aliquot of the digestion was 
checked by electrophoresis on a 1% agarose gel to ensure complete digestion of the 
plasmid, as previously.   
5.2.2.3 Transformation of electrocompetent E. coli BJ5183 cells 
BJ5183-AD-1 electroporation competent cells (Stratagene) containing the pAdEasy-1 
viral DNA backbone were transformed with the linearised shuttle plasmid to produce 
recombinant rAd5-GOI by homologous recombination. 
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Electrocompetent BJ5183 cells stored at -80oC  were   gently   thawed   on   ice   and   40   μl  
aliquoted into pre-chilled 1.5 ml Eppendorf tubes on ice.  Plasmid DNA (5 ng) was 
added to the cells, gently mixed and transferred to a pre-chilled 0.2 cm gap 
electroporation cuvette on ice.  The sides of the electroporation cuvette were dried with 
a paper towel, and placed inside the electroporator (Eppendorf Electroporator 2510).  
Cells  were  electroporated  at  25  μF,  200  Ω, 2.5 kV, and preheated (37oC) SOC medium 
(1 ml) added immediately after electroporation.  Transformed cells were transferred to a 
1.5 ml Eppendorf tube, and incubated at 37oC for 1 hr, shaking at 250 rpm.  Different 
volumes  (50,  100  and  850  μl)  of  transformed  cells  were  spread  onto  LB-agar containing 
the appropriate antibiotic for the plasmid encoded resistance  (50  μg/ml  kanamycin)  and  
incubated overnight at 37oC. 
Small, well-isolated colonies (small colonies are more likely to contain successful 
recombinants than larger colonies) were inoculated into LB-Kan, and Miniprep isolation 
and purification of plasmid DNA carried out as previously.  The size of the supercoiled 
DNA was checked on a 0.8% agarose gel to confirm recombination had occurred, and 
clones with a supercoiled band larger than the 12 kb marker on the 1 kb+ ladder were 
chosen for further restriction enzyme digestion.   
Promising clones were digested separately with PacI and HindIII, and digestion 
products resolved by electrophoresis on a 1% agarose gel, as previously.  PacI digestion 
yielded a band of either 4.5 or 3 kb, and a larger band at >30 kb where homologous 
recombination had occurred, and the stability of the genome was checked by HindIII 
digestion.  Suitable clones (4 μl   Miniprep DNA) were transformed into chemically 
competent E. coli DH5α  cells,  and  Miniprep  isolation  and  purification of the amplified 
DNA carried out, as previously. 
5.2.2.4 Culture of the packaging cell line, HEK293 cells 
HEK293  cells  were  maintained   in  T75   flasks   in  Dulbecco’s  modified  Eagles  medium  
(DMEM, Invitrogen) supplemented with 10% (v/v) FCS (Invitrogen), 50 U penicillin 
and   100   μg   streptomycin   (Penicillin-Streptomycin, Invitrogen).  When confluent, the 
medium was removed and 1 ml Trypsin (0.5% (v/v00 in 5.3 mmol/L EDTA 
(Invitrogen) was used to detach cells from the surface of the flask.  DMEM (10 ml) was 
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then added to the cell suspension, and 1.5 ml was transferred to each new T75 flask 
containing 13.5 ml fresh culture medium.  Cells were passaged every 2-3 days.  For 
experiments, cells were seeded onto 28 mm culture dishes (1 ml of detached cell 
suspension added to 1 ml of fresh medium) or larger T175 flasks for virus amplification 
(3 ml of detached cell suspension added to 22 ml of fresh medium). 
5.2.2.5 Transfection of HEK293 cells with the adenoviral DNA 
rAd5-GOI  DNA  (10  μg)  was  digested  with  100  U  PacI in 1x NEBuffer 1 and BSA at a 
final   concentration   of   100  μg/ml   in   a   total   volume  of   100  μl,   overnight   at   37oC.  An 
aliquot of the digestion was checked by electrophoresis on a 1% agarose gel to ensure 
complete digestion of the plasmid.  Digested DNA was purified by isopropanol 
precipitation.  1 volume of isopropanol and 0.1 volumes of NaOAc were added to the 
digested DNA and mixed well.  DNA was pelleted by centrifugation at 16,000 rpm for 
15 min (4oC), and the pellet washed with 0.5 ml 70% ethanol before a final 
centrifugation at 16,000 rpm for 5 min (4oC).  Centrifugation steps were carried out in 
an Eppendorf bench-top centrifuge (5417R).  Ethanol was removed and the pellet 
allowed to air dry for 10-15 min, before resuspension of rAd5-GOI  in  20  μl  TE,  pH  8.0  
overnight at 4oC. 
HEK293 cells, cultured as described in the previous section (Section 5.2.2.11) were 
plated at 6 x 105 cells per well in a 6-well plate that had been incubated overnight at 
37oC, so cells were approximately 50-60% confluent (but not more than 70% confluent) 
prior to transfection.  All of the linearised rAd5-GOI viral DNA was used to transfect 
HEK293  cells  using   the  Polyfect   transfection  reagent   (Qiagen).     20  μl   linearised  virus  
DNA was mixed  with  80  μl  OptiMEM  and  20  μl  Polyfect  in  an  Eppendorf  tube,  flicked  
to mix (to minimise risk of shearing the DNA) and allowed to incubate at room 
temperature   for   10   min.      600   μl   DMEM  was   added   to   the   transfection   mix,   600   μl  
DMEM removed from the well of HEK293 cells to be transfected, and all of the 
transfection mix added to the well of cells, taking care not to disturb the cell monolayer.  
Transfected HEK293 cells were incubated at 37oC/5% CO2 for 14-20 days, until most 
cells exhibited cytopathic effects, and CFP/YFP expression monitored from 5-7 days.  
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5.2.2.6 Large scale amplification, purification and titration of recombinant 
adenovirus 
HEK293 cells were plated at 6 x 105 cells per well in a 6-well plate and subsequently 
incubated overnight at 37oC, so cells were approximately 50-60% confluent (but not 
more than 70% confluent) prior to adenoviral infection.  The adenovirus was added 
directly to the well of cells in a careful manner so as not to disturb the monolayer.  
Infected HEK293 cells were incubated at 37oC/5% CO2 until cell lysis was observed 
(usually 2-3 days). 
Virus replication within HEK293 cells results in cell lysis, which is observable through 
the   ‘rounding   up’   and   detachment   of   cells   from   the   surface   of   the   culture   plate.    
Following infection of HEK293 cells with adenovirus, CFP/YFP expression was 
monitored, and was seen to occur in localised areas or patches of cells, indicating the 
replication and release of adenoviruses and infection of nearby cells for further viral 
replication.  When approximately   50%  of  HEK293   cells  were   either   ‘rounded   up’   or  
detached of the surface of the culture dishes (2-3 days after adenoviral infection), cells 
were scraped up into the medium (2 ml) using a cell scraper and transferred to a 15 ml 
Falcon tube.  Cells were lysed by three cycles of freezing in liquid nitrogen, followed by 
thawing in a water bath at 37oC and vortexing.  The cell debris was pelleted by 
centrifugation at 800 x g for 10 min, and the supernatant gently added to the medium of 
HEK293 cells grown to 70-80% confluence in a T75 flask. 
The next rounds of viral replication were generally more rapid, and the majority of 
HEK293 cells were detached 2-3 days after infection.  Cells were scraped into the 
medium of the flask, pelleted by centrifugation at 800 x g for 10 min, and all but 2 ml of 
supernatant removed before the above process of freeze-thawing and re-infection was 
repeated, until finally ten T175 flasks of HEK293 cells had been infected with the 
adenovirus.   
Cells from the ten T175 flasks were scraped into the media, cells pelleted at 800 x g for 
10 min, and all of the supernatant removed.  The cell pellet was resuspended in 2 ml 
PBS per adenovirus being amplified, subjected to three cycles of freeze-thawing, and 
cell debris pelleted by centrifugation at 800 x g for 10 min.  The supernatant was 
transferred to a fresh tube for purification of the adenovirus.   
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5.2.2.7 Purification of adenovirus 
A discontinuous CsCl gradient was set up in an ultracentrifuge tube, with 4 ml 1.4 g/ml 
CsCl (heavy) and 1.25 g/ml CsCl (light).  The cleared virus suspension was gently 
overlaid onto the gradient, and centrifuged at 20,000 rpm for 2 hr (20oC) with slow 
acceleration and no brake, in a Sw41 Ti swing-out rotor (Beckman.  After 
centrifugation, two viral bands were visible on the gradient, the lower of which is close 
to the interface between the two phases and contains the intact adenovirus, which was 
removed with a needle and syringe in a volume of approximately 2 ml.  The purified 
virus was transferred to dialysis tubing and dialysed against autoclaved virus dialysis 
buffer (10% (v/v) glycerol, 1 mmol/L MgCl2, 10 mmol/L Tris, pH 7.4) over 24 hr at 
4oC with 3-4 buffer changes, to remove the CsCl.  The virus was stored in aliquots at -
80oC. 
5.2.2.8 Calculation of MOI 
To determine the titre of the purified adenovirus, HEK293 cells were seeded into a 96-
well plate and allowed to adhere for 24 hr, at which point they had reached 
approximately 70-80% confluence.  The purified viral stock was subjected to serial 
dilution in DMEM culture medium, from 10-5 to 10-11,  and  10  μl  of  diluted  viral  stock  
added   to   the   90   μl  medium   in   each  well   of   a   96-well plate.  Each serial dilution of 
adenovirus was added to a whole row of the plate, as shown below, and DMEM culture 
medium alone was added to the final row. 
Cells were incubated at 37oC/5% CO2, the medium was replaced in wells that were not 
obviously infected after 5 days and the plate was scored for infection after 8 days, using 
CFP/YFP expression, by visualisation of the cells using a fluorescence microscope and 
UV lamp.  Any well containing any infected CFP/YFP-expressing cells was scored 
positive, and any well containing exclusively uninfected cells was scored negative.  The 
number of wells infected at each serial dilution of the adenovirus were tabulated as the 
percentage of cells infected and used to determine the virus titre using the equation 
described by Nicklin and Baker.302 
Calculation of the PFU of an adenovirus: 
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Proportionate distance, PD = (A-50)/(A-B) 
A = % response greater than 50% 
B = % response less than 50% 
Log10(TCID50)(infectivity dose) = log of dilution giving a response > 50% - PD 
Final virus titres: 
Epac1-camps   1.85 x 1010 PFU/ml 
PLM-Epac1-camps  4.31 x 1010 PFU/ml 
5.2.3 Transfection of plasmid constructs in HEK293 cells 
HEK293 cells, cultured as described in Section 5.2.2.11, were plated at 6 x 105 cells per 
well in a 6-well plate that had been incubated overnight at 37oC, so cells were 
approximately 50-60% confluent (but not more than 70% confluent) prior to 
transfection.      2   μg   of   plasmid   DNA   was   used   to   transfect   HEK293   cells   using   the  
Polyfect transfection reagent as described in Section 5.2.2.12.  Transfected HEK293 
cells were incubated at 37oC/5% CO2 for 48 hr.  
5.2.4 Isolation and culture of ARVMs 
The experiments in this chapter were performed using ARVMs isolated from the hearts 
of adult (250 – 300 g body weight) male Wistar rats (B & K Universal), as described in 
Chapter 2 (Section 2.3.1).  Cells were maintained in culture for biochemical analysis, as 
described in Section 2.3.3.2. 
5.2.5 Adenoviral infection of ARVMs 
ARVMs maintained in culture overnight were counted in three different fields (top, 
middle and bottom of well) of two wells of each 6-well culture plate, using an eye-piece 
graticule under 100x magnification, covering an area of 1 mm2.  ARVMs were counted 
if they crossed the top and right borders of the grid, but not if they crossed the bottom or 
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left borders, and cells were averaged to obtain the mean number of cells per mm2, which 
was subsequently multiplied by 962 (to account for the area of each well of a 6-well 
culture plate) to calculate the number of cells per well.   
This was used to calculate the volume of virus to add to each well to achieve the desired 
multiplicity of infection (MOI), using the following equation: 
Volume  added  (μl)  =  (Required  MOI  x  number  of  cells)/(PFU/μl) 
ARVMs were infected with adenovirus after the culture medium was replaced, at 
varying MOIs (10, 30, 100, 300 and 1000).  ARVMs were incubated with the 
adenovirus for 24, 48 or 72 hr at 37oC/5% CO2 without replacement of the culture 
medium.   
5.2.6 Fluorescence confocal microscopy 
All  of  the  work  described  in  Section  5.2.6  was  undertaken  with  the  assistance  of  our  ‘in-
house’  confocal  microscopy  technician  Dr  Peter  Stevenson.   
5.2.6.1 Principles 
In laser scanning confocal microscopy, a point light source (laser) is projected through 
an objective onto a specific object plane of a fluorescent specimen. To generate an 
image of the whole object plane, the specimen is scanned point- by- point and line-by-
line through the use of a computer-controlled x-y axis light deflection system. The 
resulting sequence of florescent light points are captured by the same objective lens and 
focused onto a photomultiplier (converting the optical signal into electrical signals) via 
a dichroic mirror. Any reflected excitation light captured by the objective is deflected 
away by this dichroic mirror, ensuring that only emitted light can reach the 
photomultiplier. The electrical output from the photomultiplier is relayed to the 
computer and is built into the image that is displayed on the monitor. 
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5.2.6.2 Preparation of ARVMS for confocal microscopy 
The culture medium was aspirated from ARVMs maintained in culture and infected 
with adenoviruses, and cells were washed with 2 ml of PBS which was removed 
immediately by aspiration.  For some experiments, live myocytes were directly imaged 
with confocal microscopy.  In other cases, myocytes were fixed by incubation in 4% 
(v/v) paraformaldehyde (Agar Scientific; 1 ml per well) in PBS for 10 min, washed in 2 
ml PBS (3 x 5 min washes) and stored at 4oC  in  PBS.    One  drop  of  Lisbeth’s  medium 
(30 mmol/L Tris, pH 9.5, 70% (v/v) glycerol, 5% (w/v) n-propyl gallate) was applied to 
the cells and a cover slip put on top.  The edges of the plate were removed and cells 
mounted onto a glass microscope slide using glue to attach the dish to the slide, and nail 
varnish to secure the cover slip.  Slides were stored at 4oC until examination under the 
confocal microscope.   
5.2.6.3 Fluorescence cell imaging and FRET monitoring 
Fluorescent images of specimens were acquired by confocal laser scanning on a Leica 
Sp5 II system equipped with Argon lasers (458, 476, 488 and 514 nm), Helium-Neon 
lasers (HeNe 543 and 633 nm) and a UV-diode (405 nm).  Optical slices  (~  1  μm)  of  
ARVMs were captured using a HCX L APO CS 63x/1.4 oil immersion lens, a frame 
size of 1024 x 1024 pixels at a pixel depth of 8 bit, a scan frequency of 400 Hz (4 frame 
average), and an exposure time of 30 ms.  The excitation and emission/detection 
wavelengths for the fluorescent proteins used in confocal microscopy experiments are 
detailed in Table 5.1.  Fluorescent images were background-corrected by subtracting 
autofluorescence intensities of untransfected cells (or background with no cells) from 
the emission intensities of fluorescent cells expressing the sensors.  The ratios of cyan-
to-yellow emissions were then calculated at different time points and normalised by 
dividing all ratios by the emission ratio just before stimulation, thereby setting the basal 
emission ratio to 1.0.  Further image processing was carried out using LAS AF software 





Table 5.1 Excitation wavelengths and emission collection spectra for CFP and YFP 
used in confocal microscopy experiments.    
Fluorophore Excitation wavelength (nm) Emission collection spectra (nm) 
CFP 436 465-505 
YFP 514 525-600 
5.2.6.4 Acceptor photobleaching 
FRET efficiency was determined by acceptor photobleaching; briefly, YFP was 
photobleached by intense illumination with a maximum laser output in the YFP channel 
(70x).  CFP fluorescence intensities before and after YFP photobleaching was then 
calculated.   
5.2.7 FRET monitoring using a dual photometer setup  
ARVMs on coverslips were placed on an inverted NIKON microscope and excited at 
436 nm.  Emission of CFP and YFP was detected simultaneously through 470 ± 20 and 
530 ± 25 nm band-pass filters placed inside two separate photo multipliter tubes.  Data 
were digitised and FRET was expressed as a ratio of CFP to YFP signals, the value of 
which was set to 1.0 at the onset of experiments.  Changes are expressed as percent 
deviation from this initial value of 1.0.   
5.2.8 Pharmacological treatment of ARVMs  
For assessment of agonist stimulation on FRET responses of the Epac1-camps and 
PLM-Epac1-camps, maximal concentrations of ISO or FRSK was added to ARVMs 
infected with the recombinant adenoviruses and the responses were measured using 
either fluorescence confocal imaging or the dual-photometer setup, as described in 




5.2.9 Sample preparation for SDS-PAGE 
Adenovirally-infected myocytes in culture at 37oC/5% CO2 for 24, 48 or 72 hr were 
lysed with 2x SDS sample buffer and the proteins subsequently scraped off the wells as 
described in Section 2.5.2. 
5.2.10 SDS-PAGE/Western blotting 
SDS-PAGE/WB was used to detect the expression of Epac1-camps and PLM-Epac1-
camps using antibodies against GFP, PLM-Ser63 and total PLM, as described in 
Chapter 2 (Section 2.5.5).  The incubation times for each of the primary and secondary 


















5.3.1 Molecular structure of Epac1-camps and PLM-Epac1-camps 
Epac1-camps consists of a single cAMP-binding domain of Epac1 (E157-E316) 
sandwiched between the GFP variants CFP and YFP.  PLM-Epac1-camps comprises 
PLM at the N-terminus and Epac1-camps as a C-terminal tag.  Figure 5.4 shows 







Figure 5.4 Domain structure of FRET-based cAMP sensors used in confocal 
microscopy experiments. 
(A) Epac1-camps, consisting of E157 – E316 of Epac1 sandwiched between CFP and 
YFP and (B) PLM-Epac1-camps, which has a full-length human PLM sequence (amino 
acids 1 – 92) attached to the YFP moiety of the original construct (adapted from 30).       
5.3.2 Characterisation of Epac1-camps and PLM-Epac1-camps in HEK293 
cells 
5.3.2.1 Intracellular localisation pattern of plasmid constructs 
The transfection efficiency of the plasmid constructs encoding for Epac1-camps and 
PLM-Epac1-camps in HEK293 cells was approximately 60% (data not shown).  Epac1-
camps showed a uniform distribution within the cell bodies while PLM-Epac1-camps 
was found to localise predominantly to membrane regions.  Representative images are 
shown in Figure 5.5 [Panels A & B].  For both constructs, the CFP and YFP 
fluorescence signals were found to correspond to each other in both intensity and 
location, indicating that both the sensors were intact upon transfection, with the two 







 CFP YFP Merge 
A 
 
   
B 
 
   
Figure 5.5 Intracellular localisation of FRET-based cAMP sensors in HEK293 cells.   
Confocal microscopy images of HEK293 cells transfected with (A) Epac1-camps or (B) PLM-
Epac1-camps.  HEK293 cells that were approximately 50-60% confluent were transfected for 
48  hr  with  Polyfect  transfection  reagent  using  2  μg  of  plasmid  DNA,  and  confocal  microscopy  
was subsequently used to image the transfected cells.  CFP and YFP fluorescence signals 
are displayed in separate channels, and a merged image of CFP and YFP is also shown.  
The CFP and YFP moieties were individually excited at wavelengths of 436 nm and 514 nm 
respectively.   
5.3.2.2 Molecular weight of gene products 
SDS-PAGE/Western blotting was carried out to check the size of the gene products 
being expressed.  As deduced from the molecular weights of the individual components, 
Epac1-camps and PLM-Epac1 camps should have molecular weights of approximately 
70 and 85 kDa respectively.  Using both anti-GFP and anti-PLM antibodies, we 
observed bands corresponding to these theoretical weights for products expressed from 
both pcDNA constructs, and also from the pShuttle vector containing the GOI PLM-
Epac1-camps.  The recombinant virus expressing PLM-Epac1-camps could not be 
detected, likely due to the fact that it is a large plasmid and therefore is poorly 
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transfected in HEK293 cells.  Our results indicated that the plasmid constructs were 






Figure 5.6 Molecular weight of plasmid gene products expressed in HEK293 cells. 
Western blots of HEK cells transfected with pCDNA3 constructs encoding Epac1-
camps and PLM-Epac1-camps, the pShuttle construct encoding PLM-Epac1-camps 
and the  radPLM-Epac1-camps, a larger plasmid used in recombinant adenovirus 
generation.   
 
For each construct, HEK293 cells   were   transfected   with   2   μg   of   plasmid  DNA   using  
Polyfect transfection reagent.  Cell lysates were subjected to SDS-PAGE (10% gel) and 
WB analysis using (A) anti-GFP or (B) anti-total PLM N1 antibodies.  Blots are 
representative of at least three individual experiments.  
5.3.3 Characterisation of Epac1-camps and PLM-Epac1-camps in ARVMs 
In order to use these sensors as a tool in ARVMs, we incorporated the GOIs into 
adenoviral vectors.  As in HEK293 cells, the intracellular expression patterns of the 
recombinant adenoviruses and molecular weights of the gene products in the infected 
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myocytes were investigated using confocal microscopy and SDS-PAGE/WB 
respectively. 
5.3.3.1 Intracellular localisation pattern of recombinant adenoviruses 
Figure 5.7 shows representative images of ARVMs that have been infected with the 
recombinant adenoviruses expressing Epac1-camps or PLM-Epac1-camps.  The 
transfection efficiency of the recombinant viruses expressing the two sensors in 
ARVMs was approximately 40% at 300 MOI (data not shown).  As observed in 
HEK293 cells, Epac1-camps was found to be distributed throughout the cytosol, but the 
fluorescence signals were determined to be more intense at the striations of the plasma 
membrane [Figure 5.7; Panel A].  In contrast, PLM-Epac1 was found to only minimally 
localise to the sarcolemmal membrane of ARVMs; rather, we observed a predominant 
localisation of the sensor to the perinuclear regions of the myocytes [Figure 5.7; Panel 
B], which is in direct contrast to confocal images previously generated by our laboratory  
showing an exclusive pattern of membrane staining by anti-PLM antibodies [Figure ]  
For both cAMP sensors, the same pattern of expression was found across the different 
MOIs, although as expected, fluorescence intensities were greater with high MOIs.  In 
all cases, CFP and YFP fluorescence signals obtained from infected ARVMs were 
found to correspond to each other in intensity and location, suggesting that the 
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Figure 5.7 Intracellular localisation of FRET-based cAMP sensors in ARVMs.   
Confocal microscopy images of ARVMs infected with (A) Epac1-camps or (B) PLM-Epac1-
camps.  ARVMs cultured overnight were infected for 48 hr with adenoviral vectors at 300 
MOI and confocal microscopy was subsequently used to image the infected myocytes.  CFP 
and YFP fluorescence signals are displayed in separate channels, and a merged image of 
CFP and YFP is also shown.  The CFP and YFP moieties were individually excited at 
wavelengths of 436 nm and 514 nm respectively.   
5.3.3.2 Molecular weight of gene products 
To investigate the molecular weights of Epac1-camps and PLM-Epac1-camps in the 
recombinant adenoviruses, cell lysates from ARVMs that have been infected with 
adenoviral vectors expressing the constructs at a range of MOIs (10, 30, 100, 300 and 
1000) for three different durations of infection (24, 48 or 72 hr) were subjected to SDS-
PAGE/WB analysis using anti-GFP, anti-Ser63 and anti-total PLM antibodies.   
To identify the molecular weight of Epac1-camps, we used an anti-GFP antibody to 
detect the CFP/YFP fluorophores (previous attempts at probing with an anti-Epac1 
antibody produced no signals even after optimisation of the protocol) in ARVMs 
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infected with the recombinant adenovirus expressing Epac1-camps.  Using the anti-GFP 
antibody, we observed a single band at approximately 37 kDa and a cluster of bands at 
50 kDa region that seemed to be MOI-dependent, in contrast to the expected weight of 
70 kDa [Figure 5.8; Panels A-C].  The number of bands was found to increase with a 
longer duration of infection [Figure 5.8; Panels A-C].  These observations were 
somewhat unexpected considering that the same antibody was used to pick up bands at 
approximately 70 kDa in HEK293 cells transfected with the plasmid construct [Figure 






Figure 5.8 Molecular weight of Epac1-camps expressed in ARVMs.   
Western blots of ARVMs infected with Epac1-camps.  ARVMs cultured overnight were 
infected for (A) 24 hr; (B) 48 hr or (C) 72 hr with the adenoviral vector at 10, 30, 100, 
300 or 1000 MOI.  Cell lysates were subjected to SDS-PAGE (10% gel) and WB 
analysis using an anti-GFP antibody.  Blots are representative of at least three individual 
experiments.   
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A similar pattern of expression was detected with this antibody for expression of PLM-
Epac1-camps at a single time-point [Figure 5.9].  In an attempt  to  produce  a  ‘cleaner’  
signal, we used the anti-Ser63 antibody to detect the PLM portion of the sensor.  As 
with the anti-GFP antibody, multiple sets of bands were observed using the anti-Ser63 
antibody that were seemingly dependent on both MOI and duration of infection; a 
dominant   band   and   a   ‘shadow’   band   at   between 75 kDa and 100 kDa [Figure 5.10; 
Panels A-C] and another set of bands at the 50 kDa region [Figure 5.10; Panels A-C].  
An almost identical pattern of expression was observed with the anti-total PLM 
antibody, although the signals generated seemed to be more pronounced across the 
MOIs [Figure 5.10; Panels A-C].     
On the whole, the signals observed with either antibody after 24 hr were quite weak, 
while in ARVMs infected with PLM-Epac1-camps for 48 hr at 300 or 1000 MOIs, the 
expression level of the recombinant adenovirus reached an easily detectable level, and 
was quantitatively similar to the expression level of basal PLM, indicating the presence 
of an adequate amount of the protein being expressed in the ARVMs.  After 72 hr, 
similar levels of expression were reached with infection at lower MOIs; however, the 
extra 24 hr of culture was found to result in an increased level of apoptosis.  Hence 
structural and functional characterisation of PLM-Epac1-camps was carried out in 
myocytes that have been infected with the recombinant adenovirus at either 300 or 1000 





Figure 5.9 Molecular weight of PLM-Epac1-camps expressed in ARVMs.   
Western blot of ARVMs infected with PLM-Epac1-camps.  ARVMs cultured overnight 
were infected with the adenoviral vector at 10, 30, 100, 300 or 1000 MOI for 24 hr.  
Cell lysates were subjected to SDS-PAGE (10% gel) and WB analysis using an anti-




Figure 5.10 Molecular weight and relative expression level of PLM-Epac1-camps in ARVMs.   
Western blot of ARVMs infected with PLM-Epac1-camps, in addition to native levels of PLM.  ARVMs cultured overnight were infected with the 
adenoviral vector at 10, 30, 100, 300 or 1000 MOI for (A) 24 hr; (B) 48 hr or (C) 72 hr.  Cell lysates were subjected to SDS-PAGE (10% gel) 
and WB analysis using either an anti-PLM-Ser63 antibody or anti-total PLM N1 antibody.  Blots are representative of at least three individual 
experiments.   
             A                                             B                                          C 
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5.3.4 Functional characteristics of Epac1-camps and PLM-Epac1-camps 
Following the structural characterisation of Epac1-camps and PLM-Epac1-camps in 
ARVMs, the functional characteristics of these sensors were assessed. 
5.3.4.1 FRET monitoring in ARVMs 
We previously made use of dual excitation of CFP and YFP to generate fluorescent 
signals; since FRET relies on transfer of energy between two fluorophores in proximity 
to each other – in this case, from CFP to YFP – we tested whether single excitation of 
CFP would result in both CFP and YFP emission and vice versa.  For both Epac1-
camps and PLM-Epac1-camps, CFP excitation at 436 nm was found to result in both 
CFP and YFP emissions [Figure 5.11; Panel B & Figure 5.12; Panel B], in an identical 
manner to the dual excitation of both fluorophores [Figure 5.12; Panel A & Figure 5.13; 
Panel A], while YFP excitation resulted in only YFP emission, with no CFP 
fluorescence detected [Figure 5.11; Panel C & Figure 5.12; Panel C].  This indicates the 
presence of FRET between the two fluorophores, thus implying that the sensors were 
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Figure 5.11 FRET monitoring of Epac1-camps in ARVMs.   
Confocal microscopy images of Epac1-camps: (A) upon dual excitation of both CFP and 
YFP; (B) excitation of CFP only and (C) excitation of YFP only.  ARVMs cultured overnight 
were infected for 48 hr with an adenoviral vector expressing Epac1-camps at 1000 MOI and 
confocal microscopy was subsequently used to image the infected myocytes.  CFP and YFP 
fluorescence signals are displayed in separate channels, and a merged image of CFP and 
YFP is also shown.  The CFP and YFP moieties were excited at wavelengths of 436 nm and 
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Figure 5.12 FRET monitoring of PLM-Epac1-camps in ARVMs. 
Confocal microscopy images of PLM-Epac1-camps: (A) upon dual excitation of both CFP 
and YFP; (B) excitation of CFP only and (C) excitation of YFP only.  ARVMs cultured 
overnight were infected for 48 hr with an adenoviral vector expressing PLM-Epac1-camps at 
1000 MOI and confocal microscopy was subsequently used to image the infected myocytes.  
CFP and YFP fluorescence signals are displayed in separate channels, and a merged image 
of CFP and YFP is also shown.  The CFP and YFP moieties were excited at wavelengths of 





5.3.4.2 FRET efficiency  
The efficiency of FRET is defined as the proportion of donor molecules that transfer 
their excitation state energy to the acceptor molecules, and is a measure of the change in 
FRET signal in going from minimal to maximal cAMP levels.  One way in which FRET 
efficiency can be determined is using acceptor photobleaching experiments.  In this 
case, upon excitation of CFP, photobleaching of donor YFP molecules in selected 
regions of the myocyte using intense illumination for 60-120s was found to result in an 
increase in CFP fluorescence intensity (although not observable by eye, it was detected 
using computer software; see Figures 5.13 and 5.14; Panels A & B), suggesting that 
CFP and YFP are functionally sensitive to each other and capable of generating a FRET 
signal.  Using this approach, FRET efficiency was determined to be approximately 20% 






Figure 5.13 FRET efficiency of Epac1-camps in ARVMs. 
Confocal microscopy images of Epac1-camps upon acceptor photobleaching.  ARVMs 
cultured overnight were infected for 48 hr with an adenoviral vector expressing Epac1-camps 
at 1000 MOI and confocal microscopy was subsequently used to image the infected 
myocytes (A) before photobleaching of YFP and (B) after photobleaching of YFP moieties in 
selected regions of the myocyte with intense illumination.  CFP and YFP fluorescence 
signals are displayed in separate channels, and a merged image of CFP and YFP is also 
shown.  The CFP moiety was excited at a wavelength of 436 nm.  FRET efficiency was 








Figure 5.14 FRET efficiency of PLM-Epac1-camps in ARVMs. 
Confocal microscopy images of PLM-Epac1-camps upon acceptor photobleaching.  ARVMs 
cultured overnight were infected for 48 hr with an adenoviral vector expressing PLM-Epac1-
camps at 1000 MOI and confocal microscopy was subsequently used to image the infected 
myocytes (A) before photobleaching of YFP and (B) after photobleaching of YFP moieties in 
selected regions of the myocyte with intense illumination.  CFP and YFP fluorescence 
signals are displayed in separate channels, and a merged image of CFP and YFP is also 
shown.  The CFP moiety was excited at a wavelength of 436 nm.  FRET efficiency was 
determined to be ~20% (n=4).         
 
5.3.4.3 FRET signal characteristics 
Subsequent to our structural and functional characterisation of Epac1-camps and PLM-
Epac1-camps, we attempted to characterise the amplitude and duration of the FRET 
signal in response to changes in [cAMP]i using fluorescence confocal microscopy and a 
dual-photometer setup.   
5.3.4.3.1 Fluorescence confocal microscopy measurements 
Using fluorescence cell imaging, a camp-dependent FRET change in response to the 
addition of a saturating concentration of ISO or FRSK was not observed for PLM-
Epac1-camps, with no change in CFP or YFP fluorescence intensities after agonist 
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Figure 5.15 cAMP-induced FRET signal produced by PLM-Epac1-camps in ARVMs.   
Confocal microscopy images of PLM-Epac1-camps (A) prior to treatment with ISO and (B) 
after treatment with 1 μmol/L ISO.  ARVMs cultured overnight were infected for 48 hr with an 
adenoviral vector expressing PLM-Epac1-camps at 300 MOI and confocal microscopy was 
subsequently used to image the infected myocytes before and after addition of a saturating 
concentration of ISO to the myocytes.  CFP and YFP fluorescence signals are displayed in 
separate channels, and a merged image of CFP and YFP is also shown.  The CFP moiety 
was excited at a wavelength of 436 nm.     
 
5.3.4.3.2 Dual photometer setup measurements 
Figure 5.16 demonstrates the FRET response to an intracellular elevation of cAMP.  
Excitation of the CFP moiety in PLM-Epac1-camps at a wavelength of 436 nm led not 
only to CFP emission at ~480 nm but also to YFP emission at ~525 nm.  Addition of a 
saturating concentration of FRSK resulted in a progressive reduction in YFP and 
increase in CFP fluorescence, demonstrating a loss in FRET (represented as the ratio of 





Figure 5.16 Quantitative assessment of cAMP-induced FRET signal produced by 
PLM-Epac1-camps in ARVMs.   
Dual-photometer measurement of FRET signal generated by PLM-Epac1-camps in 
response to cAMP elevation with FRSK in ARVMs.  ARVMs cultured overnight were 
infected for 48 hr with an adenoviral vector expressing PLM-Epac1-camps at 300 MOI and 
ratiometric measurements were made using a dual-photometer setup.  A saturating 
concentration of FRSK was added directly to the myocytes during the experiment.  CFP 
and YFP fluorescence signals are displayed in red and yellow respectively, while the green 
trace indicates the YFP/CFP ratio.  The CFP moiety was excited at a wavelength of 436 










5.4 Discussion  
To develop a new generation of FRET-based cAMP reporters, several research groups 
have attempted to use the cAMP effector Epac as a backbone.  It has been suggested 
that cAMP binding to Epac induces a conformational change that liberates the catalytic 
domain of Epac from intrasubunit allosteric inhibition.299  In 2004, Ponsioen and co-
workers generated a construct in which full-length Epac1was fused amino terminally to 
CFP and carboxyl terminally to YFP.297  In the same year, DiPilato and co-workers 
generated a sensor based on Epac1 by sandwiching the full length protein between 
ECFP and citrine (an improved version of YFP) respectively, termed ICUE1.296  Both of 
these sensors were shown to induce a cAMP-dependent FRET change in response to 
cAMP elevation.  In contrast, Nikolaev and colleagues demonstrated that a single 
cAMP-binding domain is sufficient to generate a conformational change detectable by 
FRET, generating a construct based on the binding domain of Epac1 (E157-E316) 
sandwiched between CFP and YFP, termed Epac1-camps.30  Based on structural data 
for cAMP binding to Epac1,303 this implies that positioning of CFP and YFP directly on 
the cAMP-binding domain of these Epac proteins is sufficient to result in a change in 
the distance between the fluorophores in response to the cAMP-induced conformational 
switch.  The fact that these sensors are catalytically active is all the more unexpected 
when considering that previous attempts at generating chimeric proteins based on 
various Epac truncations resulted in sensors that were either catalytically inactive and 
therefore unresponsive to cAMP elevation, or capable of only producing a weak FRET 
signal compared to the full-length construct.297  This discrepancy could potentially be 
caused by use of different linkers connecting sequences of Epac and fluorescent proteins 
in individual constructs and the different cell types for testing these constructs.   
In order to directly monitor cAMP dynamics at the membrane in the vicinity of PLM, 
PLM-Epac1-camps was generated (see Section 5.2.1), which we hypothesised to be 
specifically localised to the plasma membrane but otherwise possessing the same 
functional characteristics as Epac1-camps.  As aforementioned, fusion of specific 
targeting motifs to the basic Epac1 sensor has been previously attempted.  For instance, 
the attachment of ICUE1 to targeting motifs for the plasma membrane, nucleus and 
mitochondria has been shown to successfully localise the reporter to these particular 
regions of the cell.296     
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Our imaging experiments demonstrated that the expression pattern of the plasmid 
construct encoding for Epac1-camps in HEK293 cells was predominantly cytosolic 
(using both CFP and YFP fluorescence signals), which corresponds to initial 
observations by Nikolaev and colleagues, who found a uniform distribution of the 
sensor throughout the cytosol of CHO-A2B cells.30  They attributed this to the fact that 
the sensor contains only the cAMP-binding domain of Epac; on the other hand, the two 
aforementioned full-length Epac1 sensors were found not only to be localised to the 
cytosol, but also to the nuclear envelope and to perinuclear compartments, in addition to 
mitochondria.296  In contrast, we observed using YFP fluorescence that approximately 
60% of HEK293 cells transfected with the PLM-Epac1-camps construct displayed 
membrane localisation, consistent with the idea that under normal physiological 
conditions, PLM is selectively expressed in the sarcolemma of cardiac myocytes, and 
the inclusion of the PLM sequence in the construct should target the sensor exclusively 
to the membrane.  We had initially expected a more predominant pattern of membrane 
localisation in these cells; the fact that we observed a cytosolic distribution of this 
reporter in some of the transfected HEK293 cells may reflect the possibility that the 
construct was being overexpressed in our experimental system, or the inherent 
differences between HEK293 cells (which do not normally express PLM) and ARVMs.   
The use of monomolecular sensors records conformational changes that result in either 
the distance or the orientation of the probes (it is often difficult to experimentally 
distinguish between the two potential mechanisms) and has several advantages over 
sensors constituted of two separate proteins, such as PKA-based FRET sensors.  One 
advantage is that unlike PKA probes, whereby the expression levels of the two 
fluorophore-labeled subunits have to be carefully matched to ensure reliable 
measurement, the two fluorophores on a monomolecular sensor are always expressed at 
a 1:1 stoichiometry if it remains intact.  Furthermore, changes in the localisation and 
resultant artefact (such as fluorescence quenching) will affect both probes at the same 
time; as a result, intramolecular FRET will usually outweigh more complex interactions.   
Importantly, for both Epac1-camps and PLM-Epac1-camps, we found equal expression 
levels of CFP and YFP upon individual excitation of the fluorophores at 436 and 514 
nm respectively in virtually all of the transfected cells, with the localisation pattern and 
fluorescence intensities of the two fluorophores corresponding to each other in the vast 
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majority of cases.  This suggests that the sensor was intact in these cell types and that 
the CFP and YFP moieties were attached to the same protein.  These observations are 
consistent with our WB experiments using both the anti-total PLM N1 antibody and an 
anti-GFP antibody, with the bands observed corresponding to the respective molecular 
weights of the gene products, indicating that their structures remained unaltered after 
transfection of the plasmid constructs. 
We subsequently incorporated the constructs into adenoviral vectors to allow their 
characterisation in ARVMs, and we investigated the pattern of expression in response to 
a range of MOIs.  In imaging experiments, the uniform distribution of Epac1-camps in 
ARVMs observed across the different MOIs tested is generally consistent with its 
cytosolic localisation in HEK293 cells, although the fluorescence signal was observed 
to be greater at the striated junctions of the plasma membrane, suggesting that increased 
cAMP levels are present at the membrane regions surrounding the T-tubules, since one 
would not expect the sensor to be localised to these regions otherwise under normal 
circumstances.  Interestingly, its localisation pattern is virtually identical to that of 
Epac2-camps in ARVMs, which we also investigated, suggesting that the cAMP 
binding domain of Epac proteins is preferentially targeted to sites with high [cAMP].   
In contrast, we found that although there is some evidence for membrane localisation of 
PLM-Epac1-camps, the majority of the sensor population expressed was targeted 
exclusively to the perinuclear region in these cells, in sharp contrast to our hypothesised 
model of membrane localisation, based on previous observations of predominantly 




Figure 5.17 Membrane staining of 
PLM and NKA α1 subunit in 
ARVMs. 
Confocal microscopy image of an 
ARVM immunolabelled with 
antibodies against PLM (red), the 
NKA α1 subunit (green), and co-
localisation between PLM and the 
NKA (yellow).  Nuclei were stained 
with DAPI (blue). 
 
We initially proposed that this observation could be explained by the sensor being 
overexpressed, which led to incorrect intracellular trafficking of the sensor.  Therefore, 
the relatively large fluorescence signal produced by the significant proportion of the 
protein that ended up in the perinuclear region would mask the significantly smaller 
signal generated by the sensor at the membrane.  However, WB experiments 
demonstrated that even at 1000 MOI, the amount of PLM-Epac1-camps was not 
significantly higher than the amount of endogenous PLM normally present in ARVMs.  
Additionally, we found that the pattern of expression remained identical for both low 
and high MOIs, with little evidence of selective membrane localisation of PLM-Epac1-
camps, suggesting that an inherent property of the sensor conferred incorrect trafficking 
and expression in this experimental system.  This was surprising considering that the 
construct seemed to be expressed correctly in HEK293 cells, suggesting either an 
alteration of the molecular structure of PLM-Epac1-camps occurred in the process of 
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generating the recombinant adenovirus,  or that the structure of the sensor was somehow 
incompatible with the trafficking system in cardiomyocytes.   
As PLM-Epac1-camps was found to be not localised to the membrane, this suggested 
that PLM had been cleaved off either during the process of generating the recombinant 
adenovirus or after adenoviral infection in ARVMs.  However, if this were the case, one 
would expect a uniform distribution of the truncated sensor within the cytosol, as PLM-
Epac1-camps minus PLM would produce Epac1-camps.  However, PLM-Epac1-camps 
was selectively targeted to the perinuclear region in our study.  In WB experiments, 
probing with either the anti-Ser63 or anti-total PLM N1 antibody produced bands at 
approximately 75-85 kDa and 35-50 kDa for all MOIs investigated.  The theoretical 
molecular weight of PLM-Epac1-camps is approximately 85 kDa.  Additionally, we 
noticed that the gene product in the plasmid construct transfection experiments was also 
running at 75 kDa on our gels, suggesting that the structure of PLM-Epac1-camps in the 
adenoviral vector was intact but was running at 10 kDa below its theoretical weight.   
This infers that one population of the sensor could have been structurally unaltered 
while the 35 kDa band suggested that in another population of PLM-Epac1-camps, 
approximately 40% of the gene product had been cleaved off, although at least a portion 
of the PLM sequence must have been intact as it could be detected by the relevant 
antibodies.  Considering that PLM-Epac1 camps is constituted of PLM-YFP-Epac1-
CFP (See Section 5.2.1 for further details), this population likely constituted the intact 
PLM sequence in addition to a portion of the YFP moiety.  This implies that a third 
population of the sensor constituting the remaining portion of YFP, the cAMP binding 
site on Epac1, in addition to CFP, was present in the infected ARVMS, but could not be 
detected using the anti-PLM-Ser63 or the anti-total PLM N1 antibodies, as PLM was 
absent.  Unfortunately, probing with an anti-GFP antibody revealed no further insights 
into the specificities of these truncated proteins as we detected a multiplicity of bands, 
most of them likely to be nonspecific for PLM-Epac1-camps or Epac1-camps.  It 
remains unclear why the first population of PLM-Epac1-camps, which should have been 
relatively intact, was not targeted to the membrane, unless it too had undergone 
modification after adenoviral infection.  We attempted to identify sites within the amino 
acid sequence of PLM-Epac1-camps that could be susceptible to degradation or 
alteration during intracellular trafficking, but the linker region between PLM and the 
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YFP moiety constituted approximately only three base pairs.  It is possible that 
erroneous folding of the protein had occurred during incorporation of the GOI into the 
recombinant virus or after the adenoviral vector had been expressed in the myocytes.    
Consistent with our observations in HEK293 cells, we found that the localisation 
patterns of CFP and YFP corresponded to each other upon individual excitation of the 
two fluorophores, with an equal level of intensity of the two fluorophores detected.  On 
the whole, our findings suggest that the 75 kDa population of the sensor was primarily 
targeted to the perinuclear region and contributed to the CFP and YFP signals detected 
in the imaging experiments, while the 35 kDa population lacked intact YFP or CFP 
moieties, and therefore would not have contributed to the observed signals.  What 
remains unclear is whether the third population contributed to the CFP signal, as it 
theoretically would have had an intact CFP moiety, although we found no discrepancy 
between the CFP and YFP channels in any of the infected myocytes that we 
investigated.     
These findings, although unexpected, prompted us to investigate whether the intact 
population of PLM-Epac1-camps was catalytically active and capable of producing a 
cAMP-dependent FRET response upon cAMP elevation.  FRET depends not only on 
the distance of the two fluorophores, but also on their spectral overlap and their relative 
orientation, and that the readouts can be affected by a number of parameters such as 
fluorescence quenching which require a number of careful controls.304  One significant 
disadvantage of monomolecular cAMP reporters is that having two probes attached to a 
single protein generally produces less FRET, since the two probes will rarely move far 
away from each other to cause full loss of FRET.  Particularly in the case of GFP 
variants such as CFP and YFP, the probes are large compared to the movements that 
they report, and they are quite flexibly attached to the proteins of interest, allowing for 
wide differences between the distances of the two probes and their attachment points.  
In most of the tested cells, significant FRET was observed, suggesting that CFP and 
YFP were in close proximity to each other.  However, while FRET measurements 
indicate distances between the two probes, they do in general provide only relative 
information about distances between the attachment points in the proteins of interest.  
Therefore, these measurements, on their own without other structural information, are 
not really suited to elucidate molecular movements.  However, they do indicate that 
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movements happen, and they reliably report when and where in a cell they happen.  
Indeed, in the course of designing new sensors, several constructs with fluorophores 
attached in different positions or with variable linkers between the GFP variant and 
effector molecule are often tested to maximise the efficiency of energy transfer, as is the 
case here.   
The efficiency of FRET is defined as the proportion of donor molecules that transfer 
their excitation state energy to the acceptor molecules; this proportion depends on 
optimal (ideally parallel) orientation of the donor and acceptor dipoles.  However, this is 
not often straightforward because while the molecular structures of the proteins to 
which the probes are attached are known, the structure of the overall sensor remains 
unclear, as is the case here. Relative FRET efficiency can be determined from the ratio 
of acceptor to donor fluorescence when the donor fluorophore is excited; in confocal 
imaging experiments, we found that upon single-channel excitation of CFP at 436 nm, 
fluorescent signals from both CFP and YFP were observed, suggesting energy transfer 
to YFP.  However, care must be excised as the FRET signal might simply have resulted 
from the bleed-through of donor fluorescence into the acceptor detection channel, as we 
did not correct for the overlap between the closely matched excitation spectra of CFP 
and YFP.305  We therefore proceeded to determine the FRET efficiency of these sensors 
by acceptor photobleaching and calculating the relative increase in donor emission.   
Although precise intracellular environments may influence these values, the FRET 
efficiency of 20% for PLM-Epac1-camps was similar to that for Epac1-camps, and is 
highly consistent with the value obtained for Epac probes in general, suggesting that 
despite the unexpected pattern of localisation, PLM-Epac1 was capable of generating a 
FRET signal (although the increase in CFP emission was not discernible by eye).  
Likewise, we found that the change in the FRET response upon addition of saturating 
concentrations of ISO could not be detected using fluorescence confocal imaging; in 
this setting, the time taken to scan each image frame may limit the temporal resolution, 
and the higher intensity of the focused laser beam could result in greater photobleaching 
and loss of signal integrity over time.  The most likely explanation for our observation is 
that our confocal microscope setup was not sensitive enough to detect the quantitatively 
small changes in the FRET signal.   
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In contrast, the relatively robust increase in YFP/CFP ratio as detected by the dual-
photometer setup suggests that PLM-Epac1-camps is capable of generating a FRET 
signal in response to an elevation in intracellular cAMP concentration.  The use of a 
saturating concentration of FRSK to directly activate AC-mediated production of cAMP 
meant that we could be sure a substantial rise in total intracellular cAMP levels had 
been induced, unlike ISO, which may increase cAMP concentration within specific 
intracellular compartments.  In vitro studies have demonstrated that the affinity of the 
single cAMP-binding site on Epac is at least an order of magnitude lower than PKA;303 
as a result, many Epac-based sensors allow higher cAMP concentrations to be 
visualised at the expense of lower concentrations of the second messenger, since their 
KD values generally lie between  14  and  50  μmol/L.  This characteristic of PLM-Epac1-
camps is particularly suited to investigating PDE function, since experiments involving 
the addition of a submaximal [ISO] followed by treatment with rolipram could lead to a 
significant degree of cAMP accumulation (akin to the PDE inhibition experiments 
described in Chapters 3 and 4), which could saturate probes with high sensitivity to 
cAMP.  Indeed, awareness of the FRET efficiency and dynamic range for a given sensor 
is essential to appreciate the amplitude of any cAMP rise detected and to avoid 
misinterpretation of results, and further experiments are required to quantify the kinetic 
properties of PLM-Epac1-camps, including its dynamic range, sensitivity as well as its 
on- and off-rates.  
In conclusion, our findings confirm that the binding domain of Epac, a protein that is 
highly expressed in many different tissues, provides an excellent backbone for 
fluorescent probes to monitor the dynamics of cAMP in ARVMs.  PLM-Epac1-camps, 
the novel Epac-based cAMP reporter that we have generated, and whose structural and 
functional parameters have been partly characterised here, is potentially capable of 
measuring cAMP in the physiological range with high temporal and spatial resolution.  
Our finding that this particular sensor is displaying   an   ‘incorrect’   localisation pattern 
may reflect a particular structural defect that will need to be overcome.  However, 
considering the encouraging functional characteristics observed to date, it is reasonable 
to propose that when used in conjunction with Epac1-camps, our novel sensor could be 
ubiquitously applied to study the regulation and biological functions of cAMP in cardiac 
myocytes in both the absence and presence of PDE inhibition.  
Chapter 6 
185 
6 FINAL CONCLUSIONS 
PLM is the accessory protein to the cardiac NKA; it physically associates with the pump 
and is responsible for regulating its activity during sympathetic stimulation.    
The primary objective of the project was to identify the possible roles that different PDE 
families within the heart may play in modulating cAMP-PKA dependent 
phosphorylation of PLM and how these translate into changes in NKA activity. As per 
this objective, the work described in this thesis has confirmed the involvement of 
individual PDE subtypes in the regulation of intracellular cAMP signalling to the 
cardiac PLM-NKA complex under neurohormonal stimulation, and provided some 
interesting insights into their roles which could be further explored in subsequent 
studies.   
Our experimental model consisted of acute treatment of ARVMs with a number of 
family-selective PDE inhibitors in the absence and presence of ISO; changes in the 
biochemical and functional parameters of the PLM-NKA complex were subsequently 
assessed using biochemical and electrophysiological means.  The consistently high 
basal phosphorylation level of PLM, including at the PLM-Ser68 site, could potentially 
compound investigation into PLM phosphorylation and/or NKA activity using 
pharmacological agents that raise intracellular cAMP and PKA levels.  However, for 
each set of experiments, we were able to determine a suitable submaximal [ISO] that 
enabled the effects of the chosen PDE inhibitors to be accessed.  Other practical 
considerations included the relative selectivity of each of the PDE inhibitors for the 
individual cardiac PDE subtypes of interest, in addition to the usage of ISO as a 
classical   activator   of   the   β-AR signalling pathway, and were experimentally justified 
based on comparison with the literature.   
Collectively, our main findings consist of the identification of PDE4 as playing a 
predominant role in modulating PKA phosphorylation of PLM-Ser68, while both PDE2 
and PDE4 seem to be important for regulating cAMP signalling to the NKA.  The 
results have interesting implications as they suggest a scenario whereby intracellular 
cAMP signals to the NKA are modulated via the modulation of PKA-mediated PLM-
Ser68 phosphorylation by PDE4, in addition to a yet identified mechanism involving 
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PDE2 activity that could potentially influence NKA function independent of PLM 
phosphorylation.  The notion that PDE4 is involved in regulating cAMP signalling to 
the PLM-NKA complex is in accordance with the extensive body of both cell-based and 
in vivo findings underlining the predominant role of PDE4 in modulating cardiac 
function in  the  rodent  heart  upon  β-AR stimulation.  For example, it is known that PKA 
phosphorylation of a number of proteins and ion channels integral to the cardiac ECC 
process, such as PLB and the LTTC, are regulated to an extent by PDE4 activity.  Our 
observation that PDE4-mediated changes in PLM-Ser68 status corresponds to a change 
in NKA activity is wholly consistent with the well-established role of PLM acting as a 
intermediate   PKA   target   to   functionally   link   the   β-AR receptor with pump function 
during sympathetic activation. 
Our series of biochemical experiments suggested potential differential roles of PDE4 in 
regulating PKA phosphorylation of ECC proteins, with the pattern of PLM 
phosphorylation subtly differing to those for PLB and cTnI.  These data are consistent 
with the increasingly popular notion that individual isoforms within the PDE4 family 
may possess non-redundant functional roles, with the actions of the individual variants 
being localised to distinct intracellular compartments through physical coupling of the 
enzymes to the target proteins either directly or indirectly via intermediate protein 
scaffolds.     Certainly,  our   finding   that  PDE2  may  be   responsible   for  modulating  β-AR 
activation of NKA suggests the involvement of such compartmentalisation at play, 
considering the low relative activity of PDE2 in the rodent heart.  What also remains 
unclear currently is the exact nature of the mechanism by which PDE2 modulates 
cAMP signalling to the pump.  Since it seems to be able to modulate NKA activity 
without exerting a change in PLM phosphorylation status, it is possible that PDE2 
activity may serve to indirectly influence pump function by regulating a component 
involved in other signalling pathways to PLM delineated to date, with glutathionylation 
or palmitoylation being possible mechanisms.     
The conclusions that we have drawn serve to highlight some of the shortcomings of the 
pharmacological approach that was employed to investigate cardiac PDE function 
throughout this project.  Firstly, selectivity of the inhibitors for the different PDE 
subtypes is by necessity relative and not absolute.  This means that firstly, the idea of 
our   results   merely   reflecting   a   product   of   ‘dirty   pharmacology’,   although   unlikely,  
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cannot be completely ruled out.  The other key disadvantage of these inhibitors is that 
they do not enable individual PDE isoforms to be studied, and different approaches are 
therefore required for investigating whether PDE2 and PDE4 modulate cAMP signals to 
the NKA in a compartmentalised manner.   
The targeting of individual PDE isoforms to specific intracellular locations may require 
a physical association of the enzymes with a specific protein.  Our efforts with the use 
of both a co-IP and peptide displacement approach to probe this possibility (see 
appendices) yielded little conclusive evidence of a physical interaction between cardiac 
PDE4 isoforms and PLM.  Attempts to assess whether PDE2 isoforms are situated in 
proximity to the PLM-NKA complex remain ongoing, and could provide more concrete 
support of a compartmentalised model of PDE2 –mediated NKA function.  
From a functional perspective, the generation and subsequent characterisation of two 
cAMP sensors should theoretically allow the intricate monitoring of cAMP dynamics 
within the myocyte in both the absence and presence of PDE inhibition.  Such an 
approach relies on the correct targeting of the sensors, but the expression of PLM-
Epac1-camps  was  found  to  be  ‘faulty’  during  our  preliminary  characterisation.    Further  
work is clearly required in order to address the problems underlying this issue, although 
once resolved, the possibility of being able to measure subsarcolemmal gradients of 
cAMP in conjunction with real-time measurements of pump current using VPC in the 
presence of a PDE inhibitor (in the presence of ISO, FRSK or other membrane-
permeable cAMP analogs) is highly encouraging.  Such an approach could be further 
expanded to include the use of siRNAs and dominant-negative peptides, which would 
allow investigation into the contribution of selective PDE isoforms to regulation of 
cAMP signalling to the PLM, and using this potentially versatile experimental system 
would thus overcome any selectivity issues associated with the pharmacological 
inhibitors.  
On the whole, considering the importance of the NKA in upholding normal cellular 
function – in particular its indirect control of the ECC process – it is only logical to 
suggest that the work described in this thesis has some physiological relevance central 
to our current understanding of PLM/NKA regulation.  As aforementioned, it has 
recently been shown that PLM phosphorylation and cardiac NKA activity are negatively 
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regulated by PP-1, with this regulatory mechanism being counteracted by PP1-inhibitor 
1.237  Such a mechanism suggests a contribution of local kinase signalling to PLM and 
is markedly perturbed in failing hearts favouring PLM dephosphorylation and NKA 
deactivation and may therefore contribute to maladaptive hypertrophy and 
arrhythmogenesis via chronically elevated intracellular Na and Ca concentrations.237  
Thus termination of the cAMP/PKA signals to PLM is likely to be a crucial component 
of the regulation of NKA activity.    
In the longer term, our observations of PDE-dependent modulation of PLM 
phosphorylation and cardiac NKA activity may serve not only as a foundation for 
further basic studies but may also support work with a more clinical orientation.  
Selective targeting of individual components of the Ca cycling process, such as PLB 
and SERCA, is increasingly viewed as a promising new therapeutic strategy for treating 
HF.306  As such, it would be logical to propose that PDE2 and PDE4, being modulators 
of cAMP and thereby PKA signalling, could potentially be among the most important 
regulators  of  NKA  activity  during  β-AR stimulation, and an undermining of their levels 
of expression and/or activity could potentially contribute to the progression of various 
pathologies, including cardiovascular diseases, as outlined in Chapter 1 (Sections 1.2.3 
– 1.2.5).  Indeed, selective PDE5A inhibition with sildenafil has been shown to rescue 
left ventricular dysfunction and cardiac remodelling in an in vivo HF model,307 while it 
has been suggested the PLM-Ser69 phosphorylation could contribute to sildenafil-
induced cardioprotection against reperfusion injury in the mouse via a NO/cGMP-
dependent pathway.308  Clearly, a greater understanding of how alterations  in 
intracellular signalling related to individual PDE isozymes  could potentially overcome 
some of the current difficulties encountered in the prevention and treatment of these 
diseases.  Therefore, further investigation into the roles of several of the individual 
isoforms within the PDE and PDE4 families in both healthy and diseased hearts is likely 
to augment our current view of their roles in maintaining a balanced profile of NKA 
function under normal circumstances, and perhaps provide insights into  novel 
therapeutic approaches in which the activity of individual PDE variants could be 
selectively targeted during cardiac dysfunction.   
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Another of our hypotheses was that PLM may directly bind individual PDE4 isoforms.  
To further investigate any direct physical interaction between PLM and such isoforms, 
preliminary co-IP experiments were undertaken.  All the work described in Appendix I 
was undertaken by our project collaborator Dr William Fuller, University of Dundee.   
PLM  was   shown   to  be   successfully   ‘pulled-down’  with   the  NKA  antibody   [Figure  1;;  
Panel A] but collectively, the data obtained from this series of experiments were 
inconclusive.  Despite the presence of bands at 75 kDa, which corresponded to the 
molecular weights of PDE4B [Figure 1; Panel C], and at 100 kDa, which corresponded 
to PDE4A [Figure 1; Panel B] and PDE4D [Figure 1; Panel D] respectively, the quality 
of the data set was compromised by a multitude of non-specific bands across the 
samples.  Specifically, multiple bands were observed in the unfractionated cardiac 
homogenate for all of the PDE4 antibodies tested, with PDE4B additionally binding to a 
component of the molecular ladder.   Furthermore, the bands at 25 kDa and 100 kDa 
could likely be attributed to binding of the primary antibody to IgGs present in the 
samples, which may be overcome in future experiments by pre-boiling the samples prior 
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Figure A1 Potential physical interaction between PLM and PDE4 in PLM-WT and PLM-KI hearts. 
Western blots of PLM-NKA co-IP probed with PDE4A, B and D antibodies.  (A) A NKA-α1  antibody was first used to pull down PLM in both PLM-WT 
and PLM-KI (3sa) heart homogenate samples.  For co-IP  of  FXYD1  and  the  NKA  α1-subunit, samples were lysed in PBS supplemented with 6 mg/ml 
octaethylene glycol monododecyl ether (C12E8, Sigma), plus protease and phosphatase inhibitors.  Samples were agitated gently for 30 min at 4°C 
and diluted 1:1 with PBS (plus protease and phosphatase inhibitors), and insoluble material was removed by centrifugation (15,000 g, 5 min).  
Supernatants were agitated overnight at 4°C with anti-NKA  α1-subunit monoclonal C464.6 (Santa Cruz Biotechnology), immune complexes were 
harvested with protein G Sepharose for 2 hr at 4°C, and beads were washed 5 times with 0.5 mg/ml C12E8 in PBS supplemented with protease and 
phosphatase inhibitors. To avoid the confounding presence of mouse IgG in immunoprecipitated samples, successful co-IP of PLM was confirmed 
using an antibody raised in chickens (Chemicon).  The membranes were then probed with antibodies against (B) PDE4A, (C) B and (D) D (generated 
by our project collaborator, Dr. George Baillie, University of Glasgow).  The darkened marker on the left of each blot indicates the theoretical 
molecular weight of the individual PDE4 subfamilies.    
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APPENDIX II 
To further investigate the manner in which PLM binds PDE4, ARVMs were treated 
with a specially designed PDE4-PLM disruptor peptide (generated by our project 
collaborator, Dr George Baillie, University of Glasgow).  PDE4 isoforms are thought to 
bind directly to their signalling partners (or to AKAPs) via their unique N-terminal 
region, which is distinct to each isoform, and the notion of displacing PDE4s using 
peptides is relatively well established.  This particular disruptor peptide, rather than 
based on the PDE4 binding sequence, is instead based on the last 16 amino acids of 
PLM and the sequence is virtually identical to that belonging to a peptide representing 
the 19 C-terminal residues of PLM (54-72) used in a previous study in our laboratory.217  
This particular sequence of PLM has been determined to directly bind purified PDE4 
using peptide array technology developed by Dr George Baillie (unpublished data).   
The control peptide, on the other hand, consists of another sequence of PLM that does 
not bind PDE4.  Dr George Baillie had hypothesised that this peptide would induce a 
similar functional response to Rol; that is, increase cAMP levels and thus PKA 
phosphorylation of PLM by displacing PDE4 away from the immediate vicinity of 
PLM.  
Disruptor peptide: {Ste}-EGTFRSSIRRLSTRRR 
Control peptide: {Ste}-QRTGEPDEEEGTFR 
Both the disruptor and the control peptides consist of an identical stearate group to 
enable penetration through the plasma membrane.  The treatment of ARVMs with this 
peptide was largely similar to the protocol outlined in Chapter 3 (Section 3.2.2), with 
the exception that the disruptor and control peptides were incubated with the cells at 10 
μmol/L for 2 hr rather than 10 min to facilitate entry into the cell.  All treatment groups 
were exposed to an equal amount of DMSO (0.1%).  PLM-Ser68 phosphorylation levels 
were subsequently analysed as outlined in Chapter 2 (Sections 2.5.5 and 2.5.6).     
The inhibitor peptide markedly reduced PLM-Ser68 phosphorylation in both the 
absence and presence of ISO, in contrary to initial expectations that the peptide behaves 
in an analogous manner to Rol [Figure 1; Panel A].  Incidentally, the 19 aa peptide 
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aforementioned was shown to inhibit the NKA in VPC experiments, which we always 
assumed that this was because it displaced phosphorylated PLM off the pump.  Since 
the addition of this peptide did not seem to enhance PLM-Ser68 phosphorylation under 
both basal conditions and β-AR stimulation, this implies that PLM does not bind a local 
pool of PDE4 directly under normal circumstances, at least not involving this particular 
PLM domain. On the other hand, if PDE4 is targeted to the proximity to the protein, our 
results may reflect a displacing of endogenous PLM and/or an augmentation of the basal 
activity of the PDE4 enzymes induced by the peptide.  An alternative explanation for 
our findings is that an AKAP in the vicinity of PLM normally functions as an 
intermediate complex for binding of PLM to PDE4, and the peptide served to displace 
the AKAP from its normal location, thereby reducing cAMP-PKA signalling to PLM.  
This possibility is consistent with the notion that PLM may not be binding PDE4 in a 
direct manner, and the requirement of an intermediate protein could be investigated 
using AKAP-specific antibodies in co-IP experiments in the future.     
A definitive conclusion remains elusive; one obstacle is the lack of understanding of the 
manner in which the disruptor peptide displaces PDE4 from PLM.  Since this putative 
binding sequence on PLM is also the region that contains all three phosphorylatable 
residues, PDE4 might sterically hinder the access of PKA to PLM-Ser68.  Whether our 
results are merely reflecting the actions of an incorrectly designed pharmacological 
agent  must  be  considered,  and  delineation  of  the  peptide’s  mechanism  of  action  may 
shed further light onto this issue.  For instance, it would be useful to determine whether 
the peptide activates PDE4 or a phosphatase (identity not yet known) in proximity to 
PLM and/or inhibits PKA or AC. 
Furthermore, it is possible that our observations are merely a result of cell apoptosis 
induced by the presence of the peptide (and/or the stearate groups) for 2 hr, a relatively 
extensive treatment time.  Supporting this possibility is the observation that the control 
peptide also led to a reduction in PLM-Ser68 phosphorylation level, although the effect 
was not statistically significant [Figure 1; Panel B].  Despite this, analysis of the total 
actin levels across the treatment groups did not show a marked reduction in the 
peptides-treated wells.  Importantly, the pattern of PLM-Ser68 phosphorylation was 
found to be completely consistent with that of PLB-Ser16, giving rise to the possibility 
that the peptide-mediated actions on PLM were non-specific [Figure 1; Panel C]. 
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In conclusion, the disruptor peptide tested is unlikely to be displacing PDE4 binding to 
PLM, either due to the peptide not functioning correctly or the fact that PDE4 does not 
directly interact with PLM under normal circumstances.  Further work is required to 
fully distinguish the effects of this peptide on PLM-Ser68 phosphorylation.   
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Figure A2 PLM-Ser68 phosphorylation levels in response to treatment with a PDE4-PLM disruptor peptide in the absence and presence 
of a submaximal [ISO].   
ARVMs were treated with a PDE4-PLM disruptor peptide or a control peptide (A) alone or (B) in combination with 10 nmol/L ISO.  Negative and 
positive controls comprised of ARVMS challenged with 0.1% DMSO and 300 nmol/L PMA (not shown) respectively.  ARVMs in all treatment groups 
were exposed to 0.1% DMSO.  SDS-PAGE (15% gel) and WB analysis was used to analyse PLM-Ser68 and PLB-Ser16 phosphorylation levels 
using an anti-phospho PLM-Ser68 antibody.  All samples were subjected to complementary WB analysis using an anti-total actin antibody, to 
demonstrate equal protein loading between samples.  Membranes were subsequently stained with Coomassie Blue to demonstrate equal protein 
loading and transfer.  Densitometry values for PLM-Ser68 were normalised to those for total actin and subsequently normalised to the DMSO 
control to generate fold values.  Data are expressed as means ± SEM (n=6).  (C) Representative blot of PLM-Ser68 phosphorylation levels in 
response to pharmacological treatment.   
 
 
 
